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Dynamics of Tissue-Resident Regulatory T Cell Populations 
 
Abstract 
  In recent years, there has been a worldwide increase in obesity, which parallels a 
rise  in  pathologies,  including  type  2  diabetes,  collectively  termed  the  metabolic 
syndrome.  Chronic,  low-grade  inflammation  has  been  implicated  as  a  major  link 
between  these  diseases.  Recent  work  showed  the  presence  of  a  unique  subset  of 
CD4
+Foxp3
+  regulatory  T  cells  residing  in  visceral  adipose  tissue  (VAT  Treg)  with 
PPAR-γ being the key transcription factor responsible for their phenotype and function 
in controlling adipose tissue inflammation and, thereby, insulin sensitivity. VAT Tregs 
inversely  correlated  with  insulin  resistance.  In  contrast,  there  was  a  dramatic  age-
associated  increase  in  frequency  of  VAT  Tregs  in  lean  animals,  correlating  with 
continued insulin sensitivity, despite significant increases in body and adipose tissue 
weights. This increase in Treg frequencies was not observed in other lymphoid and non-
lymphoid tissues, including the subcutaneous fat depot. We characterized this unique 
age-associated increase in VAT Tregs through the use of adoptive transfer models, in 
vivo labeling and tracking systems, parabiosis, and analysis of the T cell receptor (TCR) 
repertoire used by VAT Tregs. Our findings indicate that the progressive increase in 
VAT Tregs is not due to conversion of conventional CD4
+ T cells nor to substantial   iv 
infiltration of Tregs from the circulation and secondary lymphoid organs. However, by 
analyzing the TCR repertoire on a single-cell level we uncovered a striking oligo-clonal 
expansion of VAT Tregs, suggesting their accumulation results from in situ proliferation. 
We  further  showed  that  this  accumulation  is  dependent  on  major  histocompatibility 
complex (MHC) class II, but not on CD1d. Finally, we showed that IL-33 was able to 
induce  proliferation  of  VAT  Tregs.  In  parallel,  we  extended  our  analysis  of  TCR 
repertoire to the Treg population residing in skeletal muscle. In acute and chronic models 
of muscle injury, muscle-resident Tregs underwent a substantial clonal expansion, with a 
particular clone being detected in multiple individuals. Taken together these studies 
highlight the importance of proliferation as a mechanism of Treg accumulation in tissues 
in response to acute and chronic inflammation.  
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Chapter 1: Introduction 
 
  Regulatory  T  cells  (Treg cells),  defined  by  their  expression  of  the  forkhead-
winged helix transcription factor, Foxp3, are one of the main guardians of the immune 
system. A large body of literature described the origin, stability, and function of Treg 
cells in maintaining immune homeostasis and implicated this cell subset in control of 
autoimmunity, allergic reactions, and inflammation, as well as responses to pathogens 
and commensals. More recently, Treg cells have also been shown to play key roles in 
various  non-immune  contexts,  including  helping  to  maintain  insulin  sensitivity  and 
potentiating muscle regeneration after injury. 
 
1.1: Regulatory T cell biology: 
1.1.1: Early work and identification of Foxp3 
  The concept of immunologic tolerance has long been proposed, however the 
dominant cell types and mechanisms remained elusive. In 1995, a seminal paper by 
Sakaguchi et al. described a subset of CD4
+ T cells that expressed high levels of the 
high affinity interleukin 2 receptor-α (IL-2Rα) chain, CD25, on their cell surface and 
were  able  to  suppress  autoimmune  inflammation  elicited  by  lymphopenic 
complementation and neonatal thymectomy (Sakaguchi et al., 1995). While the CD25
+ 
T cell population was enriched in Treg cells, it also contained recently activated naïve T 
cells, so it was important to have a more accurate cell marker in order to identify the 
molecular mechanisms involved in Treg differentiation and function. Studies on human   2 
patients  with  a  fatal  immunodysregulation  polyendocrinopathy  and  enteropathy,  X-
linked  (IPEX)  syndrome,  as  well  as  scurfy  mutant  mice,  pathologic  conditions 
characterized by uncontrolled lymphoproliferation and multiorgan autoimmunity, have 
led to the identification of Foxp3 as the characteristic marker of Tregs involved in their 
differentiation, maintenance, and functions (Brunkow et al., 2001; Chatila et al., 2000; 
Bennett et al., 2001; Wildin et al., 2001). The notion that Treg cells play a dominant role 
in maintaining immune homeostasis was further substantiated by observations that the 
transfer of adult Foxp3
+ Treg cells, wild-type (WT) bone marrow, or the expression of a 
transgene-encoded WT Foxp3 allele could rescue scurfy mutant mice (Khattri et al., 
2003; Fontenot et al., 2003).  
 
1.1.2: Differentiation of Treg cells 
  Tregs  can  differentiate  in  the  thymus  (tTregs)  or  as  a  result  of  conversion  of 
conventional  CD4
+ T  (Tconv)  cells  into  Tregs  in  the  periphery  (pTregs).  Although  the 
function and numerical contributions of the pTreg pool remain a topic of debate, they 
have been definitively shown to contribute significantly to oral tolerance, colonization 
by intestinal commensal microbiota, and fetal-maternal tolerance. Mice with a deletion 
of the conserved noncoding sequence 1 (CNS1) enhancer region in the Foxp3 locus, 
necessary  for  differentiation  of  pTregs,  displayed  an  altered  composition  of  the 
commensal microbiota, as well as increased inflammation in the gastrointestinal tract 
and  lung  airways  (Josefowicz  et  al.,  2012b).  In  addition,  CNS1-mutant  mice  in 
allogeneic,  but  not  syngeneic,  pregnancies  had  decreased  frequencies  of  Tregs  and   3 
increased  inflammation  in  deciduas,  which  led  to  increased  resorption  of  embryos 
(Samstein et al., 2012b). 
  A  much  larger  body  of  literature,  however,  has  focused  on  Treg  cell 
differentiation in the thymus. Proper differentiation of tTreg cells is dependent, in part, 
on  T  cell  receptor  (TCR)  signaling,  costimulation,  and  cytokine  signaling.  Thymic 
differentiation  of  Treg  cells  with  a  specific  transgene-encoded  TCR  required  the 
expression of the cognate ligand (Kawahata et al., 2002; Apostolou et al., 2002; Jordan 
et al., 2001). Additionally, effector T cells transduced with TCRs isolated from Tregs, but 
not from naive T cells, were able to proliferate and cause autoimmune inflammation in 
lymphopenic recipients (Hsieh et al., 2004), highlighting a degree of self-specificity 
among  Treg  cells.  However,  TCR  repertoire  analyses  revealed  that  TCR  sequences 
between Tregs and Tconvs were similarly broad and only partially overlapping (Hsieh et 
al.,  2006;  Wong  et  al.,  2007;  Feuerer  et  al.,  2009),  suggesting  a  broad  range  of 
specificities among Tregs. Additionally, mice carrying transgene-encoded TCRs derived 
from Treg cells supported the differentiation of very few Foxp3
+ tTregs, a phenomenon 
that could be overcome by drastically reducing the frequency of precursors expressing 
the transgene-encoded TCR, which resulted in an increased frequency of differentiating 
tTregs (Leung et al., 2009; Bautista et al., 2009; Dipaolo and Shevach, 2009). These 
findings suggested the presence of a selecting “niche” for tTregs with severe intraclonal 
precursor  competition,  limiting  the  number  of  Tregs  expressing  TCRs  of  identical 
specificities and allowing for generation of a broad Treg TCR repertoire. Furthermore, 
by analyzing a panel of TCRs with a wide range of reactivity to ovalbumin (OVA), the   4 
authors showed that TCR affinity for OVA correlated with increased niche size for Treg 
differentiation in the rat insulin promoter (RIP)-mOVA self-antigen tolerance model 
(Lee et al., 2012). Consistent with the idea of increased TCR signaling, differentiating 
tTregs  expressed  elevated  levels  of  CD5,  programmed  cell  death  protein  1  (PD-1), 
cytotoxic  T  lymphocyte  antigen-4  (CTLA-4),  glucocorticoid-induced  tumor  necrosis 
factor receptor (GITR), and OX40 (Fontenot et al., 2005b). It is likely that signals from 
TCR:self-petide  interaction  lead  to  a  balance  between  negative  selection  and  tTreg 
differentiation when receiving additional signals. Indeed, likely due to increased TCR 
signaling, differentiating Tregs required TGF-β (Ouyang et al., 2010a) and common γ-
chain cytokine signaling (Tai et al., 2013; Burchill et al., 2007; Fontenot et al., 2005a) 
leading to signal transducer and activator of transcription (Stat)5 activation in order to 
overcome Bcl-2-regulated apoptosis (Ouyang et al., 2010a). Conversely activation of 
PI3K-Akt pathway diminished tTreg differentiation (Patton et al., 2006; Haxhinasto et 
al., 2008) primarily due to decreased translocation to the nucleus and decreased binding 
of the promoter and CNS2 of the Foxp3 locus by Foxo1 and Foxo3 (Ouyang et al., 
2010b; Kerdiles et al., 2010). 
  Consistent  with  the  idea  of  TCR-mediated  differentiation,  major 
histocompatibility  complex  (MHC)  class  II  molecules  are  required  for  tTreg 
differentiation  (Fontenot  et  al.,  2005b).  Furthermore,  decreased  expression  of  MHC 
class  II  specifically  on  medullary  thymic  epithelial  cells  enhanced  tTreg  cell 
differentiation and decreased clonal deletion in TCR transgenic mice expressing the 
cognate ligand in the thymus (Hinterberger et al., 2010). Finally, a TCR sequence that   5 
was  enriched  in  multiple  independent  mice  (MJ23)  has  been  recently  isolated  from 
prostate tumor-infiltrating Tregs (Malchow et al., 2013). In MJ23 TCR-transgenic mice, 
Tregs localized exclusively to the prostate and draining lymph nodes even in the absence 
of the tumors, highlighting that their localization to the prostate was independent of 
inflammation. In addition, differentiation of MJ23 TCR-transgenic tTregs was dependent 
on expression of autoimmune regulator (AIRE) and provided the first example of tissue-
resident Tregs differentiating in the thymus in response to self-antigen.  
  Beyond TCR signaling, tTreg differentiation also required CD28 costimulation 
(Salomon  et  al.,  2000;  Tai  et  al.,  2005),  leading  to  induction  of  Foxp3  through 
activation of NF-κB and binding of c-Rel to noncoding sequence elements in the Foxp3 
gene  (Isomura  et  al.,  2009;  Long  et  al.,  2009;  Zheng  et  al.,  2010).  Foxp3,  while 
absolutely critical for proper Treg function and maintenance, alone did not account for 
the entire Treg phenotype. Some canonical Treg genes, such as IL2ra, Ctla4, and Icos 
were still upregulated in differentiating tTregs of mice where green fluorescent protein 
was  inserted  into  the  Foxp3  locus  rendering  the  endogenous  Foxp3  protein 
nonfunctional (Gavin et al., 2007; Lin et al., 2007). Additionally, transduction studies 
have determined that Foxp3 accounted for the induction of ~10-11% of the canonical 
Treg  signature,  while  the  rest  of  the  signature  required  the  expression  of  other 
transcription factors such as GATA-1, Helios, IRF4, Eos, Lef1, and others (Hill et al., 
2007; Fu et al., 2012). In addition, a variety of epigenetic modifications important for 
Treg  differentiation,  maintenance,  stability,  and  function  have  also  been  described 
(Samstein et al., 2012a; Zheng et al., 2010).    6 
1.1.3: Treg cell control of inflammation 
 
  Foxp3 plays an important role in differentiation and maintenance of the Treg cell 
phenotype.  Conditional  knockouts  of  Foxp3  in  T  cells,  using  a  Cre  recombinase  to 
delete floxed Foxp3 alleles, led to the recapitulation of the fatal multiorgan autoimmune 
disease seen in scurfy mutant mice, including massive lymphoproliferation, diabetes, 
enteropathy, thyroiditis, and exfoliative dermatitis (Fontenot et al., 2003). In addition, 
depletion of Foxp3
+ Treg cells in adult mice expressing the diphtheria toxin receptor 
under the control of Foxp3 promoter/enhancer elements (Foxp3
DTR) showed that Treg 
cells are required for immunologic homeostasis throughout life (Kim et al., 2007). 
  Multiple  molecular  mechanisms  of  Treg  cell-mediated  suppression  have  since 
been  shown  to  be  important  in  different  inflammatory  contexts  (Josefowicz  et  al., 
2012a). Tregs can secrete anti-inflammatory cytokines, such as interleukin-10 (IL-10) 
(Rubtsov  et  al.,  2008),  transforming  growth  factor-β  (TGF-β)  (Li  et  al.,  2007),  and 
interleukin-35 (IL-35) (Collison et al., 2007). Additionally, Tregs mediate suppression 
via expression of a panel of cell surface molecules: CD25 deprives effector T cells and 
NK cells of IL-2 and inhibits their proliferation (Sitrin et al., 2013; Pandiyan et al., 
2007) and CTLA-4 modulates the activation state of antigen presenting cells, inhibiting 
their ability to activate effector T cells (Wing et al., 2008; Friedline et al., 2009). 
  Inflammatory responses are heterogeneous in their nature, composed of different 
combinations  of  effector  cells  and  polarization  states;  therefore,  broadly-functioning 
molecular mechanisms are unlikely to account for the heterogeneity and specificity of   7 
Treg-mediated suppression of inflammation and control of immune homeostasis. Instead, 
Tregs coopt portions of molecular programs expressed by the effectors that are being 
suppressed,  thereby  allowing  Tregs  to  be  recruited  to  and  retained  at  the  site  of 
inflammation, and to initiate proper suppression mechanisms. Indeed it was shown that 
transcription factors, key in differentiation of various T helper subsets were upregulated 
in  Tregs  and  loss  of  these  transcription  factors  led  to  uncontrolled  inflammatory 
responses. Tregs express T-bet (Koch et al., 2009), IRF4 (Zheng et al., 2009), STAT3 
(Chaudhry et al., 2009), and BCL6 (Chung et al., 2011; Linterman et al., 2011) to 
control Th1, Th2, Th17, and Tfh responses, respectively. 
  Given  the  potent  role  of  Tregs  in  controlling  a  plethora  of  inflammatory 
responses, it was logical to evaluate their role in contexts that have not been historically 
associated with inflammation. 
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1.2: Inflammation in obesity and insulin resistance  
  1.2.1: Molecular mediators of adipose tissue inflammation  
  Over the past several decades, there has been a world-wide increase in obesity, 
in parallel with an impressive rise in a cluster of abnormalities termed the “metabolic 
syndrome”, including type-2 diabetes (TD2). According to the latest estimates from the 
Centers for Disease Control, over 25 million people in the United States suffer from 
diabetes, which is associated with tremendous societal and economic burdens (Center 
for Disease Control and Prevention, 2011). There is by now a large body of evidence 
that implicates obesity in provoking chronic, low-grade inflammation, which, in turn, 
promotes  metabolic  dysregulation  and  systemic  insulin  resistance  (Shoelson  et  al., 
2006; Hotamisligil, 2006). It turns out that the function of adipose tissue is not limited 
to  the  storage  of  excess  triglycerides,  but  that  it  is  also  an  active  endocrine  organ 
playing multiple roles in orchestrating system-wide metabolism. A seminal insight into 
the  pro-inflammatory  potential  of  adipose  tissue  in  response  to  obesity  came  from 
Hotamisligil et al., who demonstrated increased levels of tumor necrosis factor-α (TNF-
α) mRNA in adipocytes in visceral adipose tissue (epidydimal, omental, etc.), but not 
subcutaneous fat, of obese versus lean mice (Hotamisligil et al., 1993). Since then, an 
increasing number of adipocyte-derived mediators, collectively called adipokines, have 
been  described.  These  molecules,  which  can  increase  or  decrease  in  response  to 
extended caloric excess, have multiple effects on a variety of cell populations, both 
locally in adipose tissue and systemically (Ouchi et al., 2011). They include, but are not 
limited to, interleukin-1β (IL-1β) (Jager et al., 2007), IL-6 (Rotter et al., 2003), serum   9 
amyloid  A3  (SAA3)  (Han  et  al.,  2007),  and  macrophage  chemoattractant  protein-1 
(MCP-1) (Kamei et al., 2006). Obesity, by triggering endoplasmic reticulum (ER) stress 
(Ozcan et al., 2004), hypoxia (Halberg et al., 2009), and oxidative stress (Minamino et 
al., 2009), results in adipocyte dysfunction, dysregulated expression of adipokines, and 
inappropriate inflammatory responses (Shoelson et al., 2006; Hotamisligil, 2006). There 
are changes in the cellular composition of adipose tissue, including adjustments in the 
numbers, phenotypes, and localization of multiple immune cell subsets. There are also 
systemic metabolic alterations through a complex signaling network that affects insulin 
signaling in the liver, kidney, and skeletal muscle. Activation of NF-κB (Yuan et al., 
2001)  and  the  JUN  N-terminal  kinase  family  of  serine/threonine  protein  kinases 
(Hirosumi et al., 2002) leads to phosphorylation and inactivation of the insulin receptor 
substrate family, which collectively results in tissues becoming unresponsive to insulin 
signaling (Elchebly et al., 1999; Ozcan et al., 2004; Feinstein et al., 1993). (Figure 1.1)  
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Figure 1.1: Obesity results in systemic, chronic, low-grade inflammation and insulin resistance. 
Excess  weight  gain  leads  to  necrotic  and  apoptotic  death  of  adipocytes,  thereby  activating  various 
inflammatory  responses  such  TLR  and  inflammasome  activation,  release  of  reactive  oxygen  species 
(ROS), and endoplasmic reticulum (ER) stress. In response to these inflammatory stimuli, adipocytes and 
infiltrating leukocytes release a variety of pro-inflammatory mediators that act locally in adipose tissue 
and distally in liver, muscle, and kidneys to inactivate insulin receptor substrates (IRS), leading to insulin 
resistance and persistent high blood glucose. Taken from (Cipolletta et al., 2011) Copyright 2011 Elsevier 
Ltd.    11 
1.2.2: Innate immune system in obesity 
  A number of studies have implicated subsets of innate immune system cells, 
such as neutrophils, type 2 innate lymphoid cells (ILC2), mast cells, and macrophages 
in obesity-induced pathology. In mouse model of obesity, neutrophils infiltrate adipose 
tissue within the first three weeks of high fat diet (HFD), revealing their possible role in 
early phases of adipose tissue inflammation (Talukdar et al., 2012; Elgazar-Carmon et 
al., 2008). Neutrophils have been shown, given appropriate inflammatory cues, to expel 
extracellular traps, termed NETs, which consist primarily of extruded chromatin and 
serine  proteases.  These  NETs  possess  direct  antimicrobial  activity  and  also  act  to 
amplify  the  immune  response  through  recruitment  of  additional  circulating  immune 
cells.  Genetic  ablation  of  neutrophil  elastase  alleviated  inflammation  and  improved 
metabolic  indices,  while  injection  of  recombinant  elastase  led  to  development  of 
glucose intolerance even in mice on a normal chow (NC) diet.  
  To  date,  the  largest  body  of  evidence  implicates  subsets  of  macrophages/ 
monocytes  as  major  effectors  in  obesity-induced  pathology.  Accumulations  of  large 
numbers  of  macrophages  around  dead  adipocytes,  forming  “crown-like  structures,” 
have been observed in visceral fat tissue of obese mice and humans (Cinti et al., 2005; 
Weisberg et al., 2003). Under normal chow conditions, adipose tissue presents an anti-
inflammatory environment, where resident macrophages display a phenotype similar to 
the anti-inflammatory or alternatively-activated “M2” state, producing factors such as 
interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) (Mosser and Edwards, 
2008; Odegaard et al., 2007; Fujisaka et al., 2009; Kamei et al., 2006; Lumeng et al.,   12 
2007a;  Lumeng  et  al.,  2007b).  In  contrast,  in  obese  adipose  tissue,  resident  and 
infiltrating macrophages appear to be in the pro-inflammatory or classically activated 
“M1” state, synthesizing numerous inflammatory factors, including TNF-α, IL-6, matrix 
metalloproteinases,  and  peroxisome  proliferator  activated  receptor-γ  (PPAR-γ), 
(Lumeng et al., 2007a; Lumeng et al., 2007b; Weisberg et al., 2003; Kamei et al., 2006; 
Fujisaka et al., 2009). In addition, adipose-tissue macrophages can also modulate the 
functions  of  infiltrating  CD4
+  T  cells  to  polarize  toward  a  pro-inflammatory  Th1 
phenotype (Moraes-Vieira et al., 2014). 
  It is important to note, however, that, while adipose tissue macrophages have 
been historically subdivided into M1 and M2 subsets (Lumeng et al., 2007a; Lumeng et 
al., 2007b), and this is an attractively simple dichotomy, recent studies have challenged 
this binary classification, instead arguing in favor of a spectral classification (Mosser 
and  Edwards,  2008;  Shaul  et  al.,  2010;  Herrero  et  al.,  2010).  A  recent  study 
demonstrated the importance of the NLRP3 (nucleotide-binding domain leucine-rich 
repeat containing family, pyrin domain containing 3) inflammasome in activation of 
adipose-tissue  macrophages  and  subsequent  development  of  insulin  resistance 
(Vandanmagsar et al., 2011). The inflammasome is a key player in sensing various 
“danger” stimuli, leading to secretion of IL-1β and initiation of a pro-inflammatory 
immune response (reviewed in Schroder and Tschopp, 2010). Previous studies have 
demonstrated that cholesterol or similar crystals cause Nlrp3 inflammasome activation 
in macrophages found in atherosclerotic lesions (Duewell et al., 2010; Rajamaki et al., 
2010). By analogy, one might speculate that HFD leads to formation of cholesterol   13 
crystals activate the Nlrp3 inflammasome, in particular in adipose tissue macrophages, 
resulting  in  a  pro-inflammatory  activation  state  and  ultimately  resulting  in  systemic 
inflammation  and  insulin  resistance.  Additionally,  activation  of  adipose  tissue 
macrophages has been shown to result from recognition of free fatty acids by Toll-like 
receptors (TLR) 2 and 4 in mice on HFD (Nguyen et al., 2007).  
  Since  insulin  sensitivity  closely  correlates  with  the  presence  of  anti-
inflammatory,  M2-like  macrophages,  several  studies  have  focused  on  particular 
populations of anti-inflammatory innate immune cells residing in VAT of lean mice. 
One such immune cell subset is eosinophils, known to circulate in an immature state 
and enter tissues following their maturation. In lean VAT, eosinophils produced high 
levels of IL-4, key cytokine for the differentiation and survival of anti-inflammatory, 
M2-like  macrophages;  additionally,  eosinophil  numbers  inversely  correlated  with 
adipocity (Wu et al., 2011). Mice with reduced eosinophil numbers due to a genetic 
deficiency (Gata1
-/- mutants) had increased adipocity, decreased glucose tolerance and 
worsened  insulin  resistance;  however,  IL-5  transgenic  mice  that  have  increased 
eosinophil levels, showed markedly improved metabolic indices that correlated with an 
increase in M2-like macrophages. ILC2s are a major source of IL-5 and IL-13 in lean 
VAT and their number decrease with HFD treatment (Molofsky et al., 2013). IL-33-
mediated  increase  of  ILC2s  led  to  increases  in  eosinophils  and  anti-inflammatory 
macrophages in VAT. 
  Mast cells potentiate obesity-associated inflammation (Liu et al., 2009). Mast 
cell numbers are increased in adipose tissue of obese mice and humans compared with   14 
lean controls. Additionally, mice with a genetic mast cell deficiency and mice treated 
with a mast cell stabilizing drug displayed significantly reduced body weight and VAT 
mass during HFD treatment due to decreased adipose tissue and muscle angiogenesis 
and increased apoptosis. It is important to point out that the primary effect of mast cell 
stabilization  was  on  obesity-induced  weight  gain  that  secondarily  altered  insulin 
sensitivity. Finally, using genetic knockouts, the authors showed that IL-6 and IFN-γ 
produced by mast cells were the key cytokines for attenuating weight gain. 
     15 
  1.2.3: Adaptive immune system in obesity 
 
  Even  though  the  contributions  of  the  innate  immune  system  have  been  the 
central focus of many obesity-related studies, recently a growing interest in the adaptive 
immune system has emerged.  
  The  role  of  B  cells  in  insulin  resistance  remains  poorly  understood,  as 
conflicting reports regarding their pro- or anti-inflammatory effects have emerged in the 
literature. IL-10-producing B cells, termed Bregs, are abundant in lean adipose tissue, but 
declined  in  various  models  of  obesity,  including  Lep
ob/ob  mice  and  HFD  feeding 
(Nishimura et al., 2013). B-cell specific deletion of IL-10 resulted in increased adipose 
tissue inflammation during HFD treatment and a decline in metabolic indices, which 
could be reversed via transfer of WT Bregs, arguing for an anti-inflammatory role for B 
cells.  However,  other  studies  found  that  B  cells  were  part  of  the  pro-inflammatory 
infiltrate in the VAT during HFD feeding (Duffaut et al., 2009; Winer et al., 2011; 
DeFuria  et  al.,  2013).  B  cell-deficient  mice  had  decreased  VAT  inflammation  and 
improved insulin sensitivity on HFD; reintroduction of B cells from mice on HFD, but 
not NC, led to an increase in inflammation and worsening of insulin sensitivity (Winer 
et al., 2011; DeFuria et al., 2013). Interestingly, decreased insulin sensitivity in HFD 
mice could be recapitulated by transferring the serum IgGs alone from mice on HFD, 
but not NC, into B cell-null recipients (Winer et al., 2011). A possible reconciliation of 
these  seemingly  contradictory  results  is  that  lean  VAT  contains  primarily  anti-
inflammatory  Breg  cells  that  are  replaced  in  obesity  by  pro-inflammatory  B  cells,   16 
mirroring the balance and dynamics of regulatory and effector T cell subsets in lean and 
obese adipose tissues (discussed below). 
  Effector and regulatory T cells have been the focal point in characterizing roles 
of the adaptive immune system in type-2 diabetes. It is not surprising that T cells have 
been implicated given their crucial roles in various other inflammatory diseases. Initial 
studies showed an increased frequency of CD3
+ T cells in obese human patients and 
mice (Kintscher et al., 2008). Both CD4
+ and CD8
+ T cells have been identified as key 
players in adipose tissue inflammation. 
  In response to HFD feeding, CD8
+ T cells infiltrated obese adipose tissue prior 
to the increase in macrophages (Nishimura et al., 2009). Depletion of CD8
+ T cells via 
antibody treatment or genetic knockout resulted in decreased macrophage infiltration 
into adipose tissue and improved insulin sensitivity. Additionally, CD8
+ T cell depletion 
resulted in decreased production of key pro-inflammatory mediators such as TNFα, IL-
1, IL-6, RANTES, and MCP-1. Several in vitro experiments suggested that CD8
+ T 
cells isolated from obese adipose tissue had a highly activated phenotype and produced 
large  quantities  of  pro-inflammatory  mediators  known  to  function  in  macrophage 
recruitment and activation (Nishimura et al., 2009; Yang et al., 2010). The frequency of 
CD44
+ CD62L
- effector memory CD8
+ T cells was significantly higher while CD44
-
CD62L
+ CD8
+ T cell frequency was decreased in obese compared with lean adipose 
tissue, consistent with the model of an activated phenotype of CD8
+ T cells in obese fat 
(Yang et al., 2010). In addition, studies in mice deficient for the costimulatory protein, 
CD40, found increased adipose tissue inflammation and a corresponding increase in   17 
insulin resistance, which was characterized by increased infiltration of CD8
+ T cells and 
macrophages in VAT (Wolf et al., 2014; Yi et al., 2014). Transfer of CD8
+ T cells from 
CD40-KO,  but  not  WT,  mice  into  recombination-activating  genes  (RAG)-null 
recipients  led  to  increased  inflammation  and  insulin  resistance  (Yi  et  al.,  2014). 
Conversely,  antibody-mediated  depletion  of  CD8
+  T  cells  was  able  to  ameliorate 
inflammation and insulin resistance in CD40-KO mice. Findings from these studies 
suggest that obese adipose tissue leads to activation of CD8
+ T cells, which, in turn, 
leads to recruitment and differentiation of activated macrophages to adipose tissue via 
pro-inflammatory  mediators.  However,  the  dominant  role  of  CD8
+  T  cells  in  VAT 
inflammation was challenged by the finding that mice enriched in CD8
+ T cells due to 
genetic  deletion  of  MHC  class  II,  thereby  lacking  in  CD4
+  T  cells  and  Tregs,  were 
protected from obesity-induced insulin resistance (Deng et al., 2013).  
  More attention has been given to the CD4
+ T cell subset due to their ability to 
promote inflammation and recruit macrophages. Currently, the role of CD4
+ T cells in 
adipose tissue inflammation remains unclear with multiple conflicting reports. In recent 
years, several studies characterized the pro-inflammatory properties of effector CD4
+ T 
cells in VAT. These studies found a significant increase in CD4
+ T cells residing in 
adipose tissue of obese human patients and mice (Yang et al., 2010; Winer et al., 2009). 
VAT  CD4
+  T  cells  were  enriched  for  CD44
+  CD62L
-  effector  memory  T  cells, 
suggesting their increasingly activated phenotype compared with CD4
+ T cells isolated 
from lean adipose tissue (Yang et al., 2010). TCR analysis revealed a repertoire bias 
among T cells isolated from obese adipose tissue compared with lean adipose tissue,   18 
suggestive of antigen driven T cell activation and expansion and/or infiltration (Yang et 
al., 2010; Winer et al., 2009; Feuerer et al., 2009). Closer analysis of adipose tissue-
resident  effector  CD4
+  T  cells  revealed  that  HFD  feeding  induced  a  Th1  T  cell 
phenotype, (Strissel et al., 2010; Winer et al., 2009) characterized by production of 
IFNγ.  A  proposed  model  suggests  that  during  development  of  obesity  there  is  a 
phenotypic activation of T cells from a Th2 state to a pro-inflammatory and pathogenic 
Th1  state  (Winer  et  al.,  2009)  leading  to  secretion  of  IFNγ  and  an  increase  in  M1 
macrophages. Indeed, there is a decrease of Gata3
+ CD4
+ T cells in adipose tissue of 
obese mice compared with lean controls; however the conclusion that these cells are 
Th2 cells is unsubstantiated. Additionally, isolated VAT CD4
+ T cells produced higher 
levels  of  IFNγ  isolated  from  obese  mice  than  from  lean  mice.  Increase  in  IFNγ 
expression levels led to accumulation of M1 macrophages in obese fat and elevated 
expression  of  TNFα,  RANTES,  and  MCP-1  (Rocha  et  al.,  2008).  Finally,  inflamed 
adipose  tissue  further  propagates  Th1  T  cell  polarization  through  the  production  of 
leptin,  which  can  act  on  T  cells  directly  and  indirectly  to  promote  increased 
proliferation and cytokine production, specifically IL-2 and IFN-γ (Lord et al., 1998). 
  In contrast to the aforementioned pro-inflammatory role of VAT CD4
+ T cells, 
one study proposed a protective role for effector CD4
+ T cells in ameliorating obesity-
associated  insulin  resistance  (Winer  et  al.,  2009).  In  this  study,  CD4
+ T  cells  were 
adoptively transferred into RAG-null mice leading to decreased body weight, fat pad 
mass,  and  improved  insulin  sensitivity.  The  authors  attributed  improved  metabolic 
parameters observed after the transfer of total CD4
+ T cells to the protective role of Th2   19 
CD4
+ T cells. An alternative interpretation of these results is that the improvement of 
metabolic parameters is due to lower body weight in the recipient mice and insulin 
sensitizing effect of Treg cells, which were not excluded from the transferred population. 
Under  lymphopenic  conditions  in  RAG-null  recipients,  CD4
+  T  cells  can  become 
activated and differentiate into Th2 cells, as suggested by the authors, but these T cells 
also differentiate into Th1 and Th17 subsets (Goldrath et al., 2004). Furthermore, a 
recent paper showed that VAT Treg cells are the dominant Gata3
+ population among 
VAT CD4
+ T cells (Cipolletta et al., 2012); therefore the loss of Gata3
+ CD4
+ T cells 
following  HFD  treatment  could  be  actually  due  to  loss  of  Treg  cells  in  abdominal 
adipose  tissue  and  cannot  be  equated  to  loss  of  Th2  cells.  Taken  together  the  data 
presented  in  this  paper  should  be  re-examined,  and  the  insulin-sensitizing  effects 
demonstrated in this study could be attributed in some cases to weight loss and in other 
cases to the protective effect of transferred Treg cells. 
Traditionally, activation of effector CD4
+ T cells proceeds via recognition of 
peptide  antigens  presented  by  MHC  class  II  molecules  on  the  surface  of  antigen-
presenting  cells,  such  as  dendritic  cells  and  macrophages,  in  combination  with 
engagement  of  costimulatory  molecules  and  polarization  by  cytokines.  In  adipose 
tissue, macrophages express high levels of MHC class II and costimulatory molecules, 
CD80 and CD86, all of which are further upregulated in response to HFD (Morris et al., 
2013). VAT macrophages were able to stimulate proliferation of antigen-specific CD4
+ 
T cells when cultured together. Adipose tissue macrophages can become activated by 
high  levels  of  retinol  binding  protein  4  (RBP4)  through  a  JNK-dependent  pathway   20 
leading to polarization of CD4
+ T cells toward the pro-inflammatory Th1 state (Moraes-
Vieira et al., 2014). Additionally, two studies have also attributed the expression of 
MHC  class  II  molecules  and  subsequent  activation  of  CD4
+  T  cells  to  adipocytes 
themselves (Deng et al., 2013; Meijer et al., 2011). It is an attractive idea that upon 
encountering stress adipocytes themselves are able to modulate effector T cells without 
the need for macrophage intermediates, especially since leptin, produced by adipocytes, 
can promote polarization of T cells towards the Th1 state (Lord et al., 1998). However, 
these studies did not definitively address the possibility of macrophage contamination in 
the adipocyte isolations and in vitro adipocyte differentiation (Charriere et al., 2003), 
which could offer an alternative interpretation of the data. 
In contrast to the pro-inflammatory effector T cells, CD4
+ Foxp3
+ Tregs reside in 
visceral adipose tissue (VAT Tregs) and are important regulators of VAT inflammation 
and insulin resistance (Feuerer et al., 2009; Cipolletta et al., 2012; Ilan et al., 2010; Eller 
et al., 2011; Deiuliis et al., 2011). Gene expression profiling of VAT Tregs revealed that 
they  expressed  ~60%  of  the  canonical  Treg  signature,  which  included  the  hallmark 
transcripts encoding Foxp3, CD25, CTLA-4, GITR, OX40, and IKAROS family zinc 
finger 2 (Ikzf2). Decreases in VAT Tregs in obesity during HFD treatment correlated 
with  increased  macrophage  and  monocyte  numbers  in  VAT.  Experimental 
manipulations of the total Treg pool led to “guilt-by-association” dissection of VAT Treg 
functions. Systemic depletion of Tregs using Foxp3
DTR quickly led to increases in VAT 
inflammation and impairment of insulin receptor signaling in adipose tissue, liver, and 
muscle.  Conversely,  in  vivo  Treg  expansion  using  IL-2/anti-IL-2  cytokine-antibody   21 
complexes led to improved glucose tolerance and insulin receptor signaling. Systemic 
depletion and expansion of Tregs, did not allow for specific interrogation of VAT Treg 
function in controlling adipose tissue inflammation and insulin sensitivity. However, 
gene expression profiling revealed that PPARγ is highly expressed specifically in VAT 
Foxp3
+ Tregs (Feuerer et al., 2009; Cipolletta et al., 2012) and is able to interact with 
Foxp3 (Cipolletta et al., 2012), which allowed for the specific interrogation of VAT 
Tregs. PPARγ stimulation by the thiazolidinedione drug pioglitazone (Pio) increased Treg 
cell numbers in VAT, but not in spleen, of obese mice on HFD, leading to improved 
insulin sensitivity. Finally, mice carrying a Treg-specific deletion of Pparg (Treg-Pparg 
mut mice), showed a drastic loss of VAT Tregs, leading to a reduction insulin sensitizing 
effects of Pio. The absolute requirement of PPARγ expression in VAT Tregs for proper 
control of adipose tissue inflammation and maintenance of insulin sensitivity can be 
thought of as an extension of the idea (discussed earlier) that Treg cells express key 
transcription factors of the inflammatory cells that are being suppressed. 
Taken  together  these  studies  point  to  a  complex  interaction  between  various 
immune  cell  types  that  are  modulated  in  response  to  changes  in  adipose  tissue 
homeostasis.  To  generalize,  the  overall  immune  cell  milieu  shifts  from  an  anti-
inflammatory composition (high levels of Tregs, Bregs, eosinophils, ILC2s, and M2-like 
macrophages) in lean VAT to a pro-inflammatory one (increased levels of CD8
+ T cells, 
Th1 cells, mast cells, neutrophils, M1-like macrophages) in obese VAT. (Figure 1.2).  
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Figure 1.2: Cellular and metabolic alterations in adipose tissue during obesity. In lean mice, the 
abdominal adipose tissue hosts anti-inflammatory macrophages, as well as an elevated fraction of Tregs. In 
obese mice, by contrast, there is a switch in cellular equilibrium: more CD8+ than Th1 CD4+ T cells, 
fewer regulatory T cells and a preponderance of pro-inflammatory macrophages. These effector cells 
promote inflammation and exacerbate adipose tissue dysfunction through the production of inflammatory 
cytokines. Taken from (Cipolletta et al., 2011) Copyright 2011 Elsevier Ltd. 
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Therefore,  given  the  importance  of  Tregs  in  suppression  of  a  variety  of 
inflammatory  responses  and  in  promoting  immune  homeostasis,  their  presence  in 
adipose tissue is critical for protection from adipose tissue inflammation and insulin 
resistance. Interestingly, VAT Tregs accumulate with age in lean mice to frequencies 
>50% of the VAT-resident CD4
+ T cells, which is a much larger fraction than the ~10-
20% found in lymphoid and non-lymphoid tissues, including the subcutaneous adipose 
depots. This degree of expansion of Tregs was quite striking and warranted a closer 
examination. 
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Chapter  2:  Accumulation  of  Foxp3
+  regulatory  T  cells  in  lean  visceral  adipose 
tissue  results  from  MHC  class  II-dependent  clonal  proliferation  and  long-term 
persistence. 
 
Introduction 
 
VAT Tregs accumulate with age in lean mice despite significant increases in body 
and adipose tissue weights. The age-associated accumulation of VAT Tregs is intriguing 
because changes specifically in visceral, but not subcutaneous, fat depots have been 
implicated in insulin resistance. Furthermore, Treg-Pparg mut mice had a decrease in 
numbers  of  Treg  cells  exclusively  in  VAT  even  in  the  absence  of  HFD  challenge, 
highlighting  the  requirement  of  PPARγ  for  VAT  Treg  recruitment,  retention,  and/or 
survival. We wanted to more carefully characterize the dynamics and the mechanism of 
VAT Treg accumulation in lean adipose tissue. A deeper understanding of the underlying 
VAT Treg cell biology could provide insights into what causes the loss of VAT Tregs 
during HFD diet and leads to the over-exuberant inflammatory response in VAT. 
The majority of Tregs differentiate in the thymus as a subset of the total CD4SP 
population (tTregs). However, a small fraction can differentiate in the periphery from 
mature  Tconv  cells  under  a  variety  of  conditions  pTregs  (reviewed  extensively  in 
(Josefowicz et al., 2012a) and (Bilate and Lafaille, 2012)), and were shown to play key 
roles in controlling inflammation in variety of tissues such as lung, gut, and decidua 
(Josefowicz et al., 2012b; Samstein et al., 2012b).   25 
In addition, studies using Tregs carrying transgene-encoded TCRs showed that 
Tregs  proliferated  in  tissues  to  control  the  inflammatory  response  in  an  antigen-
dependent manner (Rosenblum et al., 2011; Malchow et al., 2013; Seneschal et al., 
2012). Similarly, the TCR repertoire of VAT Treg cells from lean mice was distinct from 
that  of  VAT  Tconvs,  as  well  as  that  of  Treg  and  Tconv  cells  isolated  from  secondary 
lymphoid  tissues,  which  suggested  a  degree  of  antigenic  imprinting  (Feuerer  et  al., 
2009).  Furthermore,  there  were  several  examples  of  VAT  Treg  cells  with  the  same 
protein sequence and different nucleotide sequences in the CDR3 region, the region 
most responsible for interaction with peptide-MHC complexes.  
Finally, Tregs can also migrate to sites of inflammation in order to suppress the 
immune  response  via  a  process  that  is  governed  by  the  specific  combinations  of 
chemotactic molecules and their receptors. Previous studies showed that monocytes and 
macrophages could be recruited to VAT by chemokine- and receptor-mediated fashion, 
for example via recognition of MCP-1 produced in VAT by CCR2 on monocytes and 
macrophages (Kanda et al., 2006; Weisberg et al., 2006). VAT Tregs expressed high 
levels of several chemokine receptors, including CCR2, which correlated with PPARγ 
expression (Cipolletta et al., 2012). Additionally, a number of other transcripts that were 
under-  and  over-expressed  in  VAT  Tregs  were  molecules  involved  in  leukocyte 
migration and extravasation. 
Therefore, we hypothesized that the accumulation of Tregs in lean VAT could 
result from local conversion of Tconv cells into pTregs, in situ proliferation of resident Treg   26 
cells,  recruitment  of  Tregs  from  the  lymphoid  organs  and  circulation,  or  some 
combination of the aforementioned mechanisms. 
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Materials and Methods: 
 
Mice 
C57BL/6 mice were purchased from Jackson Laboratories. Foxp3
DTR, Foxp3
iGFP, and 
Kaede.B6  mice  were  obtained  from  A.  Rudensky,  V.  Kuchroo,  and  O.  Kanagawa, 
respectively. Male mice of specified ages were used for all of the studies. All mice were 
bred in our specific pathogen-free facilities at Harvard Medical School. Experiments 
were conducted under protocols approved by Harvard Medical School’s Institutional 
Animal Care and Use Committee. 
 
Cell isolation 
Epididymal fat pads and spleens were excised, cut into small pieces, and digested for 20 
minutes with 1.5 mg/ml of collagenase type II (Sigma) in PBS supplemented with 1% 
fetal calf serum. Cell suspensions were then filtered through a 40-micron sieve, and the 
SVF fraction was collected after centrifugation at 450g for 10 min.  
 
Flow cytometry 
For T-cell analysis, cells were stained with varying combinations of anti-CD45 (clone 
30-F11),  -CD45.1  (A20),  -CD45.2  (104),  -CD3  (145-2C11),  -CD4  (GK1.5),  -CD8 
(5H10),  and  -CD25  (PC61)  antibodies  (Biolegend),  anti-Nrp1  (R&D)  and  -ST2 
(RMST2-2) (eBiosciences); and were fixed, permeabilized and intracellularly stained 
for Foxp3 (FJK-16s), Ki67, BrdU (Bu20A), Helios, and GATA3 (TWAJ) according to   28 
the manufacturer’s instructions (eBiosciences); when using Foxp3
iGFP mice endogenous 
GFP  expression  was  used.  Cells  were  analyzed  using  an  LSRII  instrument  (BD 
Bioscience) and FlowJo software. 
 
Kaede.B6 photoconversion 
Mice were anesthetized with ketamine/xylazine in combination (10 mg/kg/2 mg/kg ip). 
The fur attached to the skin covering the CLNs was removed using depilatory cream, 
applied for 2 mins. Mice were placed on their backs with an aluminum foil blanket 
covering all but the depilated area, and violet light (Electra Pro Series 405 nm Violet 
Handheld Laser, Laserglow Technologies) was shone onto the exposed area for a period 
of 3.5 mins, the pre-established time for effective but innocuous photoconversion at this 
anatomical site. In order to manipulate the size of the light field (beam diameter: 3.5 
mm) so that both CLNs could be exposed, we attached a lens to the laser to de-focus the 
beam, and the source of the de-focused light beam was positioned 28cm above the 
mouse. 
 
Thymectomy 
Mice were anesthetized with ketamine/xylazine in combination (10 mg/kg/2 mg/kg ip). 
The fur attached to the skin covering the CLNs was removed using depilatory cream, 
applied  for  2  mins.  An  incision  was  made  cutting  the  first  3  ribs  and  thymus  was 
excised using forceps. Skin was closed and secured with 2-3 clips.  
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Parabiosis surgery 
Mice were anesthetized with 2.5% avertin (15 µl per g of body weight). Mice were 
shaved along opposite lateral flanks. Skin was wiped with alcohol prep pads and further 
cleaned with Betadine solution and 70% isopropyl alcohol. Mirrored incisions were 
made  on  lateral  aspects  of  both  mice,  and  ventral  and  dorsal  skin  flaps  were 
approximated by staples to conjoin the mice. Additional sutures were placed through 
the  olecranon  and  knee  joints  to  secure  the  legs.  In  some  cases,  thymectomies 
(described above) were performed just prior to parabiosis surgery. 
 
Intrathymic injections 
Mice  were  anesthetized  with  ketamine/xylazine  in  combination  and  given  an 
intrathymic injection of 10 µl of a 5 mg/ml solution of sulfo-NHS-LC biotin (Pierce 
Chemical Co.) per lobe. 24 hours later thymus, epididymal fat pads and spleen were 
isolated,  processed  for  staining  (described  above)  and  stained  with  streptavidin-
conjugated PE and other markers for analysis by flow cytometry. 
 
Transfers 
5 x 10
6 CD4
+Foxp3
- Tconv cells or 1 x 10
6 CD4
+Foxp3
+ Treg cells were sorted from 
pooled spleens and LN of CD45.1 Foxp3
iGFP mice and transferred i.v. into 20-week old 
CD45.2 Foxp3
iGFP recipient mice. Recipient mice were sacrificed 4 weeks after transfer 
and LN, spleen, and epididymal fat pads were isolated and analyzed by flow cytometry.  
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BrdU incorporation 
5-bromo-2’-deoxyuridine powder (Sigma) was added to the drinking water (0.8 mg/mL) 
and protected from light. BrdU in water was changed every 2 days for 5 weeks. 
 
Single-cell sorting, RT-PCR and TCR sequence analysis 
CD4
+Foxp3
+ and CD4
+Foxp3
- T cells from VAT and LN of 25-30-week old Foxp3
iGFP 
mice were first sorted in bulk before resorting as individual cells on MoFlo (Beckman 
Coulter) into wells of 96-well PCR plates containing the reverse transcriptase reaction 
mix and cDNA was prepared as described by (Wong et al., 2007). Extreme caution was 
taken to minimize PCR and cross-contamination between wells. Preparation of reverse 
transcriptase reaction mix, cDNA synthesis, and first round of PCR was performed in a 
different building from second round PCR and final PCR product isolation. At least 2 
columns  of  every  plate  were  left  blank  for  negative  controls  to  monitor  for 
contamination. Experiments showing evidence of PCR contamination were discarded. 
Resulting cDNA (1.5 µl) from each cell was split to perform multiplex nested PCR 
reactions  to  amplify  the  corresponding  CDR3α  and  CDR3β  transcripts  using  the 
protocol and CDR3β primers published in (Baker et al., 2002). Primers used to amplify 
CDR3α were designed based on nucleotide sequences of the TCRα families from the 
IMGT  database  (http://www.imgt.org;  (Brochet  et  al.,  2008)).  Aliquots  of  the  PCR 
products were visualized on a 1.5% agarose gel. Samples containing PCR product for 
both TCRα and TCRβ chains were cleaned up using ExoSAP-IT For PCR Clean-Up 
(Affymetrix) per manufacturers protocol and were subjected to automated sequencing   31 
(Dana-Farber/Harvard  Cancer  Center  High-Throughput  Sequencing  Core).  Raw 
sequencing files were filtered for sequence quality, processed in automated fashion, and 
parsed using IMGT/V-QUEST (Brochet et al., 2008). Only sequences that produced 
functional  in-frame  rearrangements  of  both  TCRα  and  TCRβ  chains  were  used  for 
analysis. 
 
EdU labeling 
For quantification of in vivo T cell proliferation, 1mg EdU was injected iv, and 4hrs 
later  cells  were  processed  for  detection  by  the  Click-iT  EdU  kit  following 
manufacturer’s protocol (Molecular Probes).  
 
Diptheria toxin administration for in vivo Treg depletion 
Foxp3
DTR+ mice and Foxp3
DTR- control littermates were injected ip with DT (Sigma), at 
10 ng/g body weight, for 2 consecutive days. 
 
IL-33 administration 
Mice were injected ip with recombinant IL-33 (Biolegend), at 2 µg per injection every 3 
days for 1 week prior to analysis. 
 
Statistical analyses 
Data were routinely presented as means ± S.D., significance assessed by the Student's t 
test or ANOVA using Prism 5 (GraphPad Software). A P value of <0.05 was deemed 
statistically significant. * p<0.05, ** p<0.01, *** p<0.001   32 
Results 
None of the pTreg hallmarks observed among VAT Tregs  
 
Currently  there  are  no  accepted  markers  to  definitely  distinguish  tTregs  and 
pTregs; however, low or negative expression of Ikzf2 (Helios) (Thornton et al., 2010; 
Verhagen and Wraith, 2010; Akimova et al., 2011) and of Neuropilin-1 (Nrp1) (Yadav 
et al., 2012; Weiss et al., 2012) are characteristic of pTregs. We looked at expression of 
Nrp1 and Helios among Tregs from the spleen, subcutaneous lymph nodes (LN), and 
VAT of 15- (early phase of accumulation) and 25- (peak of accumulation) week old 
mice. VAT had significantly lower levels of Helios
- Tregs (Figure 2.1A) and similar 
frequencies of Nrp1
- Tregs (Figure 2.1B) compared with Tregs residing in the spleen and 
lymph nodes.  
To  directly  address  whether  Foxp3
-CD4
+  Tconv  cells  could  turn  on  Foxp3 
expression in adipose tissue to become pTregs, we performed a transfer experiment. We 
sorted Foxp3
- Tconvs from a reporter mouse line, where an internal ribosomal entry site 
followed by a gene encoding green fluorescent protein (GFP) were inserted downstream 
of the internal stop codon of the Foxp3 gene (Foxp3
iGFP). Sorted CD45.1 Foxp3
- Tconv 
cells were transferred into lean congenic CD45.2 recipients. Four weeks after transfer, 
we  consistently  saw  a  very  small  population  (~0.04%  of  total  Foxp3
+  Tregs;  ~787 
cells/spleen and ~52 cells/LN) of donor Foxp3
+ pTregs in spleen and LN, but we did not 
detect converted pTregs among Tregs in VAT in any of the recipient mice from multiple 
independent transfer experiments (Figure 2.1C).    33 
 
 
Figure 2.1: No hallmarks of pTregs observed among VAT Tregs.  
(A, B) Representative flow cytometry plots of Helios (A, left) and Nrp1 (B, left) expression among CD4
+ 
Foxp3
+  Tregs  isolated  from  LN,  spleen,  and  VAT  of  15  and  >25  week  old  mice.  Quantification  of 
frequency of Helios
- (A, right) and Nrp1
- (B, right) cells as a percentage of total Tregs. n = 4 for each age; 
pooled data from 2 independent experiments. 
(C) Foxp3
- Tconv cells from spleens and LN of CD45.1 Foxp3
iGFP mice were transferred i.v. into CD45.2 
Foxp3
iGFP recipient mice. Representative flow cytometry plots from LN and VAT of recipient mice (top) 
and quantification of donor pTregs as a percentage of total Foxp3
+ Tregs (bottom left) and as total number of 
cells recovered per organ (bottom right). n = 9; pooled data from 3 independent experiments. 
All plots show means and standard deviations. 
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To further evaluate the contribution of pTregs to the total VAT Treg population, 
we  used  gene  expression  profiles  from  various  pTreg  populations  that  have  been 
previously  generated  in  our  lab  and  were  used  to  define  unbiased  gene  expression 
“signatures”  for  those  pTreg  subsets  (Feuerer  et  al.,  2010).  We  chose  to  generate 
signatures of pTregs from two models of in vivo conversion and from in vitro induced 
Tregs  (iTregs).  In  the  first  in vivo  model,  Foxp3
+  cells  were  generated  by  low  dose 
administration of antigen, delivered to dendritic cells (DCs) by recombinant anti-DEC-
205 antibodies fused to the influenza hemagglutinin (HA) peptide (Kretschmer et al., 
2005) (referred to as “DEC205 pTregs”). In the second model, conversion of naïve CD4
+ 
Tconvs was achieved by transferring them into RAG-null mice, where the lymphopenic 
environment resulted in expression of Foxp3 in 5-10% of transferred cells (Haribhai et 
al., 2009) (referred to as “RAG-transfer pTregs”). Finally, we also used iTregs, which 
were generated from Tconv cells that were activated in vitro in the presence of IL-2 and 
TGFβ (Chen et al., 2003)  (referred to as “TGFβ iTreg”). 
We used the fold-change/fold-change (FC/FC) plots to compare gene expression 
profiles from pTreg and Tconv cells from the same experiments (on the x-axis) versus ex 
vivo LN Treg and Tconv cells (on the y-axis). This allowed us to exclude genes from the 
signatures  that  were  differentially  expressed  due  to  experimental  manipulations  for 
generation of pTregs (Figure 2.2A). We did not observe enrichment of any of the pTreg 
signatures in VAT versus LN Treg cells (Figure 2.2B). Taken together these data argue 
that generation of pTregs from mature Tconv cells accounts for very few, if any, VAT Treg   35 
 
Figure  2.2:  Generation  of  pTreg  signatures  and  analysis  of  VAT  Tregs  for  enrichment  of  pTreg 
signatures 
(A)  Schematic  representation  of  the  strategy  used  to  generate  pTreg  signatures  Left:  FC/FC  plots 
comparing vis-à-vis gene expression profiles from pTregs versus corresponding Tconvs (x-axis) and ex vivo 
isolated LN Tregs versus Tconvs (y-axis). Differentially expressed genes (> 2 fold) up-regulated (red) or 
down-regulated (blue) in were selected. Middle: genes highlighted (from left panel) on a plot comparing 
normalized expression values of LN Tregs and pTregs. Right: genes that were > 1.5 fold up- or down-
regulated represented the pTreg signature. 
(B)  Volcano  plots  comparing  VAT  versus  LN  Tregs  isolated  from  30-week  old  mice  (in  triplicate). 
Indicated signatures were overlaid on each plot. P values were generated using chi-squared test. 
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cells and therefore is not the primary mechanism underlying accumulation of Tregs in 
lean VAT. 
 
Minimal recruitment and retention of Tregs from lymphoid organs and circulation 
in VAT 
 
Kaede  transgenic  (Kaede.B6)  mice  (Tomura  et  al.,  2008)  express  a 
photoconvertible fluorescent protein, Kaede, in all cells under the control of β-actin 
promoter/enhance  elements.  Upon  transcutaneous  exposure  to  violet  light,  Kaede 
irreversibly changes in color from green to red, thereby “photo-tagging” (Kaede-Red) 
the cells present at the site of photoconversion in a minimally perturbant way, and 
allows for tracking of Kaede-Red cells in peripheral tissues using flow cytometry. We 
tracked the migration of Tregs from the cervical LN (CLN) to the VAT and the other 
peripheral  LNs  24,  48,  and  72  hours  following  photoconversion  (Figure  2.3A). 
Consistent  with  previous  findings  from  our  laboratory  (data  not  shown),  Tregs  were 
slower than Tconvs in their egress from the LN (Figure 2.3B); however, the majority of 
Kaede-Red Tregs had egressed from the CLN by 24 hours after photoconversion. We 
then  looked  for  Kaede-Red  Tregs  in  two  compartments:  the  inguinal/auxillary  LNs 
(iLN/aLN) and the VAT. The iLN/aLN reflected the circulating Treg pool among the 
secondary lymphoid organs, which served as a benchmark against which to measure the 
migration of Treg to VAT. Kaede-Red Tregs preferentially recirculated to other lymphoid 
organs, as evidenced by a 2-3-fold higher frequency of Kaede-Red Tregs in the iLN/aLN   37 
 
 
 
Figure 2.3: Steady-state migration of LN Tregs to VAT and other LN. 
(A) Experimental setup and representative flow cytometry plots of CD4
+ T cells isolated from CLN, 
aLN/iLN, and VAT immediately after (0 hr) and 24, 48, and 72 hours after photoconversion. 
(B) Frequency of Kaede-Red
+ Tregs and Tconvs immediately after photoconversion (0hr) and after egress at 
24, 48, and 72 hours after photoconversion. 
(C) Frequency of Kaede-Red
+ cells as a percentage of total Tregs in VAT and iLN/aLN at indicated time 
points after photoconversion. 
(D) Migration of Tregs and Tconvs to VAT as a ratio of analogous populations migrating to iLN/aLN at 
indicated time points after photoconversion. 
(E) Frequency of Kaede-Red
+ cells as a percentage of total Tregs in VAT and iLN/aLN 24 and 72 hours 
after photoconversion in 16- and 24- week old mice. 
All data are n= 6-10 from 2-3 independent experiments. All plots show means and standard deviations.  
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compared with the VAT (Figure 2.3C). It is important to point out that a small fraction 
of  Tregs  was  indeed  able  to  migrate  from  the  CLN  to  the  VAT  at  steady-state. 
Additionally, there were no changes in frequencies of Kaede-Red Tregs in the iLN/aLN 
or the VAT throughout the 72-hour experimental window (Figure 2.3C). To further 
assess  the  selective  migration  of  Kaede-Red  Tregs  to  the  VAT,  we  quantified  the 
frequency  of  Kaede-Red  Tregs  and  Tconvs  in  the  VAT  compared  with  analogous 
populations in the iLN/aLN (migration ratio). On average, Kaede-Red Tregs migrated 
preferentially  to  the  iLN/aLN  (migration  ration  <  1);  however,  in  some  individual 
animals  Kaede-Red  Treg  migration  to  the  VAT  was  preferred  (migration  ratio  >  1) 
(Figure 2.3D). We did not observe any differences in preferential migration between 
Tregs and Tconvs to the VAT compared with iLN/aLN (Figure 2.3D). Finally, we looked 
at the effect of age on Treg migration to the VAT by comparing mice at 16 and 24 weeks 
of age. Again, we did not observe any significant effects of age in migration of Kaede-
Red Tregs to the iLN/aLN and the VAT in the two age groups (Figure 2.3E). 
The  Kaede.B6  model  allowed  us  to  study  the  Treg  migration  at  steady  state; 
however, longer term studies were technically challenging, due to turnover or dilution 
of the photoconverted Kaede protein. We hypothesized that the small fraction that is 
able to migrate from the LN to the VAT might be able to accumulate given enough time 
and  account  for  a  larger  fraction  of  the  total  VAT  Treg  pool.  To  supplement  our 
Kaede.B6 studies with longer term migration experiments, we transferred Foxp3
+ Tregs 
sorted from LN and spleens of CD45.1 Foxp3
iGFP mice into lean, congenic CD45.2 
Foxp3
iGFP  recipients.  After  4  weeks,  Tregs  in  the  spleen  and  LN  contained  a  small   39 
fraction of transferred Tregs; however, this fraction was significantly lower and virtually 
unditectable  in  the  VAT  (Figure  2.4A).  These  findings  were  in  line  with  the 
observations  made  with  Kaede.B6  mice,  suggesting  that  Tregs  from  LN  and  spleen 
preferentially  migrate  back  to  lymphoid  organs  and  do  not  accumulate  to  a  large 
fraction of VAT Tregs. 
We wanted to investigate the effects of continuous Treg migration on the total 
VAT Treg pool over an extended period of time. For these studies, we conjoined CD45.1 
mice  with  CD45.2  partners  by  parabiosis  for  4  to  6  weeks,  which  allowed  cells  to 
circulate between the two animals and reach an equilibrium. We found that the Tregs in 
the spleen had equilibrated between the partners (chimerism of 39.8±4.2% after 4 weeks 
and  42.9±8.3%  after  6  weeks),  but  the  level  of  chimerism  was  significantly  lower 
among VAT Tregs (chimerism of 17.2±5.8% after 4 weeks and 23.9±5.8% after 6 weeks) 
(Figure 2.4B), signifying that the majority of the VAT Treg pool was composed of non-
circulating  cells.  Furthermore,  there  were  no  significant  differences  in  chimerism 
among Tregs, in either the spleen or the VAT, among pairs of mice that were conjoined 
for  4  or  6  weeks  (Figure  2.4B),  which  suggested  that  the  observed  differences  in 
chimerism between VAT and spleen Tregs were stable overtime.  
In summary, short- and longterm migration studies argue that although a few 
Tregs can migrate from spleen and LN to VAT at steady-state, those cells account for 
only a small fraction of the total VAT Treg pool and are not able to account for the total 
VAT Treg accumulation over time. 
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Figure 2.4: Circulating Tregs do not accumulate in VAT over time 
(A) CD4
+Foxp3
+ Treg cells were sorted from spleens and LN of CD45.1 Foxp3
iGFP mice and transferred 
i.v. into CD45.2 Foxp3
iGFP recipient mice. Representative flow cytometry plots of CD4
+ T cells from LN 
and VAT of recipient mice (left); quantification of donor Tregs expressed as a percentage of total Foxp3
+ 
Tregs (right). n = 7; pooled data from 3 independent experiments 
(B) Schematic representation of parabiosis experiments: CD45.1 and CD45.2 mice were joined together 
for 4 or 6 weeks (left). Chimerism of Tregs in spleen and VAT (right). Chimerism = % donor / (% donor + 
% host). n = 6-8 for each length of parabiosis; pooled data from 2 independent experiments. 
All plots show means and standard deviations. ** p<0.01, *** p<0.001 
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VAT Tregs have similar proliferative capacity, but lower turnover compared with 
splenic Tregs 
 
  Recruitment of circulating Tregs and conversion of Tconvs into pTregs were minor 
contributors to the accumulating VAT Treg pool. We therefore hypothesized that in situ 
proliferation of Tregs in the VAT may be the dominant mechanism. Accumulation of a 
cell population in a given location could be a result of increased rate of proliferation or, 
conversely, decreased turnover rate. We first tested whether VAT Tregs have a higher 
proliferative capacity compared with splenic Tregs. EdU (5-ethynyl-20-deoxyuridine), 
incorporated by cells in S phase, was detected in similar fractions of Tregs in VAT and 
spleen after 4 hours of labeling, regardless of age (Figure 2.5A). Consistent with data 
from EdU-labeling experiments, we detected Ki67, which is expressed in all stages of 
the cell cycle except for the resting, G0, phase, in comparable fractions among Tregs 
from VAT and spleen (Figure 2.5B). Taken together, these data suggested that VAT 
Tregs did not possess an increased proliferative rate that would account for their ability to 
accumulate. 
  Since VAT and spleen Tregs had similar proliferation rates, we measured their 
turnover  using  long-term  bromodeoxyuridine  (BrdU)  incorporation  followed  by  a 
BrdU-free chase. Mice were given BrdU in their drinking water for 5 weeks, starting at 
15 weeks of age, to stably label the pool of dividing cells. There were no differences in 
the rate or extent of BrdU incorporation between VAT and splenic Tregs, paralleling our 
findings  using  EdU  and  Ki67  (Figure  2.5C  left  panel).  After  5  weeks,  BrdU  was   42 
 
Figure 2.5: VAT Tregs have similar proliferative capacity, but lower turnover compared with splenic 
Tregs 
(A)  EdU  uptake  by  T  cells  in  spleen  and  VAT  of  15-  and  30-week  old  mice.  Representative  flow 
cytometry plots; frequencies indicate %EdU
+ among Tregs (top) or Tconvs (bottom). 
(B) Quantification of Ki67 expression by T cells in spleen and VAT of 15- and 30-week old mice as a 
percentage of Foxp3
+ Tregs. 
(C) BrdU incorporation and chase experiment: schematic representation of experimental protocol (top). 
Quantification of BrdU
+ as a percentage of Foxp3
+ Tregs in spleen and VAT of mice analyzed on indicated 
days (bottom left). Quantification of remaining BrdU
+ Foxp3
+ Tregs in spleen and VAT of mice analyzed 
on indicated days as a percentage of the starting BrdU
+ Foxp3
+ Treg pool on day 0 of chase (bottom right). 
Exponential decay line was fitted to each data set; equation, R
2 value, and half-life are presented (bottom 
right) 
All data are n= 5-10 from 2-3 independent experiments. All plots show means and standard deviations.  
** p<0.01, ***p<0.001 
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removed from the drinking water, which allowed us to measure the loss of BrdU
+ Tregs 
from  VAT  due  to  egress,  cell  death,  or  both.  We  found  that  VAT  Tregs  persisted 
significantly longer than spleen Tregs, evidenced by a higher fraction of the initial BrdU
+ 
Treg pool remaining in VAT compared with the spleen (Figure 2.5C right panel). The 
calculated half-life for VAT Tregs was 24.5 days compared with half-life of 10.8 days for 
spleen Tregs and a half-life of 16.5 days for VAT Tconvs, which would account for the 
increase in VAT Treg frequency over time. Taken together our findings indicate that 
although Tregs proliferate at the same rate in the VAT and the spleen, VAT Tregs have a 
much slower rate of turnover, thereby allowing them to accumulate over time. 
 
VAT Tregs are clonally expanded and display a unique TCR repertoire 
 
  We analyzed the complementarity-determining region (CDR) 3 of the TCRα 
and  TCRβ  chains  on  a  single-cell  level  in  order  to  assess  the  clonality  of  the  Treg 
populations in VAT and LN of 25-30 week old mice (Figure 2.6). This analysis allowed 
us to determine the contribution of the progeny originating from a single precursor to 
the overall VAT Treg population and also to look for similarities in TCR repertoires 
between Tregs in the VAT and LN.  
  Consistent  with  the  idea  of  a  proliferation-driven  accumulation,  we  found  a 
striking degree of clonal expansion among VAT Tregs, with as much as ~77% of all TCR 
sequences among VAT Tregs of an individual mouse derived from clonally expanded 
populations, with individual clones accounting for up to ~30% of the total repertoire   44 
 
 
 
 
Figure 2.6: Schematic representation of single-cell TCR sequencing protocol 
Individual Treg or Tconv cells from VAT and LN were sorted into 96-well plates containing master mix for 
cDNA synthesis using TCRα and β constant region primers; cDNA was split in half and two rounds of 
nested multiplex PCR were used to separately amplify the TCRα and TCRβ CDR3 regions. Final PCR 
product was submitted for sequencing. 
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(Figure 2.7A). This observation was in stark contrast to VAT Tconvs and LN Tregs (Figure 
2.7B-D),  where  we  found  very  few  sequences  that  repeated  more  than  one  time. 
Furthermore, we did not find a single instance of sequence overlap between VAT Tregs 
and Tconvs, consistent with previously reported sequencing results using mice with a 
genetically restricted TCR repertoire (Feuerer et al., 2009). Additionally, we did not 
find any sequences that were shared between LN and VAT Tregs highlighting the unique 
nature  of  the  TCR  repertoire  among  VAT  Tregs.  The  total  frequency  of  clonally 
expanded VAT Tregs directly correlated with the total frequency of VAT Tregs among 
VAT CD4
+ T cells (Figure 2.7E). Finally we did not detect any bias in the lengths of 
CDR3 loops (Figure 2.7F) nor the N-region length (data not shown) among the TCRs 
from clonally expanded VAT Tregs or total VAT Tregs compared with TCRs from LN 
Tregs,  arguing  that  VAT  Treg  differentiation  occurred  postnatally  when  terminal 
deoxynucleotidyl transferase (TdT) expression in the thymus was upregulated (Bogue et 
al., 1992).  
  In  summary,  the  VAT  Treg  TCR  repertoire  is  restricted,  with  a  few  clones 
expressing particular TCRs being able to proliferate and expand to account for as much 
as  30%  of  all  TCRs  among  VAT  Tregs.  In  addition,  the  absence  of  shared  TCR 
sequences  between  VAT  Tregs  and  VAT  Tconvs  as  well  as  LN  Tregs,  highlights  the 
distinctive nature of the VAT Treg TCR repertoire. 
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Figure 2.7: VAT Tregs are clonally expanded and display a unique TCR repertoire 
(A - C) TCR CDR3α and CDR3β sequences for individual cells. (A) VAT Tregs, (B) VAT Tconvs, and (C) 
LN Tregs. Each pie chart represents a single mouse. n, number of analyzed sequences per mouse. Total 
frequency of expanded clones shown at the top right. 
(D) Quantification of clonal TCR frequencies among the examined T cell subsets. Mean and standard 
deviation are plotted. Sequences obtained from n = 3-6 individual mice  
(E) Correlation between frequency of Foxp3
+ Tregs (% of CD4
+ T cells) and total frequency of repeated 
TCRs in each individual. R
2 value and p value generated using linear regression. 
(F)  Length  of  CDR3α  and  β  amino-acid  sequences  in  indicated  populations.  n,  numbers  of  unique 
sequences in each indicated population. 
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Minimal contribution of adult thymus to Gata3
+ VAT Treg pool 
 
  The  extent  of  clonality  that  was  present  among  VAT  Tregs  suggested  that  a 
“seeding” population of Tregs might infiltrate the VAT shortly after birth and proliferate 
in situ over a long period of time. This led us to hypothesize that thymic differentiation 
of Tregs in adult mice would not be required for VAT Treg accumulation. We performed 
thymectomy (Thx) experiments in mice at 3, 6, and 13.5 weeks of age, just prior to 
VAT Treg accumulation, and let the mice age until the peak of expansion at 25 weeks of 
age.  Consistent  with  the  idea  that  VAT  Treg  accumulation  occurs  primarily  due  to 
proliferation, we did not see any differences in VAT Treg expansion in mice Thx at 13.5 
weeks of age (Figure 2.8A-C). Interestingly, Thx as early as 3 weeks of age also did not 
abrogate the expansion of VAT Tregs (Figure 2.8A-C). 
  PPARγ is required for VAT Treg accumulation and for the ability of these cells to 
control  adipose  tissue  inflammation.  Previous  studies  demonstrated  that  Gata3 
expression correlated with PPARγ expression in VAT Tregs, and treatment with a PPARγ 
antagonist led to a specific loss of Gata3
+ VAT Tregs (Cipolletta et al., 2012). There is 
currently no reliable way to detect expression of PPARγ  by flow cytometry, so for the 
following studies we decided to use Gata3 as a surrogate marker for the expression of 
PPARγ. We wanted to confirm that the Tregs that accumulated in the VAT after Thx 
were bona fide VAT Tregs. Indeed we did not see any differences in frequency of Gata3
+ 
Tregs in the VAT of Thx animals compared with sham controls (Figure 2.8D). 
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Figure 2.8: Minimal contribution of adult thymus to Gata3
+ VAT Treg pool 
(A) Schematic representation of thymectomy (Thx) experiments (top) and representative flow cytometry 
plots from VAT and spleens of Thx and sham surgery mice analyzed at 25 weeks of age (bottom). 
(B - D) Quantification of (B) frequency of Foxp3
+ (% of CD4
+ T cells), (C) total numbers of Foxp3
+ Tregs 
(# per gram of adipose tissue), and (D) frequency of Gata3
+ (% of Foxp3
+ Tregs) in VAT described in (A). 
All data are n= 5-10 from 2-3 independent experiments. All plots show means and standard deviations.  
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  Experiments with Thx mice showed that VAT Tregs can expand in the absence of 
an adult thymus, but it did not allow for the dissection of the contribution of the thymus 
to the total VAT Treg pool throughout the expansion phase. To address this question we 
conjoined Thx mice with sham surgery (Sham) partners at 13.5 weeks of age for 4 
weeks (Figure 2.9A). Since there was only one thymus in each parabiotic pair, the 
differences in chimerism among Treg populations between the two partners would reflect 
the  contribution  of  tTregs  that  differentiated  during  the  course  of  the  experiment. 
Consistent  with  our  hypothesis,  the  Thx  partner  had  significantly  higher  level  of 
chimerism among Tregs in the spleen (44.9±4.3% in Thx vs 33.2±3.2% in Sham) (Figure 
2.9B), suggesting that the decreased chimerism in Sham partner reflected the lack of 
contribution of recent thymic emigrants (RTEs) to the splenic Treg pool. Similarly we 
observed a significant decrease in overall chimerism among VAT Tregs (18.1±9.4% in 
Thx vs 8.1±4.9% in Sham) (Figure 2.9C), suggesting a significant infiltration of RTE 
Tregs into VAT. However, a closer analysis of the chimerisms among Gata3
+ and Gata3
- 
VAT Treg subsets revealed that there was a significant increase in chimerism among 
Gata3
-  VAT  Tregs (Figure  2.9D);  however,  among  Gata3
+  Tregs  we  did  not  detect  a 
significant increase in chimerism, although a trend indicating a differential was evident 
(Figure 2.9E). These data suggest that VAT Tregs are composed of two population: a 
dynamic Gata3
- Treg population composed in part of cells coming from the thymus and 
circulation, and a more stable Gata3
+ Treg population that is probably composed of bona 
fide VAT Tregs.  
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Figure 2.9: Adult thymus contributes to dynamic Gata3
- VAT Treg pool 
(A)  Schematic  representation  of  parabiosis  pairs:  thymectomy  or  sham  surgeries  were  performed  on 
CD45.1 and CD45.2 mice just prior to parabiosis; pairs were conjoined for 4 weeks before analysis. 
(B) Quantification of chimerism among Tregs from the spleen. 
(C-E) Quantification of chimerism among (C) total VAT Tregs, (D) Gata3
- VAT Tregs, and (E) Gata3
+ 
VAT Tregs. 
All data are n= 8 parabiosis pairs from 2 independent experiments. All plots show means and standard 
deviations. ** p<0.01, *** p<0.001 
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  These findings indicate that the bona fide VAT Treg population, identified by the 
expression  of  Gata3,  is  seeded  in  the  VAT  at  an  early  age  and  remains  minimally 
infiltrated by circulating Tregs and RTE Treg cells. 
 
Ability of adult thymus to repopulate VAT Treg compartment is age-dependent 
 
  One explanation for the minimal contribution of RTEs to the Gata3
+ VAT Treg 
pool  in  adult  mice  is  that  the  “VAT  Treg  niche”  (a  hypothetical  combination  of 
availability of presented-antigen, prosurvival factors, co-stimulatory molecules, etc.) is 
already completely occupied by resident Tregs, thereby preventing RTEs from being able 
to be retained or to survive in the VAT. Therefore, we wanted to directly test the ability 
of adult RTEs to seed the VAT at different ages by transiently depleting the VAT Treg 
“niche”. We treated Foxp3
DTR mice of varying ages with 2 daily injections of diphtheria 
toxin (Dtx) to punctually ablate Tregs systemically for a very brief period of time, in 
order to avoid development of autoimmune pathology. The mice were allowed to age 
until  25  weeks  of  age,  at  which  point  we  assessed  the  accumulation  of  VAT  Tregs 
(Figure 2.10A). Foxp3
DTR mice treated with Dtx at 16 days or 3-5 weeks of age had the 
same frequency of total Tregs (Figure 2.10B) and Gata3
+ Tregs (Figure 2.10C) as Dtx-
treated WT controls. However, Foxp3
DTR mice treated with Dtx at 13.5 weeks of age 
failed  to  accumulate  VAT  Tregs  and  had  a  significant  decrease  in  the  frequency  of 
Gata3
+ VAT Tregs, suggesting that neither tTregs from an adult thymus or the converted 
pTregs contained the potential precursor pool capable of repopulating VAT Treg.    52 
Figure 2.10: Ability of adult thymus to repopulate VAT Treg compartment is age-dependent 
(A-C) Treg ablation in Foxp3
DTR mice via Dtx injection (A) Schematic representation of Dtx injection 
experiments. Quantification of (B) Foxp3
+ VAT Tregs (% of CD4
+ T cells) and (C) Gata3
+ Tregs (% of 
CD4
+ T cells) from Foxp3
DTR and WT littermates injected with Dtx at indicated ages. n = 3-16 mice for 
each age and genotype; data are pooled from multiple independent experiments. 
(D-E) Tracking recent thymic emigrants (RTEs) following intrathymic injections with biotin.  
(D) Quantification of Biotin
+ RTEs (% of CD4
+ T cells) in spleen (left) and VAT (right) in mice of 
indicated ages. (E) Representative flow cytometry plots of Foxp3 expression among RTEs (left) and 
quantification of percentage of Foxp3
+ cells among RTEs (right). n = 5 mice of each age; data are pooled 
from 2 independent experiments.  
All plots show means and standard deviations. * p<0.05; ** p<0.01; *** p<0.001 
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A possible explanation for the inability of adult Foxp3
DTR mice to accumulate 
VAT Tregs following Dtx was that it was simply a reflection of the decreased thymic 
output in adult mice (Palmer, 2013), thereby decreasing the chances of differentiating a 
Treg  cell  capable  of  repopulating  the  VAT.  To  test  this  directly,  we  performed 
intrathymic injections of a biotinylating agent in mice 3, 6, and 13 weeks of age, which 
allowed us to track RTEs in the periphery. Examination of the spleen and VAT revealed 
a progressive decline in RTEs in both tissues with age (Figure 2.10D). The decrease in 
RTEs  infiltrating  the  VAT  was  particularly  striking  in  13-week  old  mice,  which 
paralleled  their  inability  to  reconstitute  the  VAT  Treg  compartment  following  Dtx. 
Furthermore,  there  was  an  age-associated  decline  in  the  frequency  of  Foxp3
+  Tregs 
among  RTEs  in  the  spleen  (Figure  2.10E)  (Note  inadequate  numbers  precluded  a 
comparison with analogous populations from VAT).  
In conclusion, RTE Tregs were able to seed the VAT when the VAT Treg “niche” 
was  perturbed  in  an  age-dependent  manner.  This  age-dependence  was  a  result  of 
decreased frequency of RTEs and a more striking decrease in frequency of Foxp3
+ Tregs 
among the RTEs. 
 
VAT Treg accumulation requires MHC class II, but not CD1d 
 
The  striking  clonanlity  observed  among  VAT  Tregs  suggested  that  their 
proliferation  might  have  been  antigen-driven.  We  investigated  the  type  of  antigen 
presentation that was required for expansion of VAT Tregs. CD1d is a non-classical   54 
MHC-like antigen presentation molecule that is able to present lipid antigens. Given the 
high abundance of lipids in the VAT and the ability of VAT Tregs to take up lipid 
(Cipolletta  et  al.,  2012),  we  postulated  that  antigen-presentation  on  CD1d  may  be 
driving VAT Treg expansion. Consistent with previously published results (Lynch et al., 
2012), CD1d
-/- mice had similar levels of VAT Treg accumulation compared with WT 
mice (Figure 2.11A). Furthermore, we did not see any changes in expression of Gata3 
among VAT Tregs in CD1d
-/- and WT mice, confirming that antigen presentation by 
CD1d is not required for expansion of bona fide VAT Tregs. 
Next we investigated the role of antigens presented by MHC class II molecules 
in  driving  expansion  of  VAT  Tregs.  MHC  class  II  molecules  play  key  roles  in  Treg 
differentiation  and  maintenance;  however,  non-classical  Foxp3
+  cells  have  been 
reported in mice deficient in MHC class II (Bienvenu et al., 2005). MHC class II-null 
(H2A
-/-) mice had lower frequencies and numbers of Foxp3
+ T cells compared with WT 
mice (Figure 2.11B). Furthermore, the few Foxp3
+ T cells recovered from the VAT of 
H2A
-/-  mice  expressed  drastically  lower  levels  of  Gata3,  suggesting  that  they  were 
different from true VAT Tregs. Finally, we wanted to identify cells that express MHC 
class  II  molecules  in  VAT.  Flow  cytometric  analysis  revealed  that  MHC  class  II 
molecules restricted to the hematopoietic lineage evidenced by the expression of CD45 
(99.1±0.35% CD45
+ among I-A/I-E
+ cells) (Figure 2.11C). Among I-A/I-E
+ CD45
+, the 
majority of the cells were CD11b
+ mononuclear cells that also co-expressed F4/80, 
therefore they were likely to be macrophages.    55 
 
Figure 2.11: VAT Treg accumulation requires MHC class II, but not CD1d 
(A) Representative flow cytometry plots of VAT Tregs frequency (% of CD4
+ T cells) in WT (left) and  
CD1d
-/- (middle) mice. (Right) Gata3 expression among VAT Tregs. Data representative of n = 3 for each 
genotype. 
(B) Representative flow cytometry plots of VAT Tregs frequency (% of CD3
+ T cells) in WT (top left) and 
H2A
-/- (top middle) mice. (Top right) Gata3 expression among Foxp3
+ Tregs from VAT and spleens of WT 
and KO animals. Quantification of frequency of Foxp3
+ Tregs (% of CD3
+ T cells) (bottom left) and 
number  of  Foxp3
+  Tregs  (bottom  right).  n  =  8  for  each  genotype;  data  pooled  from  2  independent 
experiments. Plots show means and standard deviations. ** p<0.01; *** p<0.001 
(C) Identification of MHC class II expressing population in VAT. Means and standard deviations in 
different gates are indicated. Flow cytometry plots are representative of n = 5 mice from 2 independent 
experiments. 
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In  summary,  VAT  Treg  expansion  requires  the  expression  of  MHC  class  II 
molecules and the dominant population that expresses MHC class II in VAT are the 
CD45
+CD11b
+F4/80
+ mononuclear phagocytes that are likely to be macrophages. 
 
VAT Tregs express increasing amounts ST2 with age and in vivo administration of 
IL-33 elicits a potent expansion of VAT Treg  
 
  ST2 (encoded by Il1rl1) is a receptor for the “alarmin” IL-33 (Schmitz et al., 
2005). Previous results showed that Il1rl1 was part of the Pparg co-cluster (Cipolletta et 
al., 2012), a collection of genes that positively correlated with Pparg expression. In one 
study, in vivo administration of IL-33 in obese mice led to amelioration of inflammation 
and improvement in insulin sensitivity (Miller et al., 2010). The authors attributed the 
insulin sensitizing effects of IL-33 to the polarization of macrophages towards M2-like 
phenotype  and  to  an  increase  in  Th2  cells;  however,  the  study  did  not  explore  the 
potential effect of IL-33 on VAT Tregs. IL-33 was shown to be expressed in adipose 
tissue  (Wood  et  al.,  2009;  Zeyda  et  al.,  2013)  and  given  the  role  of  IL-33  as  an 
“alarmin” (Schmitz et al., 2005; Pei et al., 2014), we hypothesized that Tregs might 
accumulate in VAT in response to IL-33. 
  First,  we  analyzed  the  expression  of  ST2  on  Tregs  from  VAT  and  spleen  at 
different ages. In the spleen, the population of ST2
+ Tregs was barely detectable and 
remained stable with age (Figure 2.12A); however, there was a dramatic increase of 
ST2
+ Tregs in the VAT (~90% of VAT Tregs were ST2
+ by 30 weeks of age), which   57 
 
Figure 2.12: VAT Tregs express increasing amounts ST2 with age and in vivo administration of IL-
33 elicits a potent expansion of VAT Tregs 
(A) Representative flow cytometry plots of ST2 expression in Tregs from VAT and spleen analyzed at 
indicated ages.  
(B) Quantification of data from (A): frequency of Foxp3
+ Tregs (% of CD4
+ T cells) (red) and frequency of 
ST2
+ Tregs
 (% of Foxp3
+ Tregs) (black) in different ages. n = 4-9 for each age; data are pooled from 3 
independent experiments. 
(C-F) 8-week old mice were treated with 2 injections of IL-33 or PBS every 3 days for 1 week prior to 
analysis. Representative flow cytometry plots from spleens (C) and VAT (E) of ST2, Gata3, and Ki67 
expression  by  Tregs.  Quantification  of  Treg  frequencies,  absolute  numbers,  and  ST2,  Gata3,  and  Ki67 
expressing  populations  in  spleens  (D)  and  VAT  (F).  n  =  10  mice  per  group;  data  pooled  from  2 
independent experiments. 
All plots show means and standard deviations. ** p<0.01; *** p<0.001 
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directly correlated with accumulation of VAT Tregs (Figure 2.12A and B). Next we 
directly tested the effect of IL-33 on VAT Tregs through administration of recombinant 
IL-33 in vivo in 8-week old mice when frequency of VAT Tregs was still very low (on 
average < 15% of CD4
+ T cells). Even in the spleen, we saw a modest but significant 
increase in Treg frequency and total numbers in IL-33-injected animals compared with 
PBS-injected  controls  (Figure  2.12C).  This  increase  was  most  likely  a  result  of 
proliferation  as  we  observed  a  significant  increase  in  the  frequency  of  Ki67
+  Tregs. 
Interestingly,  IL-33  administration  led  to  a  marked  increase  in  Gata3  expression  in 
splenic Tregs. The effect of IL-33 was even more pronounced in the VAT. VAT Treg 
frequency increase 3-fold and the absolute numbers of VAT Tregs increased 15-fold 
(Figure 2.12D), which paralleled an increase in Ki67
+ fraction. There was a marked 
increase in the frequencies of ST2
+ Gata3
+ Tregs suggesting that the population of VAT 
Tregs responding to IL-33 treatment was phenotypically similar, at least by those two 
markers, to the population of bona fide VAT Tregs that expands clonally with age.  
  In summary, there is an age-associated increase in ST2 expression on VAT Tregs. 
IL-33 is produced in adipose tissue, and in vivo administration of exogenous IL-33 
could drastically expand VAT Tregs through proliferation. 
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Discussion 
 
There  is  increased  appreciation  for  the  role  of  Treg  cells  in  regulating 
homeostasis far beyond the scope of the traditional immune responses. The striking loss 
of VAT Tregs in obesity coupled with experimental and genetic manipulations of this 
population demonstrated their pivotal role in controlling adipose-tissue inflammation 
and maintaining insulin sensitivity (Feuerer et al., 2009; Cipolletta et al., 2012). The 
observation that VAT Tregs accumulated with age in lean mice to frequencies > 50% of 
the VAT-resident CD4
+ T cells, prompted us to try to get a deeper understanding of the 
mechanisms  at  play  during  this  accumulation  of  VAT  Tregs.  A  more  profound 
knowledge of the dynamics of this important population of Tregs could help explain why 
lean  mice  remained  insulin  sensitive  despite  significant  increases  in  total  body  and 
adipose  tissue  weights.  We  showed  that  VAT  Treg  accumulation  was  not  due  to 
induction  of  Foxp3  expression  in  CD4
+  Tconv  cells.  We  also  observed  minimal 
recruitment  and  migration  of  Tregs  to  VAT  from  circulation.  Instead,  VAT  Tregs 
accumulated almost exclusively via proliferation and long-term persistence in VAT. 
The analysis of the TCR repertoire of VAT Tregs revealed a striking degree of clonal 
expansion and the extent of clonality correlated with the total frequency of VAT Tregs. 
Limiting the contribution of newly differentiated Tregs via thymectomy or, conversely, 
the deletion of Tregs at various ages revealed that up to a certain age newly differentiated 
tTregs were capable of accumulation in the VAT. This potential of newly differentiated 
tTregs for retention and expansion in VAT was decreased, in parallel, with the decrease   60 
in total tTreg output from the thymus. Expression of MHC class II molecules, on either 
macrophages or adipocytes themselves, was required for VAT Treg expansion. Finally, 
VAT Tregs progressively increased with age in their expression of ST2, the receptor for 
IL-33,  and  in  vivo  administration  of  IL-33  was  able  to  dramatically  increase  the 
numbers and frequencies of Tregs in VAT that were phenotypically similar to bona fide 
VAT Tregs. 
It is highly unlikely that VAT Treg accumulation represented a conversion of 
Tconvs to pTregs since essentially all VAT Tregs expressed high levels of Helios and Nrp1, 
considered to be markers of Tregs that differentiated in the thymus. In addition, we did 
not  find  enrichment  of  more  comprehensive  “gene  signatures”  of  pTregs  in  gene 
expression profiles from VAT Tregs. Transfer of sorted Tconv cells into lean recipients led 
to conversion of donor Tconvs into pTregs in spleens and LNs of recipient mice, albeit at a 
very  low  frequency;  however,  donor  pTreg  were  not  detected  among  VAT  Tregs, 
inconsistent with the high frequencies of conversion that we would have needed to 
detect in order to be considered as the dominant mechanism of VAT Treg accumulation. 
Finally, analysis of TCR sequences from mice with genetically restricted repertoires 
(Feuerer et al., 2009) and from WT mice in our studies showed distinctly unique TCR 
repertoires  in  VAT  Tregs  and  Tconvs,  arguing  against  conversion.  However,  a  more 
definitive experiment to rule out conversion as a mechanism for VAT Treg accumulation 
would  be  to  analyze  the  accumulation  of  VAT  Tregs  in  CNS1-mutant  mice  that  are 
unable to generate pTregs.    61 
Similarly accumulation of VAT Tregs was not a result of recruitment of Tregs 
from  the  periphery.  Kaede.B6  studies  suggested  that  Tregs  preferentially  recirculate 
between  lymphoid  compartments,  which  was  confirmed  by  parabiosis  and  transfer 
experiments. Even though we saw small fractions of Tregs migrating into the VAT in all 
of our experimental models, they represented only a minor fraction of the VAT Treg 
compartment. Parabiosis experiments demonstrated that the chimerism of VAT Tregs 
was significantly lower than the chimerism of splenic Tregs. More importantly, there 
were no significant differences in chimerism of VAT Tregs comparing pairs conjoined 
for  4  or  6  weeks.  These  findings  were  inconsistent  with  the  idea  of  continuous 
recruitment of circulating Tregs to VAT, which would have predicted an increase in 
chimerism over time. 
Recruitment  of  Tregs  from  the  peripheral  lymphoid  organs  and  circulation 
seemed  like  an  attractive  hypothesis  given  studies  that  showed  recruitment  of 
monocytes,  neutrophils,  and  macrophages  to  VAT.  However,  those  studies  focused 
primarily on inflamed adipose tissue in the context of obesity, situations that correlated 
with the loss, and not accumulation, of VAT Tregs. Interestingly, the few Tregs recovered 
from obese VAT started to become more phenotypically similar to Tregs found in spleen 
and LN (unpublished observations), suggesting the possibility that in the uncontrolled 
inflammatory response in obese VAT there may actually be increased recruitment of 
circulating Tregs. On the contrary, we found that in lean VAT recruited Tregs constituted a 
minority of the total VAT Treg compartment. Furthermore, when we divided the total 
VAT Treg pool based on the expression of Gata3 in our studies combining Thx and   62 
parabiosis, we showed that the majority of migrating Tregs did not express Gata3. This 
finding is particularly interesting, since Gata3 expression correlated with expression of 
PPARγ, and Gata3
+ VAT Tregs were preferentially lost after administration of a PPARγ 
antagonist and in Treg-Pparg mut mice (Cipolletta et al., 2012). Taken together, these 
observations suggest that the bona fide VAT Treg population that possesses the majority 
of the insulin sensitizing properties is not composed of recruited Tregs.  
Instead, VAT Tregs accumulate due to local proliferation and retention in situ. 
VAT Tregs, in contrast to muscle Tregs (Burzyn et al., 2013), did not have an impressive 
proliferative  burst,  but  rather  proliferated  at  the  same  basal  rate  as  splenic  Tregs. 
However, BrdU-labeling experiments revealed that VAT Tregs were able to persist for a 
longer period of time as evidenced by their longer half-life compared with both VAT 
Tconvs and spleen Tregs. Since there is minimal recruitment of Tregs to the VAT, this 
finding also suggests that there is no sizeable egress of Tregs from the VAT; however 
this  point  requires  a  more  direct  examination.  Additional  studies  are  needed  to 
characterize the nature of the signals that allowed for enhanced survival of VAT Tregs. 
The  analysis  of  the  VAT  Treg  TCR  sequences  confirmed  and  expanded  upon  the 
previous finding (Feuerer et al., 2009) that there was antigenic pressure driving the 
selection  and  expansion  of  a  particular  repertoire  of  TCR  sequences.  We  found  an 
unexpected and striking degree of clonal restriction among TCRs isolated from VAT 
Tregs. All in all, our findings suggest that there is an initial “seeding” of the VAT, where 
< 10 Treg cells infiltrate the VAT, are retained therein, and are able to proliferate with 
age to a point where > ~70% of all VAT Tregs express one of those TCRs.    63 
  The origin of VAT Tregs remains unclear. Thymectomy experiments revealed 
that already by 3 weeks of age the VAT contained Tregs expressing the “correct” TCR to 
achieve the same levels of accumulation as seen in WT mice, which suggested that the 
adult thymus is dispensable for VAT Treg accumulation. These findings paralleled with 
the observations that when a thymectomized partner was joined to a euthymic mouse 
there were significant differences in chimerism of Gata3
- VAT Tregs, which we believe 
to be coming from the circulation. Although there was a slight, non-significant trend 
toward  increased  chimerism  among  the  Gata3
+  population  of  VAT  Tregs,  these 
differences  could  be  attributed  to  technical  challenges  arising  from  the  analysis 
performed  on  exceedingly  small  numbers  of  donor  Tregs  that  infiltrate  the  VAT, 
evidenced by the low chimerism of VAT Tregs. Taken together, these findings suggest 
that true VAT Tregs infiltrate the tissue very early and that the adult thymus has very 
minimal impact on VAT Treg expansion. 
Several immune cell subsets such as B1 cells, γδ T cell subsets, and tissue-
resident  macrophages  have  been  shown  to  develop  from  fetal  precursors,  so  it  is 
possible that VAT Tregs have a similar ontogeny. However, several lines of evidence 
suggest that VAT Tregs differentiate postnatally. First, committed adipocyte precursor 
cells  do  not  appear  until  postnatal  day  4  and  VAT  does  not  become  visible  until 
postnatal day 7 (Rosen and Spiegelman, 2014); therefore the initial infiltration by Tregs 
probably occurs sometime between days 7 and 21 (the earliest age of thymectomies in 
our studies). Second, we did not detect a bias towards a shorter CDR3 lengths in the 
TCRs isolated from VAT Tregs, suggesting that their TCR rearrangement occurred when   64 
ample  levels  of  TdT  were  expressed  in  the  thymus,  which  functions  in  addition  of 
nucleotides to generate extra diversity of CDR3 (Bogue et al., 1992). Finally, depletion 
of Tregs in Foxp3
DTR mice did not abrogate VAT Treg accumulation when performed at 
16  days  or  3-4  weeks  of  age,  suggesting  that  the  Tregs  that  differentiated  after  Dtx 
treatment contained appropriate VAT Treg precursors. However, Dtx administration into 
Foxp3
DTR mice at 13.5 weeks of age diminished VAT Treg accumulation, which could 
be explained by the decrease in total thymic output in mice of that age, and a decreased 
frequency of Foxp3
+ Tregs among RTEs. In summary, there is a window in the first 
couple of weeks after birth when Tregs differentiate in the thymus, are able to infiltrate 
the  VAT,  and  are  able  to  proliferate  with  age.  Future  studies  are  needed  to  more 
carefully characterize the timing and molecular cues required for this initial seeding 
event, as well as to characterize the phenotype of Tregs that initially infiltrate the VAT. 
Several tools would need to be developed for these studies, in particular generation of 
transgenic mice encoding a TCR isolated from a clonally expanded VAT Treg and a 
fluorescent Pparg reporter to determine the precise timing of PPARγ expression. 
Consistent  with  the  idea  that  the  TCR  is  instructive  in  proliferation  and 
expansion of VAT Tregs, we found that MHC class II molecules were required for VAT 
Treg accumulation. We identified macrophages as the dominant population in the VAT 
that  expressed  MHC  class  II  molecules,  so  the  simplest  interpretation  is  that 
macrophages  might  be  presenting  antigen  to  Tregs.  Indeed,  several  previous  reports 
indicated that VAT-resident macrophages were able to stimulate CD4
+ T cells in vitro 
and polarize CD4
+ T cells toward a Th1 phenotype in vivo (Morris et al., 2013; Moraes-  65 
Vieira et al., 2014). These findings demonstrated that VAT-resident macrophages are 
capable  of  efficient  antigen  presentation  and  T  cell  stimulation.  Furthermore,  the 
localization of macrophages around dying adipocytes, forming crown-like structures, 
raises the possibility that the components of dying adipocytes engulfed by macrophages 
may be the source of antigen for the VAT Tregs and Tconvs. This proposition is especially 
intriguing, since there is very little adipocyte death in lean fat; however, upon challenge 
with HFD, adipocyte death increases and initially is paralleled by an increase in IL-10 
producing macrophages (Strissel et al., 2007). We can extrapolate these observations to 
suggest that lean adipose tissue in aged animals is similar to that of mice in the first few 
weeks  of  HFD,  where  low  levels  of  adipocyte  death  are  controlled  by  M2-like 
macrophages that produce a lot of IL-10 and might also activate VAT Tregs. Therefore, it 
would  be  interesting  to  correlate  adipocyte  death  with  VAT  Treg  accumulation.  In 
addition to macrophages, two reports claimed that adipocytes themselves were able to 
express MHC class II molecules and were able stimulate CD4
+ T cells in co-culture 
experiments (Meijer et al., 2011; Deng et al., 2013). Imaging experiments would be 
needed to confirm the interaction between the TCR on VAT Tregs and the MHC class II 
molecules expressed on either macrophages or adipocytes. It would be interesting to 
further dissect the role of MHC class II presentation by the two cell types through the 
use of conditional knockout mice, using Adiponectin-Cre or LysM-Cre to specifically 
eliminate  expression  of  MHC  class  II  molecules  on  adipocytes  or  macrophages, 
respectively, in order to determine which cell type is required by VAT Tregs for proper 
antigen presentation and for accumulation in VAT.    66 
Several of the aforementioned lines of evidence suggested that TCR:MHC class 
II interactions are required for the accumulation of VAT Tregs, but the nature of the 
antigen  remains  unknown.  We  showed  that  antigen  presentation  on  CD1d  is 
dispensable, so it is likely that the antigen being recognized is not a lipid. However, 
several lines of evidence support the hypothesis that VAT Tregs may recognize adipose 
tissue-specific self-antigens. First, Tregs bearing the MJ23 TCR (specific for a prostate 
antigen) only infiltrated the prostate, the tissue of origin for the cloned TCR, and not 
any other tissues (Malchow et al., 2013). Second, in mice expressing an OVA-specific 
transgene-encoded TCR in combination with a second transgene, which allowed for 
inducible skin-restricted expression of OVA, there was a high frequency of Tregs that 
accumulated in the skin upon expression of OVA in order to attenuate inflammation 
driven by Tconv cells expressing the same transgene-encoded TCR. Extrapolating from 
these findings, it is likely that VAT Tregs are retained exclusively in the VAT, and 
recognize adipose-tissue specific antigens, quite possibly the same antigens that are 
being encountered by Tconvs in the VAT. 
In addition to TCR-mediated signaling, it is likely that VAT Tregs require other 
survival and proliferations signals for their expansion. Previous studies showed that 
PPARγ was required for VAT Treg accumulation. Furthermore treatment of mice with a 
pharmacological agonist of PPARγ allowed for survival and expansion of Tregs even in 
obese VAT. We found that ST2, the receptor for IL-33, was upregulated in VAT Tregs 
with age and its expression correlated with expression of PPARγ. IL-33, an IL-1 family 
member, is an “alarmin” that is released into the extracellular space as an endogenous   67 
danger signal for neighboring cells (Miller, 2011; Pei et al., 2014). Previous studies 
showed  that  IL-33  administration  improved  insulin  sensitivity,  although  the  exact 
mechanism was not clear (Molofsky et al., 2013; Miller et al., 2010). Both studies saw 
an increase in M2-macrophages and increased IL-10 production; however, one study 
suggested that the effect of IL-33 was on ILC2s, leading to eosinophil recruitment and 
polarization of macrophages (Molofsky et al., 2013), while the other report claimed that 
IL-33  promoted  accumulation  and  activation  of  Th2  cells  (Miller  et  al.,  2010).  We 
showed that administration of IL-33 also had a very profound effect on proliferation of 
VAT Tregs. The expanded population of VAT Tregs expressed high levels of Gata3 and 
Klrg1 (data not shown), markers that were lost in Treg-Pparg mut mice; suggesting that 
IL-33 was acting on bona fide fat Treg cells. Further studies will be needed to determine 
whether the effect of IL-33 on VAT Treg cells is direct, due to their own expression of 
ST2  or  if  it  acts  indirectly  through  another  cell  subset.  IL-33  was  reported  to  be 
expressed in human adipose tissue (Wood et al., 2009; Zeyda et al., 2013); therefore, 
since IL-33 is an alarmin we can speculate that as a result of adipocyte death in VAT of 
aging mice, the active form of IL-33 is released by adipocytes and can induce Tregs to 
proliferate in order to control the associated inflammation. 
In conclusion, our studies suggest that VAT Tregs differentiate in the thymus and 
infiltrate adipose tissue early after birth (probably postnatal day 7-21). Once inside the 
adipose tissue, they undergo clonal proliferation in response to antigen presented by 
MHC  class  II  molecules  by  resident  macrophages  or  adipocytes  themselves.  We 
speculate  that  the  antigen  is  likely  an  adipose-tissue-restricted  protein,  potentially   68 
derived from distressed or dying adipocytes that are picked up by macrophages. As a 
result of adipocyte death, the active form of IL-33 is released and is sensed by ST2 on 
Tregs, which, in combination with the TCR signal, results in clonal expansion and long-
term survival of VAT Tregs. 
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Chapter  3:  Clonal  expansion  of  Tregs  during  skeletal  muscle  regeneration  after 
acute and chronic injuries. 
 
Note: The contents of this chapter have been previously published (Burzyn et al., 2013). 
 
Introduction 
 
  There is a substantial accumulation of Foxp3
+CD4
+ T cells in skeletal muscle 
undergoing  repair  after  acute  injury.  Skeletal  muscle  regeneration  follows  an 
orchestrated  course  of  events  that  are  driven  largely  by  satellite  cells,  a  pool  of 
quiescent precursors closely associated with muscle fibers (Tabebordbar et al., 2013). In 
response to injury, these cells become activated, proliferate, differentiate, migrate, and 
fuse  to  form  new  myofibers.  This  series  of  events  is  controlled  by  the  sequential 
activation and repression of specific transcription factors – for example Pax7, MyoD, 
myogenin (MyoG), and MEF2 (Rudnicki et al., 2008). With muscular dystrophies, in 
which chronic myofiber loss occurs due to genetic defects, the satellite cell pool is 
called on repeatedly, so it can exhaust or lose function over time, dampening the repair 
process  (Tabebordbar  et  al.,  2013).  Additionally,  regeneration  of  skeletal  muscle  is 
accompanied  by  a  series  of  coordinated  inflammatory  events  (Tidball  and  Villalta, 
2010).  Initially,  circulating  monocytes,  neutrophils,  and  other  myeloid  mononuclear 
cells infiltrate the injured tissue. Within days, the pro-inflammatory state of the myeloid 
infiltrate switches to an anti-inflammatory phenotype, a shift that is critical for proper   70 
muscle repair. Pro-inflammatory, or M1-type, macrophages function to clear apoptotic 
or necrotic cells and derivative debris. In contrast, the anti-inflammatory, or M2-type, 
macrophages have various pro-regenerative functions, such as matrix remodeling and 
promotion  of  angiogenesis.  Ablation  or  impaired  recruitment  of  monocytes  and 
macrophages severely compromises muscle repair.  
Given the importance of VAT Tregs in promoting adipose tissue homeostasis and 
insulin  sensitivity,  where  a  proper  balance  between  pro-  and  anti-inflammatory 
macrophages is necessary, we investigated the role of Tregs in muscle regeneration. A 
unique population of CD4
+Foxp3
+ Treg cells accumulates in skeletal muscle shortly after 
acute injury (Figure 3.1) (Burzyn et al., 2013). This population is a phenotypically and 
functionally distinct population of Treg cells that rapidly accumulates in acutely injured 
skeletal muscle of mice, and correlates with the timing when invading myeloid-lineage 
cells  switches  from  a  pro-inflammatory  to  a  pro-regenerative  state.  Consistent  with 
acute muscle injury, a Treg population with similar phenotype accumulated in muscles of 
genetically dystrophic mice. Punctual depletion of Treg cells during the repair process 
prolonged  the  pro-inflammatory  infiltrate  and  impaired  muscle  regeneration,  while 
treatments  that  expanded  or  decreased  Tregs  enhanced  or  diminished  muscle 
regeneration,  respectively.  Finally,  muscle  Treg  cells  expressed  the  growth  factor 
Amphiregulin  (Areg),  which  acted  directly  on  muscle  satellite  cells  in  vitro  and 
improved muscle regeneration in vivo.  
The accumulation of Tregs at the site of injury, which correlated with increased 
inflammation and infiltration of macrophages, was quite similar to the accumulation of   71 
Tregs  in  VAT.  This  observation  led  us  to  ponder  whether  TCR-mediated  clonal 
expansion  was  driving  the  accumulation  of  Tregs  in  skeletal  muscle  following  acute 
injury and in muscles of dystrophic mice.    72 
 
 
 
 
 
Figure 3.1: Treg accumulation at the site of injury. (A-C) Cytofluorometric analyses of hind-limb 
muscle  infiltrates  after  Ctx  injury.  (A)  Top:  Ly6c  expression  by  CD11b
+  cells.  Middle  and  bottom: 
Foxp3
+ by CD4
+ cells. Numbers depict % Ly6c
low (top) or % Foxp3
+ (middle and bottom) of gated cells. 
Representative of 3 independent experiments. (B, C) Summary data on fraction and number of cells. 
Mean ± s.d. (n≥4). Data in this figure were generated by Dr. Dalia Burzyn. Taken from (Burzyn et al., 
2011) Copyright 2013 Elsevier Ltd. 
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Additional Materials and Methods 
Mice 
C57BL/10ScSn-Dmd
mdx mice  were  purchased  from  Jackson  Laboratories.  All  mice 
were  bred  in  our  specific  pathogen-free  facilities  at  Harvard  Medical  School. 
Experiments were conducted under protocols approved by Harvard Medical School’s 
Institutional Animal Care and Use Committee. 
 
Skeletal muscle injury 
Anesthetized  mice  were  injected  intramuscularly  with  0.03  ml/muscle  of  Naja 
mossambica mossambica cardiotoxin (0.03 mg/ml) (Sigma) in one or more hindlimb 
muscles 
 
Isolation of leukocytes from muscle 
TA, gastrocnemius and quadriceps muscles were excised after perfusing the mice with 
PBS. Muscles were cut in small pieces and digested for 30 minutes with collagenase II 
(2 mg/ml, Invitrogen) and DNAse I (150 mg/ml, Sigma). The digested product was 
filtered through a 70mm mesh using a plunger to disrupt undigested tissue and washed 
with DMEM supplemented with serum. To separate the leukocyte fraction, the cells 
were resuspended in 40% Percoll, overlayed on 80% Percoll and spun for 25 minutes. 
The interphase containing leukocytes was recovered, washed and stained for single-cell 
sorting for TCR sequencing.   74 
Results 
Treg cells in injured muscle are clonally expanded and display a unique repertoire 
of TCRs. 
 
  The rapid accumulation of Treg cells at the injury site (Figure 3.1) could reflect 
their influx, proliferation or some combination of the two. Assessing expression of the 
cell-cycle  marker,  Ki67,  and  incorporation  of  the  nucleotide  analog,  5-ethynyl-2’-
deoxyuridine (EdU), by muscle CD4
+ T cells four days after injury, i.e. at the peak of 
both Treg and Tconv accumulation we showed that both Tregs and Tconvs in skeletal muscle 
were actively proliferating. The level of proliferation by muscle CD4
+ T cells was much 
higher than that of their splenic counterparts (Burzyn et al., 2013). 
To assess clonality of the Treg population expanding in acutely injured skeletal 
muscle, we studied TCR repertoires by sequencing the complementarity-determining 
region (CDR)3 of both the TCR-α and -β chains of individually sorted cells. Already at 
day 2 after injury, and continuing out at least until day 8, a substantial proportion (20-
40%) of muscle Treg cells was clonally expanded (Figures 3.2A, 3.2B). This sequence 
profile contrasted starkly with that of splenic Treg cells, for which there was not one 
repeat sequence in the 672 sampled. As expected from the Ki67 and EdU stainings 
(Burzyn et al., 2013), we also found clonal expansion of muscle Tconv cells (Figure 
3.2B). However, there was not a single example of TCR-sequence sharing between 
muscle Treg and Tconv cells. 
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Figure 3.2: Clonal expansion of the Treg population at the injury site. (A) TCR CDR3-α and CDR3-
β  sequences  for  individual  cells.  Each  pie  chart  represents  a  single  mouse.  n:  number  of  analyzed 
sequences per mouse. Total frequency of expanded clones shown at the top right. (B) Summary of clonal 
TCR frequencies over time. Open circles correspond to mice analyzed later in independent experiments 
for  Figure  3.4.  (C)  Identical  paired  CDR3-α  and  β  sequences  found  in  multiple  individuals  in 
independent  experiments.  Two  CDR3α sequences  from  independent  mice  bear  two  conserved 
substitutions. Taken from (Burzyn et al., 2013) Copyright 2013 Elsevier Ltd. 
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In the muscle Treg datasets, there was a striking case of a repeatedly detected 
TCR: identical paired CDR3 α and β (and corresponding nucleotide) sequences picked 
up in multiple mice in completely independent experiments (Figure 3.2C). (Note that 
extensive precautions were taken to avoid contamination in this highly sensitive assay, 
and each sequencing plate was rigorously monitored). Interestingly, there were a few 
Treg cells (from multiple individuals) that had the same TCR-β chain paired with an α 
chain  whose  CDR3  was  modified  only  conservatively  (AV→VL).  These  repeat 
sequences were found in mice 2 or 4, but not 8, days post-injury. They never showed up 
in  the  bulk  spleen  Treg  or  muscle  Tconv  cell  pools.  These  data  document  an  early 
expansion of Treg (and Tconv) cells in injured skeletal muscle within days after acute 
injury.  To  detect  such  expansions  in  mice  with  an  unrestricted  TCR  repertoire  is 
unexpected  and  quite  striking.  The  muscle  Treg  microexpansions  render  this 
population’s TCR repertoire distinct from that of other Treg populations. 
 
Similar clonal expansions of Treg population are found in the damaged muscles of 
mouse models of muscular dystrophy. 
 
  In muscular dystrophies, chronic destruction of muscle fibers is accompanied by 
an inflammatory response and, in general, a permanent infiltrate. Mdx mice carry a 
nonsense mutation in the Dmd gene (encoding Dystrophin), which is analogous to those 
found in DMD patients. In the mouse model, as in the human disease, the most affected 
sites are the diaphragm and hind-limb muscles (Grounds et al., 2008). We previously   77 
showed that the fraction of Treg cells in the muscles of mdx mice was significantly 
elevated vis-à-vis the frequency in corresponding muscles of wild-type mice in multiple 
ages; however, such an increase was not observed in the spleen. 
  Given the extent of clonal expansion in muscle Tregs following acute injury, we 
reasoned that similar microexpansions may be present in the muscles of mdx mice. The 
Treg  populations  of  mdx  muscle  exhibited  clonal  expansions,  with  an  even  greater 
fraction of the population derived from expanded clones (48.3% in mdx vs. 31.2% in 
Ctx-injured mice) and an even larger average clone size (4.68% in mdx vs. 3.68% in 
Ctx-injured  mice)  than  found  for  Ctx-injured  muscles  of  wild-type  mice  (compare 
Figures 3.2A and 3.3). 
 
TCR sequences are shared between Areg
+ splenic Treg and muscle infiltrating Treg 
cells. 
 
We  showed  that  muscle  Tregs  expressed  high  levels  of  mRNA  and  protein 
encoding Areg, a protein that belongs to the epithelial growth factor (EGF) family and 
signals  through  the  EGF  receptor  (EGFR)  system  (Shoyab  et  al.,  1989).  EGFR  is 
expressed by a variety of cells, including muscle satellite cells and a myoblast cell line, 
in  which  it  appears  to  have  anti-apoptotic/survival  functions  (Golding  et  al.,  2007; 
Horikawa et al., 1999). We showed that Areg augmented colony formation of muscle 
satellite  cells  in  vitro  and  improved  muscle  regeneration  following  in  vivo   78 
 
 
 
 
 
Figure 3.3: Clonal expansion of Treg cells in muscles of dystrophic mice. Treg clonal expansion in mdx 
muscle and spleens. TCR CDR3-α and CDR3-β sequences for individual cells. Each pie chart represents 
a single mouse. n: number of analyzed sequences per mouse. Total frequency of expanded clones shown 
at the top right. Taken from (Burzyn et al., 2011) Copyright 2013 Elsevier Ltd. 
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administration. In contrast to the high frequency Areg-expressing Treg cells infiltrating 
the muscle, only a small fraction of spleen Tregs expressed Areg.  
Since Areg was expressed by a small fraction of splenic Treg cells in addition to 
a  considerable  proportion  of  muscle  Tregs,  we  wondered  whether  the  two  Areg
+ 
populations might somehow be related. The TCR repertoires of splenic Areg
+ Treg and 
muscle Areg
+ and Areg
- Treg cells shed interesting light on this issue (Figure 3.4). First, 
as opposed to the lack of clonality characteristic of bulk, unfractioned, splenic Treg cells 
(Figure 3.2A), ~5% of the splenic Areg
+ subset was clonally expanded (Figure 3.4A). 
Second, a small population of splenic Areg
+ Treg cells appeared to include a muscle 
Treg  constituent.  There  was  some  degree  of  overlap  between  the  CDR3-α  and  -β 
sequences of splenic Areg
+ Treg cells and those of muscle Tregs (Figure 3.4B). However 
the sharing of TCR sequences was independent of their expression of Areg. Third, the 
muscle  Areg
+  and  Areg
-  subsets  showed  no  difference  in  their  extent  of  clonal 
expansion  (Figure  3.4C).  Finally,  although  we  again  detected  the  oft-repeated  TCR 
sequence described in Figure 3.2, there was no bias in its representation among the 
muscle Areg
+ and Areg
- subsets.    80 
 
 
 
 
Figure 3.4: Sharing of TCR sequences between Areg
+ splenic Treg cells and muscle infiltrating Treg 
cells.  (A)  TCR  CDR3-α  and  -β  sequences  for  individual  Areg
+  splenic  Treg  cells.  Each  pie  chart 
represents a single mouse. n: number of analyzed sequences per mouse. Total frequency of expanded 
clones shown at the top right. (B) Identical paired CDR3-α (not shown) and -β sequences found in 
splenic  Areg
+  and  muscle  Areg
+  and  Areg
-  Treg  cells  from  the  same  individual  in  independent 
experiments. #: number of times the sequence was found. %: frequency of Tregs expressing the same 
sequence. (C) As in A, for muscle Treg cells. Clones represented in Areg
+, Areg
- or both subsets of muscle 
Tregs were labeled in red, blue and green, respectively. Taken from (Burzyn et al., 2011) Copyright 2013 
Elsevier Ltd. 
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Discussion 
 
Treg cells began to accumulate in injured muscle within days after an injury. The 
fact  that  none  of  their  TCRs  was  shared  with  muscle  Tconv  cells,  suggests  that  this 
enrichment is unlikely to be due to a conversion of the Tconv to the pTreg phenotype. 
Rather, the elevated levels of muscle Tregs appear to reflect population expansion: they 
were  proliferating  in  the  muscle,  substantially  more  so  than  in  the  spleen,  and 
constituted a number of clonally expanded micropopulations.  
In addition, the TCR repertoires of injured-muscle and lymphoid-organ Treg cells 
were clearly distinct. As expected, sampling of individual spleen Tregs never yielded the 
same TCR-α or -β chain sequence more than once, reflecting the huge diversity of the T 
cell repertoire. In contrast, there were striking clonal expansions in the muscle Treg 
population, and one TCR-α and -β chain pair was found over and over again in different 
individuals despite extreme caution being utilized to avoid contamination. Interestingly, 
the small subset of Areg
+ splenic Tregs did share TCR sequences with muscle Treg cells, 
whether Areg-positive or -negative. But it is not clear at present whether the splenic 
population seeds or arises from the Treg population accumulating in injured muscle. 
These findings raise the possibility that a muscle antigen might be involved in recruiting 
Treg cells to the site of injury and/or retaining them therein.  
VAT Treg cells share many of the particularities of injured-muscle Tregs: their 
enrichment, unusual transcriptome, and clonally expanded TCR repertoire ((Feuerer et 
al., 2009) and data from Chapter 2). However, none of the TCR sequences were shared   82 
between VAT and muscle Tregs, hinting at the possibility that the expansion is driven by 
a  different  set  of  tissues-specific  antigens  in  the  two  tissues.  Indeed,  this  would  be 
consistent with the observation that Tregs bearing the MJ23 TCR only infiltrated the 
prostate, the tissue of origin for the cloned TCR, and not any other tissues (Malchow et 
al., 2013). Furthermore, the fact that the same, or very closely related, sequence was 
consistently found across multiple individual mice during muscle injury suggests the 
presence of strong antigenic pressure. Indeed, it would be very interesting to see if the 
oft-repeated TCR sequence would be able to lead to efficient Treg cell differentiation, 
depend on AIRE expression, and restrict Tregs to skeletal muscle, as was the case for 
MJ23.  
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Chapter 4: General Discussion 
 
  In recent years, more attention has been paid to the role of Tregs in controlling 
non-immune functions, such as improving insulin sensitivity and potentiating muscle 
regeneration  after  injury.  Striking  effects  on  pathologies,  achieved  through  various 
experimental  manipulations  of  these  populations,  make  them  attractive  targets  for 
therapies. However, simply measuring accumulation or loss of these Treg populations 
does not paint the whole picture of complexity that is involved in the dynamics of 
tissue-resident  Tregs.  A  deeper  understanding  of  the  mechanisms  that  underlie  the 
dynamics of these populations could provide new insights into the functions of these 
cells. 
  In the case of VAT Tregs, we were considering three different mechanisms of 
expansion (recruitment, conversion, and proliferation), but were surprised to find that 
essentially only proliferation seemed to be involved in accumulation of true fat Tregs. In 
contrast, we did not find nearly the same level of clonal expansion in muscle Tregs, 
which could mean that the accumulation of Tregs in the regenerating muscle may be 
driven by recruitment rather than expansion. Indeed, the TCR sequencing data revealed 
that a few clones were shared between the Tregs isolated from muscles and spleen of the 
same  individual,  suggesting  that  the  two  compartments  may  be  linked.  Finally,  in 
contrast  to  both  the  VAT  and  muscle  contexts,  Tregs  residing  at  barrier  surfaces, 
especially in the gastrointestinal tract rely on conversion of Tconvs to pTregs in response to 
certain species of commensal microbiota. Taken together these findings provide us with   84 
a glimpse of heterogeneity and division of labor among tissue-resident Tregs through the 
lens of the methods used for tissue-accumulation. 
  Our studies on VAT and muscle Tregs allowed us to compare and contrast the 
dynamics of the two populations. An interesting contrast between muscle and VAT Tregs 
is the level of clonality seen among these cells. The muscle Treg population is dominated 
by a large number of microexpansions, while VAT Tregs are composed of only a few 
clones in each individual. This difference could reflect the length of time needed for 
expansion, a few days for muscle Tregs and months of VAT Tregs, allowing for selection 
of optimal combination of clones over time in VAT. Alternatively, the differences could 
be driven by the degree of inflammation in each situation. VAT is characterized by 
chronic low-grade inflammation that never resolves, while the inflammatory response in 
muscle injury is acute and prodigious. Consistent with this notion, mdx mice that suffer 
from a lower level of inflammation that persists for a much longer time compared with 
acute Ctx-injury displayed larger average clone size and a larger fraction of the total 
population derived from clonally expanded cells. However, an alternative explanation 
for the differences between mdx mice and the Ctx-injury model is that in the former the 
injury is driven by a single mutation and does not have nearly the level of heterogeneity 
of tissue damage that is present in Ctx-injury model. Yet a third interpretation is that the 
mechanisms of accumulation are different for muscle and fat Tregs. It is possible that 
since the inflammation is induced so rapidly and to such a large extent that a large pool 
of Tregs with a broad range of phenotypes and TCR-specificities is recruited to the site of 
inflammation. As the acute phase of inflammation resolves and the regenerative phase   85 
begins, the population of Tregs changes over time to perform different functions. This 
notion would help explain why the oft-repeated TCR sequence in the muscle Tregs was 
isolated only from mice at early, but not late, time-points after injury. In contrast, the 
more restricted TCR usage among Treg clones isolated from VAT hints that VAT Tregs 
are probably responding to a more restricted set of antigens that persist for a long time. 
This makes having a local pool of Tregs with a narrowly defined set of TCRs more 
effective at suppressing the low-grade inflammation in adipose tissue of aging mice. 
  The scope of my studies allowed us to begin making some generalizations about 
the relationships between the dynamics of a population and their function. However 
technological  challenges  and  the  difficulties  of  interrogating  the  tissue-resident  Tregs 
specifically have limited our ability to perform more complex analyses to uncover the 
relationship between TCRs of tissue resident Tregs and their corresponding functions. 
Future studies would need to focus on relating TCR sequences expressed by Tregs to the 
preferred  mechanism  of  accumulation  and  to  their  functions  in  suppressing 
inflammation.  The  emergence  of  technologies  to  profile  various  “omic-level” 
parameters  in  individual  cells  could  begin  to  answer  some  of  these  questions  and 
provide another level of complexity to the population dynamics and functions of tissue-
resident regulatory T cells. 
  Several  overarching  questions  emerge  from  these  studies:  What  are  the 
advantages and disadvantages of each of these methods of accumulation? When and 
how do tissue Tregs become specialized and begin to utilize the appropriate mode of 
accumulation? What factors and signals govern each of these mechanisms? Our current   86 
understanding is just beginning to scratch the surface of the answers to these questions 
and future studies will undoubtedly uncover even more functions and complexities of 
tissue-resident regulatory T cells. 
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SUMMARY
A clear relationship exists between visceral obesity
and type 2 diabetes, whereas subcutaneous obesity
is comparatively benign. Here, we show that adipo-
cyte-speciﬁc deletion of the coregulatory protein
PRDM16 caused minimal effects on classical brown
fat but markedly inhibited beige adipocyte function
in subcutaneous fat following cold exposure or b3-
agonist treatment. These animals developed obesity
on a high-fat diet, with severe insulin resistance and
hepatic steatosis. They also showed altered fat
distribution with markedly increased subcutaneous
adiposity. Subcutaneous adipose tissue in mutant
mice acquired many key properties of visceral fat,
including decreased thermogenic and increased
inﬂammatory gene expression and increased macro-
phage accumulation. Transplantation of subcutane-
ous fat into mice with diet-induced obesity showed
alossofmetabolicbeneﬁtwhentissueswerederived
from PRDM16 mutant animals. These ﬁndings indi-
cate that PRDM16 and beige adipocytes arerequired
for the ‘‘browning’’ of white fat and the healthful ef-
fects of subcutaneous adipose tissue.
INTRODUCTION
Obesity has become a global epidemic, contributing to in-
creases in the prevalence of type 2 diabetes, hypertension, car-
diovascular disease, and certain cancers. Generally, two broad
categories of obesity are recognized: visceral (VISC) and subcu-
taneous (SubQ). The location where fat is deposited appears
to have a great inﬂuence on the likelihood of an individual
developing many of the sequelae of obesity (Gesta et al.,
2007). Importantly, VISC adiposity is strongly associated with
increased mortality, even in individuals with a normal body
mass index (Pischon et al., 2008). SubQ adiposity, however, ap-
pears to be comparatively benign (Manolopoulos et al., 2010).
The association between regional fat deposition and adverse
health complications was ﬁrst noted with pioneering clinical
descriptions in the 1950s (Vague, 1956). It has also been recog-
nized for centuries that men have a greater propensity for depo-
sition of VISC fat, while premenopausal women have a greater
tendency to accumulate fat in SubQ stores, though substantial
variation exists in both sexes (Vague, 1947).
The relationship between site of adipose tissue accumulation
and metabolic disease has been shown in several animal
models.Transgenic miceoverexpressing 11-bHSD-1 inadipose
tissue develop VISC obesity along with insulin resistance, dia-
betes, and hyperlipidemia (Masuzaki et al., 2001). Conversely,
transgenic mice overexpressing adiponectin or mitoNEET in
adipose tissue develop remarkable SubQ obesity, but remain
metabolically healthy (Kim et al., 2007; Kusminski et al., 2012).
The functional importance of these adipose depots has been
directly demonstrated in studies showing metabolic beneﬁt
by transplantation of SubQ fat or surgical removal of VISC fat
(Gabriely et al., 2002; Tran et al., 2008).
These divergent metabolic effects of different adipose depots
have raised interest in the unique properties of VISC and
SubQ fat. VISC fat is notable for having a substantial degree of
inﬂammation when obesity is present. Originally recognized as
the secretion of TNFa and other inﬂammatory cytokines from
fat tissue of obese animals (Hotamisligil et al., 1993), it is now
known that there is a broad increase in a variety of immune cells
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103in obese fat (Weisberg et al., 2003; Xu et al., 2003). On the other
hand, SubQ fat is notable because it can easily ‘‘brown’’ when
animals are stimulated with cold, b-adrenergic agonists, or
other hormone-like stimuli (Vitali et al., 2012; Wu et al., 2013).
This browning includes the induction of UCP1 mRNA and
protein, and expression of a gene program that gives rise to
uncoupled respiration and heat production. Some stimuli, such
as the genetic ablation of RALDH1, cause considerable brown-
ing of the VISC depots in mice (Kiefer et al., 2012), but this
phenomenon is much less common than the browning of
SubQ depots.
It is now recognized that there are at least two distinct types
of brown fat cells. Classical brown adipose tissue (BAT), epito-
mized by the interscapular depot in rodents, arises from a
Myf5
+, muscle-like cell lineage. PRDM16, a transcriptional
regulatory protein, appears to control this muscle-brown fat
decision between days 9–12 of gestation in mice (Lepper and
Fan, 2010; Seale et al., 2008). The postnatal role of PRDM16 in
classical BAT has not been studied. In contrast, the UCP1
+ cells
that emerge in white fat depots under certain stimuli, termed
beige or brite cells, do not come from a Myf5
+ lineage. However,
PRDM16 also appears to be involved in the development and
function of beige cells (Ohno et al., 2012; Seale et al., 2011).
Hence, beige and classical brown fat cells both express
PRDM16 and UCP1 but they are quite distinct cell types. Beige
fat cells have now been cloned and characterized (Wu et al.,
2012). Importantly, the depots of ‘‘brown fat’’ visualized in hu-
mans share more molecular properties with rodent beige fat
than with classical BAT (Lidell et al., 2013; Sharp et al., 2012;
Wuetal.,2012).Thekite-like structure intheinterscapular region
of human infants, however, seems to have characteristics of
rodent classical BAT, and some classical brown fat cells may
be retained in adult humans (Cypess et al., 2013; Jespersen
et al., 2013; Lidell et al., 2013).
Analysis of the relative physiological importance of the
classical BAT versus the browning of white fat has been very
difﬁcult because many important browning agents, such as
cold and b-adrenergic compounds, affect both types of brown
fat cells. Similarly, while ablation of UCP1
+ cells or mutation of
Ucp1 illustrate the overall importance of brown fat in preventing
obesity and diabetes in animals, the individual contributions
of the two types of brown fat cells has been impossible to
determine (Feldmann et al., 2009; Lowell et al., 1993). Agents
that affect browning of white fat selectively, including transgenic
expression of PRDM16, have caused metabolic beneﬁt, sug-
gesting that browning of white tissues could be important (Seale
et al., 2011). On the other hand, it has been argued that there are
insufﬁcient beige cells to affect whole-body physiology under
ambient conditions (Nedergaard and Cannon, 2013).
We have now created an adipocyte-selective mutation in the
Prdm16 gene that ablates the thermogenic program of beige
fat cells, while leaving the classical BAT functionally intact.
Mice lacking beige fat function develop obesity and insulin resis-
tance when exposed to high-fat diet (HFD) and also develop
hepatic steatosis. In addition, there is a striking change in the
SubQ fat, which takes on many of the morphological and molec-
ular characteristics of VISC fat. These data demonstrate that
PRDM16 and beige fat cells are major regulators of systemic
physiology. Moreover, PRDM16 determines some of the key
functional differences between SubQ and VISC fat.
RESULTS
PRDM16 Is Enriched in SubQ Adipose Tissues and
Required for Thermogenic Gene Expression
PRDM16 is involved in the development and function of classical
brown and beige adipocytes. To determine how PRDM16 might
be involved in the function of different adipose tissues that are
considered ‘‘white,’’ we measured mRNA levels in multiple
SubQ and VISC fat depots and compared these to the classical
interscapular brown fat. Prdm16 was signiﬁcantly elevated in
two SubQ depots (inguinal and axillary) relative to the very low
levels of expression in two VISC depots (epididymal and mesen-
teric). As expected, the highest levels of expression were seen
in interscapular BAT (Figure 1A). This depot enrichment was
maintained in primary adipocytes differentiated in vitro from
the inguinal SubQ or epididymal VISC stromal vascular fraction
(SVF) (Figure 1B). Expression of Ucp1, the prototypical thermo-
genic gene, was also enriched across SubQ depots, consistent
with the presence of beige adipocytes in these pads (Figures
S1A and S1B available online). These data suggested that
PRDM16 could play a role in multiple SubQ depots.
We generated a conditional Prdm16 allele (Prdm16
lox/lox) by
engineering loxP sites ﬂanking exon 9, which we have shown
to be required for mediating the effects of PRDM16 on thermo-
genic gene expression (Seale et al., 2008)( Figure S1C). We
initially crossed Prdm16
lox/lox mice to Zp3-cre mice to generate
a germline deletion. As expected, these animals had craniofacial
defects and died within 24 hr of birth, conﬁrming that this muta-
tion created a null allele of Prdm16 (Bjork et al., 2010).
We next crossed Prdm16
lox/lox and Adiponectin-cre mice
(Eguchi et al., 2011) to generate mice with an adipocyte-speciﬁc
knockout (KO) of Prdm16 (Adipo-PRDM16 KO). This promoter
expresses cre recombinase after the early developmental time
point when the classical brown fat/muscle fate decision
has been established (Lepper and Fan, 2010). We performed
metabolic characterization of Adiponectin-cre mice and
conﬁrmed that the Cre recombinase is not likely to contribute
to the KO phenotype (Figure S1D). Analysis of mRNA expression
from multiple tissues conﬁrmed that the deletion was speciﬁc to
white and brown adipose tissues (Figure 1C). Notably, PRDM16
mRNA levels in epididymal fat trended downward in KO mice,
though expression in this depot was at the margin of detection.
The trend toward decreased Prdm16 in the kidney of KO mice
may reﬂect expression in adipose tissue surrounding this organ.
Western blotting of nuclear extracts showed a marked reduction
of PRDM16 protein in both classical BAT and inguinal SubQ
adipose tissue from KO mice (Figure 1D). PRDM16 protein was
too low to detect in the VISC depots.
PRDM16 deletion in the classical BAT resulted in a relatively
normal pattern of gene expression (Figure 1E). The SubQ
adipose tissue of Adipo-PRDM16 KO mice, however, showed
reduced expression of a broad panel of thermogenic (Dio2,
Pgc1a, and Ucp1), brown adipose identity (Cidea, Otop1, and
PPARa), and mitochondrial electron transport genes (Coxiii,
Cox5b, and Cox8b)( Figure 1F). There was no alteration in the
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104expression of Pparg, which is a general marker of adipose
differentiation. Ucp1 mRNA was reduced by 90% in the inguinal
SubQ depot. This did not reach statistical signiﬁcance (p = 0.14)
due to the large variance in Ucp1 mRNA levels in control mice.
Adipo-PRDM16 KO mice also had decreased expression of a
few of these genes in VISC adipose tissue, compared to con-
trols, though the absolute expression level of these genes was
very low (Figure S1E).
Since SubQ adipose tissues are particularly prone to inducing
a thermogenic gene program (‘‘browning’’), we examined the
effects of two potent stimuli: cold exposure and treatment with
a b-adrenergic agonist. In interscapular BAT, the thermogenic
program was induced similarly in both control and Adipo-
PRDM16 KO animals following cold exposure or CL 316,243
(hereafter referred to as CL) treatment. There were some small
but statistically signiﬁcant differences in the induction of several
genes with cold and CL treatment (Figures 2A and 2B). In
contrast, the very robust increase in the entire panel of thermo-
genic gene expression seen in control inguinal adipose tissues
(cold: 74-fold induction of Ucp1, CL: > 400-fold induction of
Ucp1) was almost completely blocked in KO animals (Figures
2C and 2D). A similar pattern showing selective effects in
SubQ adipose tissue was seen with prolonged cold exposure
for 6 days (Figures S2A and S2B). Ucp1 showed blunted induc-
tion in VISC adipose tissue of the Adipo-PRDM16 KO mice
following CL treatment, though the levels of thermogenic genes
were overall very low in this depot (Figure S2C).
The morphology and UCP1 content of these adipose depots
was also examined in control and Adipo-PRDM16 KO mice.
No differences in UCP1 were seen in the BAT between mice
of either genotype, with or without cold exposure (Figure 2E).
The SubQ adipose tissue from Adipo-PRDM16 KO mice, how-
ever, contained larger adipocytes and fewer small, multilocular
UCP1
+ adipocytes (Figure 2E). Moreover, cold exposure re-
sulted in the emergence of numerous small, multilocular
UCP1
+ adipocytes in controls, while KO mice showed no
change in appearance relative to RT (Figure 2E). Of note,
Adipo-PRDM16 KO mice showed no difference in core tem-
perature following 6 hr (Figure S2D) or 96 hr at 4C (36.04C ±
0.19 in KOs versus 35.78C ± 0.26 in controls, p = 0.44). This
further indicates that these mice have little apparent defect in
the function of BAT since ablation of classical BAT or UCP1 is
associated with severe cold intolerance (Enerba ¨ck et al., 1997;
Lowell et al., 1993).
We next asked whether these changes in the thermogenic
program of SubQ adipose tissue were cell autonomous. SubQ
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Figure 1. PRDM16 Deletion in Adipocytes Results in Altered Subcutaneous Adipose Tissue Gene Expression
(A and B) qPCR analysis of Prdm16 mRNA from multiple adipose tissues from 8- to 10-week-old, male wild-type mice (n = 9), normalized to mRNA expression in
BAT (A) or from in vitro differentiated primary adipocytes, normalized to mRNA expression in inguinal cells (n = 3) (B).
(C) qPCR analysis of Prdm16 mRNA from multiple tissues from 6- to 8-week-old male Adipo-PRDM16 KO mice (n = 4) and controls (n = 4).
(D) PRDM16 protein in nuclear extracts from BAT or inguinal SubQ adipose tissue from Adipo-PRDM16 KO and controls. PPARg and TBP protein are shown as
controls.
(E and F) Normalized gene expression of thermogenic, brown adipose, and mitochondrial genes in BAT (E) and SubQ adipose tissue (F) from Adipo-PRDM16 KO
and control mice at RT. Mice were males, 6–8 weeks old, n = 5 per group.
Data are presented as mean ± SEM. *p < 0.05. #, p = 0.053 for kidney and 0.079 for epididymal fat. See also Figure S1.
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Figure 2. PRDM16 Regulates Beige Adipose Thermogenic Gene Expression
(A–D) Normalized thermogenic gene expression in BAT (A and B) and SubQ adipose tissue (C and D) from Adipo-PRDM16 KO and control mice at RT and
following 48 hr at 4C (A and C) or following ﬁve daily injections of 1 mg/kg CL (B and D). Cold exposure was done with male 6- to 8-week-old mice, n = 5–6 per
group. CL treatment was done with female 6- to 8-week-old mice, n = 5–6 per group. Data are presented as mean ± SEM. *p < 0.05 KO versus control cold
exposed or CL treated. #, p < 0.05 KO versus control room temperature or untreated.
(E) Representative images from UCP1 immunohistochemistry on sections of interscapular BAT or inguinal SubQ adipose tissue from Adipo-PRDM16 KO and
control mice at RT or following 48 hr at 4C. Images are shown at 103 magniﬁcation. Scale bar, 100 mm.
See also Figure S2.
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106adipocytes from KO mice differentiated in vitro also showed a
signiﬁcant reduction in the expression of most thermogenic
(81% reduction in Ucp1), brown fat identity (97% reduction in
Cidea), and mitochondrial genes (80% reduction in Cox8b),
strongly suggesting a cell-autonomous role for PRDM16 in
browning (Figure S2E). Cells from Adipo-PRDM16 KO mice
also showed a blunted response to stimuli that induce browning,
such as isoproterenol and FGF21 (Figures S2F ad S2G) (Fisher
et al., 2012; Wu et al., 2013).
PRDM16 Regulates Adipose Tissue and Whole-Body
Energy Expenditure
Given the preferential effect of this PRDM16 deletion on
thermogenic gene expression in beige adipocytes, we
assessed the physiological effect of this ablation, using O2
consumption as a readout. SubQ and BAT pads were removed
from mice and O2 consumption was measured. These assays
were performed both in untreated animals and after 5 days
of CL treatment. Importantly, O2 consumption in interscapular
BAT was unchanged between KOs and controls in both basal
and stimulated states (Figure 3A). In contrast, O2 consumption
in SubQ adipose tissue from Adipo-PRDM16 KO mice was
signiﬁcantly reduced, both at baseline (36% reduced) and
following stimulation with CL (49% reduced) (Figure 3B). O2
consumption in VISC adipose tissue was below the limit of
detection in most animals. Assays in primary SubQ adipocytes
showed a signiﬁcant reduction in both total (33% reduced)
and uncoupled (51% reduced) respiration in KO cells
compared to controls (Figure 3C). Taken together, these re-
sults indicate that adipose-selective deletion of PRDM16 re-
sults in a large defect in a broad program of thermogenesis
in SubQ adipose tissue, while classical BAT is relatively
unaffected.
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Figure 3. Altered Subcutaneous Adipose
Tissue and Whole-Body O2 Consumption in
Adipo-PRDM16 KO Mice
(A and B) O2 consumption in brown (A) and SubQ
adipose tissue (B) from control and Adipo-PRDM16
KO mice. Tissues from untreated animals and ani-
mals treated with 5 daily injections of 1 mg/kg CL
were analyzed. CL treatment was done with female
6- to 8-week-old mice, n = 5–6 per group.
(C) Total and uncoupled respiration in primary SubQ
adipocytes from control and Adipo-PRDM16 KO
mice. n = 6 per group.
(D) O2 consumption in 8- to 10-week-old Adipo-
PRDM16KOandcontrolmalemice,n=8pergroup.
Data were recorded at baseline and for 6 hr
following daily injection of 0.1 mg/kg CL.
Data are presented as mean ± SEM. *p < 0.05. **p <
0.001. See also Figure S3.
This selective ablation of beige cell ther-
mogenic function offered a unique oppor-
tunity to study the role of these cells and
the browning of white fat on whole-body
physiology. When Adipo-PRDM16 KO
mice were fed a chow diet, no difference
was observed in food intake or activity between the mutant
and control groups (Figures S3A and S3B). Adipo-PRDM16 KO
mice also showed no difference in O2 consumption but did
have a signiﬁcantly increased respiratory exchange ratio (RER),
suggesting a decrease in utilization of fatty acid oxidation as
an energy substrate (Figures S3C and S3D). We also studied
these animals after injection with CL. Control animals showed
asigniﬁcantincreaseinO2consumption(6.5%–13.9%)following
each injection. KO mice showed no increase in O2 consumption,
suggesting that ablation of beige adipocyte function can affect
whole-body energy expenditure (Figure 3D).
Adipo-PRDM16 KO Mice Develop Obesity and Insulin
Resistance
Animals were then subjected to a physiological challenge in the
form of a high-fat, high-carbohydrate diet. Adipo-PRDM16 KO
mice showed no difference in body weight from control animals
on a chow diet, but demonstrated increased weight gain on a
HFD (Figures 4A and 4B). Over 7 weeks at thermoneutrality,
KOs on either a chow or HFD showed no difference in body
weight compared to controls (Figures S4A and S4B). Of note,
Ucp1 KO mice show signiﬁcant weight gain over this time period
at thermoneutrality, presumably due to defects in classical
brown fat function (Feldmann et al., 2009).
Body composition analysis was done after 16 weeks on HFD,
when the weight curves had just started to diverge. Mutant
animals had signiﬁcantly increased fat mass, with no change in
lean body mass (Figure 4C). These mice also showed an inter-
esting change in the distribution of fat mass: KO animals had
SubQ fat mass (inguinal depot) nearly twice that of controls,
while the VISC (epididymal) and BAT masses were unchanged
(Figure 4D). Metabolic analysis of mice after 2 weeks of HFD
showed no signiﬁcant differences in food intake, activity, O2
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107consumption, or RER compared to control animals (Figures
S4C–S4F). O2 consumption was also unchanged after longer
periods on HFD, likely reﬂecting the fact that indirect calorimetry
is insufﬁciently sensitive to detect small differences in energy
expenditure, which could result in modest obesity over a pro-
longed period (Butler and Kozak, 2010).
SubQ adipocytes in high-fat fed Adipo-PRDM16 KO mice
were markedly larger than those in control mice (Figure 5A).
Quantitative assessment conﬁrmed a 33% increase in mean
adipocyte area in the SubQ depot of mutant animals to a size
equivalent to adipocytes in the VISC depot (Figure 5B). KO
mice had no difference in mRNA expression levels of general
markers of adipose differentiation, though they did have a trend
toward increased Glut4 mRNA levels compared to controls
(Figure S5A). The morphology and size of VISC epididymal
adipocytes was unchanged between control and KO animals
(Figure S5B). We used ﬂow cytometry to quantitate the major
myeloid and lymphoid subsets in the adipose tissue of high-fat
fed mice. When compared to control animals, SubQ adipose
tissue from KOs had a signiﬁcant increase in the fraction and
number of CD11b
+F4/80
+ macrophages (Figure 5C), along with
increased crown-like structures (Figure 5D). These alterations
were restricted to SubQ adipose tissue, as there were no differ-
ences in the representation of CD11b
+F4/80
+ macrophages in
the VISC adipose tissue or spleen from KO animals (Figure S5C).
Nootherimmunecellsubsets,including Tregulatorycells,which
have been shown to play a role in metabolic disease (Cipolletta
et al., 2012), were altered in adipose tissue or lymphoid organs
from KO mice (Figure S5D).
We next assessed glucose homeostasis in Adipo-PRDM16
KO mice. We performed hyperinsulinemic-euglycemic clamps,
asensitivemethodforassessingwhole-bodyandtissue-speciﬁc
insulin sensitivity. These studies were performed at a time well
before the weight curves of KO animals diverged from controls
(6 weeks on HFD). There was no difference in fasting plasma
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Figure4. ObesityandAlteredFatDistribution
in Adipo-PRDM16 KO Mice
(A and B) Body weights of Adipo-PRDM16 KO and
control mice on standard chow (A) or HFD (B). HFD
was started at 4 weeks of age. Experiments were
done with male mice, n = 12–15 per group.
(C) Body composition of Adipo-PRDM16 KO and
control mice following 16 weeks on HFD. n = 12 for
controls and n = 19 for KOs.
(D) Weights of individual fat pads from Adipo-
PRDM16 KO and control mice following 18 weeks
on HFD. n = 11 per group.
Data are presented as mean ± SEM. *p < 0.05. See
also Figure S4.
glucose between groups (Figure S6A).
However, fasting plasma insulin levels
were signiﬁcantly increased (55%
increased, p < 0.05) in Adipo-PRDM16
KO mice, suggestive of insulin resistance
(Figure 6A). During the clamp, plasma
glucose levels were matched between
groups at approximately 120 mg/dl (Fig-
ure S6A). Adipo-PRDM16 KO mice showed signiﬁcant whole-
body insulin resistance as evidenced by a markedly reduced
glucose infusion rate (64% of controls) and decreased whole-
body glucose uptake (Figures S6B and 6B). Mutant mice also
demonstrated signiﬁcant hepatic insulin resistance with
decreased insulin-stimulated suppression of endogenous
glucose production (53% in KOs versus 95% in controls)
(Figure 6C). This primary alteration in adipose tissue was also
associated with hepatic steatosis in KO animals (Figure 6D).
Moreover, KO animals showed a failure in insulin-mediated
suppression of lipolysis (6% in KOs versus 45% in controls)
(Figure 6E). Although control and Adipo-PRDM16 KO mice
were dosed with the same amount of insulin, clamped insulin
levelsweremodestlyincreasedintheKOs(p=0.08,FigureS6C),
suggesting impaired insulin clearance consistent with insulin
resistance. Gene expression analysis from a separate cohort of
mice following 6 weeks HFD, showed marked reductions of
many thermogenic genes in KO SubQ adipose tissue compared
to controls. Some of these genes showed a modest, but signiﬁ-
cant, reduction in classical BAT (Figure S6D).
A bolus of
14C-2-deoxyglucose was administered to deter-
mine tissue-speciﬁc rates of glucose transport. Marked reduc-
tions in glucose uptake were observed in the SubQ (79%
decreased) and VISC fat (53% decreased) (Figure 6F). Interest-
ingly, glucose uptake in the classical BAT was actually higher
in Adipo-PRDM16 KO mice. Skeletal muscle glucose uptake
was no different between control and KO mice. These data indi-
cate that deletion of PRDM16 in adipocytes results in selectively
dysfunctional beige adipose function with strong effects on
whole-body and tissue-speciﬁc insulin sensitivity.
Adiponectin levels showed no difference between control and
KO mice (Figure S6E). Moreover, PRDM16 null adipose cells do
not appear to have cell-autonomous defects in insulin signaling,
as levels of total and phosphorylated Akt were unchanged be-
tween control and KO primary SubQ adipocytes (Figure S6F).
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108Loss of Metabolic Beneﬁt with Transplantation of
Subcutaneous Fat from Adipo-PRDM16 KO Mice
This spectrum of phenotypes in Adipo-PRDM16 KO mice
suggested that PRDM16 might be required for the healthful
actions of SubQ adipose tissue. To address this, we trans-
planted SubQ fat pads (Gunawardana and Piston, 2012) from
weanling pups of the two PRDM16 genotypes into high fat fed
wild-type recipients and animals were then maintained on
HFD. All recipients gained weight equally following the trans-
plants. A glucose tolerance test was done at 6 weeks, and a
highly signiﬁcant difference was observed between the groups,
with worse glucose tolerance in recipients of KO tissue (Fig-
ure 6G). There was no signiﬁcant difference in insulin tolerance
between these groups. This result has been replicated in a sepa-
rate cohort of transplant recipients. The inclusion of a donor
group from PRDM16 overexpressing, transgenic mice showed
that glucose tolerance appears to track with PRDM16 levels in
donor tissue (Figure S6G).
SubQ Adipose Tissue of Adipo-PRDM16 KO Mice
Acquires a Partial VISC Adipose Phenotype
The combination of adipose and hepatic insulin resistance and
the presence of larger adipocytes in KO SubQ adipose tissue
with increased macrophage accumulation suggested a pheno-
type more typical of VISC obesity. These observations indicated
that Adipo-PRDM16 KO SubQ adipose tissue might have
developed some of the deleterious characteristics of VISC adi-
pose tissue. To address this in an unbiased fashion, we used
whole-genome microarrays to deﬁne depot-speciﬁc gene
expression and then examined whether this molecular proﬁle
appeared ‘‘visceralized’’ in the SubQ adipose tissue of Adipo-
PRDM16 KO animals.
Depot-enriched gene expression was studied by comparing
RNA expression in adipose tissue from two SubQ depots
(inguinal and axillary) to that from two VISC depots (epididymal
and mesenteric). We deﬁned a VISC gene set as containing
genes with >3-fold increased expression and a p value < 0.05
between the VISC and SubQ depots. Sixty genes met these
criteria. We then determined which of these genes had expres-
sion that was enriched >2-fold in fractionated adipocytes from
VISC versus SubQ adipose tissue, to avoid studying differences
due to other cell types. Twenty-six out of 60 genes met this
requirement. We then studied the expression of these 26
visceral-selective genes in SubQ adipose tissue from control or
Adipo-PRDM16 KO mice fed a HFD. 11/26 were >2-fold
increased with p value < 0.05 in KOs versus controls. We then
A
C
D
B
Figure 5. Increased Cell Size and Macrophage Accumulation in Subcutaneous Adipose Tissue from Adipo-PRDM16 KO Mice
(A and B) Cell size in inguinal SubQ adipose tissue from male Adipo-PRDM16 KO and control mice following 18 weeks on HFD. Representative images from
hematoxylin and eosin (H&E) stained sections. Images are shown at 53 magniﬁcation. Scale bar, 100 mm. (B) Mean adipocyte area from inguinal SubQ and
epididymal VISC adipose tissue. n = 3 per group.
(C) Flow cytometry quantitation of CD11b+F4/80+ macrophages in SubQ adipose tissue from Adipo-PRDM16 KO and control mice following 6 weeks on HFD.
(D) Morphological analysis for crown-like structures using Mac-2 staining from Adipo-PRDM16 KO and control mice following 6 weeks on HFD.
For (C) and (D), experiments were done with male mice 8–10 weeks old at start of HFD, n = 5–6 per group.
Data are presented as mean ± SEM. *p < 0.05. See also Figure S5.
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109selected 30 genes at random that were expressed in SubQ
adipocytes and used these as a comparator. Only 1/30 was
>2-fold increased with a p value < 0.05 in KO versus control
adipose tissue.
These data are shown as a heat map with the color indicating
the fold-change for each gene of this VISC fat gene expression
set in SubQ adipose tissue from 11 KO mice relative to that
of the control group (Figure 7A). The acquisition of a VISC-
selective expression proﬁle is highly signiﬁcant (11/26 versus
1/30 genes, p = 0.0004 by chi-square). In addition this VISC
proﬁle contains a number of proinﬂammatory genes of known
functional importance: Serum amyloid A3 (Saa3), Angiotensino-
gen (Agt), 12/15 lipoxygenase (Alox15), Osteoprotegerin
(Opgn), and Retinaldehyde dehydrogenase 2 (Raldh2)( Fig-
ure 7B). The VISC-selective expression proﬁle also includes
three transcription factors (Tcf21, Bnc1, and Wt1)( Figure 7C).
Two of these proinﬂammatory genes (Agt and Raldh2) were
further increased in VISC adipose tissue from KO mice,
compared to controls, though the expression of the three
VISC-enriched transcription factors was unchanged (Figures
S7A and S7B). Of note, more than half of these proinﬂamma-
tory genes and transcription factors were signiﬁcantly up-
regulated in PRDM16 KO SubQ fat cells differentiated in vitro
(Figures S7C and S7D). This strongly suggests that the altered
molecular proﬁle in PRDM16 null adipose tissue is not simply a
consequence of the metabolic dysregulation seen in these
animals.
High-fat feeding also resulted in signiﬁcantly decreased
expression of typical thermogenic genes in SubQ adipose tissue
of Adipo-PRDM16 KOs (Figure 7D), suggesting a coordinated
balance between the molecular phenotype of VISC and SubQ
adipose tissue. Weconsidered whetherPRDM16might normally
induce thermogenesis and repress inﬂammation, while a VISC-
selective transcription factor might induce inﬂammation and
repress thermogenesis. The three transcription factors identiﬁed
in our VISC-enriched proﬁle (shown above) were immediate
candidates for conferring these depot-speciﬁc properties. We
focused on Wt1 because it showed cell-autonomous induction
intheabsenceofPRDM16(FigureS7D)andisstrikingly enriched
in VISC adipose tissues (Figure 7E).
We obtained Wt1
lox/lox mice (Gao et al., 2006) and crossed
them to Adiponectin-cre mice. We isolated adipose tissue SVF
from Wt1
lox/lox;cre+ (KO) and Wt1
lox/lox;cre- (control) VISC fat and
differentiated them in vitro. We detected a signiﬁcant reduction
in the native Wt1 transcript and a corresponding increase in a
deleted transcript in KO cells compared to controls (Figure 7F).
BothcontrolandKOcellsdifferentiatedequally,withnomorpho-
logical differences. There were small but signiﬁcant differences
in markers of adipocyte differentiation. Importantly, deletion of
Wt1 resulted in a striking induction of thermogenic genes (5.6-
fold for Cidea, 6.1-fold for Prdm16, and 24.7-fold for Ucp1)
and repression of several proinﬂammatory genes (46% for
Saa3 and 30% for Agt) compared to controls (Figure 7G). These
data strongly suggest that reciprocal regulation of PRDM16 and
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Figure 6. Insulin Resistance, Hepatic Steatosis, and Altered Glucose Uptake in Adipo-PRDM16 KO Mice
(A–E) Hyperinsulinemic-euglycemic clamp studies on Adipo-PRDM16 KO and control mice after 6 weeks on HFD.
(A) Fasting insulin levels.
(B) Glucose infusion rate and whole-body glucose uptake.
(C) Basal and insulin-stimulated endogenous glucose production.
(D) Liver triglyceride content.
(E) Basal and insulin-stimulated levels of nonesteriﬁed fatty acids.
(F) 2-deoxyglucose uptake in tissues from Adipo-PRDM16 KO and control mice.
Data are presented as mean ± SEM. *p < 0.05, # p = 0.09. Clamp studies were done with male mice, 8 weeks old at the start of HFD. n = 7–8 per group.
(G) Intraperitoneal glucose tolerance test (1.5 mg/kg) in male, high-fat-fed recipients of Adipo-PRDM16 KO or control SubQ adipose tissue. The GTT was done
6 weeks following transplantation. n = 6 per group. *p < 0.05 by ANOVA.
Data are presented as mean ± SEM. See also Figure S6.
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Figure 7. Induction of a Visceral Adipose Tissue Gene Expression Proﬁle in Adipo-PRDM16 KO Subcutaneous Adipose Tissue
(A) Heat map showing relative expression of VISC-selective and randomly selected genes in SubQ adipose tissue from Adipo-PRDM16 KO mice after 18 weeks
on HFD. Eachrowdepicts anindividualgene.EachcolumndepictstheexpressioninaKOsample relative totheaverageexpressionincontrolmice.Average fold
change is indicated in the column to the right. Fold change for each individual sample is color-coded according to the key.
(B and C) Normalized expression of proinﬂammatory genes (B) and transcription factors (C).
(D) Normalized expression of thermogenic genes.
For (A)–(D), gene expression was measured in male mice following 18 weeks HFD. n = 11 per group.
(legend continued on next page)
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111Wt1 is at least partly responsible for determining whether adi-
pose expresses a SubQ or VISC gene program. Interestingly,
in a differentiation time course in primary adipocytes from
Adipo-PRDM16 KO mice, successive reduction in Prdm16
mRNA levels is closely associated with progressive increases
in Wt1 mRNA levels (Figure S7E).
DISCUSSION
We have described here a mouse model with speciﬁc ablation
of beige adipocyte function. Adipo-PRDM16 KO mice have
signiﬁcant reductions in thermogenic gene expression and O2
consumption of white adipose tissue, both in the basal state
and following stimulation with cold and the b3-adrenergic
agonist CL. On the other hand, both thermogenic gene expres-
sion and O2 consumption in classical BAT appears unaffected
by PRDM16 deletion. Importantly, the direct measure of tissue-
speciﬁc glucose uptake during hyperinsulinemic-euglyemic
clampsindicatedthatthereisessentiallynofunctionaldeﬁciency
inclassicalBAT.Infact,glucoseuptake waselevatedinKOBAT,
suggesting this tissue might be compensating for the absence of
functionalbeigeadiposecells.Thismayrepresentamirrorimage
of the recent report of hyperactive beige adipose tissue in the
setting of dysfunctional classical brown fat (Schulz et al.,
2013). While deletion of PGC1a in adipocytes also leads to
impaired thermogenic function in SubQ adipose tissue and
metabolic defects (Kleiner et al., 2012; Pardo et al., 2011), the
magnitude of the defect appears far greater in the Adipo-
PRDM16 KO mice. Pgc1a expression is reduced in our KOs,
consistent with PRDM16 being upstream of PGC1a (Seale
et al., 2007).
The physiological relevance of beige fat has been questioned
since expression of Ucp1 mRNA and protein is at least an order
of magnitude lower in these cells than in classical BAT (Neder-
gaard and Cannon, 2013). While mice with more beige fat cells
have shown a protection from metabolic diseases (Seale et al.,
2011; Vegiopoulos et al., 2010), the functional role of this cell
type when present in normal amounts has not been clear. As
shown here, animals deﬁcient in competent beige adipocytes
develop late-onset obesity on HFD. This is associated with
increased fat mass, including a striking increase in SubQ adi-
pose stores. While we were unable to detect differences in
whole-body O2 consumption in the basal state, KO animals
showed signiﬁcantly reduced energy expenditure following
treatment with a b3-adrenergic agonist.
Hyperinsulinemic-euglycemic clamp studies on beige cell-
deﬁcient animals before the development of obesity showed
signiﬁcant insulin resistance, speciﬁcally affecting white adi-
pose tissues and liver. Along with this, mutant animals devel-
oped hyperinsulinemia and hepatic steatosis. This model of
insulin resistance is unusual in that glucose uptake in skeletal
muscle seems unaffected. Beige adipocytes may have as
yet undescribed actions on other tissues, with recent studies
suggesting they regulate bone metabolism (Rahman et al.,
2013).
This mouse model of beige fat deﬁciency differs in some inter-
esting ways from mouse models with speciﬁc loss of classical
BATfunction.MicewithdefectiveBATdevelopobesityandinsu-
lin resistance (Feldmann et al., 2009; Hamann et al., 1996; Tseng
et al., 2008). However, such animals tend to have defects in
maintaining core temperature. When our KO mice were placed
at 4C, they showed no alteration in body temperature.
In the absence of PRDM16, mice developed marked enlarge-
ment of the SubQ adipose tissue. Interestingly, domestic pigs,
which have abundant SubQ adipose tissue, lack functional
UCP1 (Trayhurn et al., 1989). Similarly, Adipo-PRDM16 KO
mice have virtually no UCP1 in their SubQ adipocytes. Histolog-
ical examination of the SubQ fat from these mice demonstrated
thepresenceoflarger, unilocularcells,whichbecomeequivalent
in size to VISC fat cells. KO mice also showed a virtual absence
of small, multilocular UCP1
+ adipocytes. PRDM16-deﬁcient
animals not only lose the thermogenic program characteristic
of beige adipocytes, but additionally, the SubQ adipose tissue
acquires some of the deleterious characteristics of VISC fat,
including the accumulation of macrophages. It is not yet clear
whether acquisition of this VISC phenotype is causally related
to loss of the thermogenic function of beige adipocytes or
reﬂects a separate function of PRDM16 in adipocytes. The phys-
iological signiﬁcance of this change in depot phenotype, how-
ever, is made clear by our fat transplantation studies. Animals
that received PRDM16-deﬁcient SubQ pads had signiﬁcantly
worse glucose tolerance than recipients of control fat pads,
recapitulating experimental animal models with increased VISC
fat (Masuzaki et al., 2001).
Since reduced thermogenesis in SubQ adipose tissue of
Adipo-PRDM16 KO mice is coupled to increased inﬂammatory
gene expression and macrophage accumulation, it is not
possible to disentangle the relative contribution of each of these
alterations to the overall phenotype. Our data suggest that
PRDM16 speciﬁcally affects the function of beige fat cells in
the SubQ depots and that this is the proximal defect, occurring
prior to acquisition of VISC properties upon high-fat feeding.
Additionally, a recent paper showed that PRDM16 is only de-
tected in multilocular and paucilocular cells within the omental
fat of humans with pheochromocytoma (Frontini et al., 2013),
consistent with its enrichment and selective expression in beige
adipocytes.However,wecannotexclude possibleeffectsfroma
very small amount of PRDM16 in true white adipocytes.
A comprehensive molecular analysis showed signiﬁcant
expression of a VISC gene signature in the SubQ fat of
PRDM16 KO mice. This signature was developed based on
objective criteria, using multiple depots of each type, and
employing fat cell puriﬁcation to avoid confounding by other
cell types. These data clearly suggest that deletion of PRDM16
andablation of beigeadipocytesnotonlyaffectsthermogenesis,
but also results in substantial ‘‘visceralization’’ of the SubQ
(E) qPCR analysis of Wt1 mRNA from multiple adipose tissues from 8- to 10-week-old, male wild-type mice, normalized to mRNA expression in epididymal white
adipose tissue. n = 9 per group.
(F and G) Normalized expression of Wt1 (F) and thermogenic and proinﬂammatory genes (G) in primary VISC Wt1
lox/lox;cre+ adipocytes. n = 6 per group.
Data are presented as mean ± SEM. *p < 0.05, #, p = 0.058. See also Figure S7.
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112adipose tissue. This analysis establishes with statistical signiﬁ-
cance (p = 0.0004) that deletion of PRDM16 results in acquisition
of at least some aspects of the molecular phenotype of VISC
adipose tissue. Of note, several of these VISC markers ex-
pressed in KO SubQ pads are of interest in metabolic diseases:
Agt (Kalupahana et al., 2012), SAA3 (Kwon et al., 2012), Alox15
(Nunemaker et al., 2008; Sears et al., 2009), Opgn (Skopkova ´
et al., 2007), and Raldh2 (Frey and Vogel, 2011).
Three transcription factors (WT1, TCF21, and BNC1) were
among the visceral signature genes induced in Adipo-PRDM16
KO SubQ adipose tissue. WT1 and TCF21 have known roles in
urogenital development, and KO models of these genes have
similar phenotypes (Kreidberg et al., 1993; Quaggin et al., 1999),
suggesting that WT1 and TCF21 may function in the same
pathway. WT1 is also a known tumor suppressor, which is
mutatedinWilms’tumor(Haberetal.,1990).AroleforWT1inad-
iposebiologyhasnotpreviouslybeenreported.DeletionofWt1in
primary VISC adipocytes resulted in downregulation of genes in
the VISC signature and upregulation of thermogenic genes char-
acteristic of SubQ/beige adipocytes. These data suggest an
epistatic relationship between a thermogenic program regulated
byPRDM16andaVISC-speciﬁcprogramregulatedbyWT1.This
appearsanalogoustotheregulationofthermogenesisversuslipid
storage by PRDM16 and TLE3 (Villanueva et al., 2013).
Thus, it is now clear that beige fat cells make an important
contribution to whole-body physiology of mice. In the absence
of functional beige fat, mice are prone to obesity, insulin resis-
tance, and hepatic steatosis when challenged with HFD. In light
of the presence of beige fat cells in normal adult humans (Lidell
et al., 2013; Sharp et al., 2012; Wu et al., 2012), these cells are
an attractive target for the treatment of obesity and type 2
diabetes. Thisinﬂuence of beigefat onlivermetabolism ispartic-
ularly interesting since there has been much more attention
recently to the frequency and importance of hepatic steatosis
as an important comorbidity in the metabolic syndrome (Angulo,
2002). Identiﬁcation of pharmacological activators of PRDM16
targeted to beige adipocytes could hold promise as a new class
of therapeutics.
EXPERIMENTAL PROCEDURES
Animals
Animal experiments were performed according to procedures approved by
the Dana-Farber Cancer Institute and Yale University School of Medicine
IACUC. The generation of Adipo-PRDM16 KO mice and the other mouse
strains used is described in the Extended Experimental Procedures.
Molecular Studies
qPCR and western blotting were done according to standard methods. Anti-
bodies used were PRDM16 (sheep anti-PRDM16, R&D), PPARg (Cell
Signaling), TBP (Santa Cruz), AKT and P-AKT (Cell Signaling), and Actin (Cell
Signaling). Microarray hybridization and scanning were performed by the
Dana-Farber Cancer Institute microarray core facility using Affymetrix Mouse
Genome 430A 2.0 Gene Chip arrays. The GEO accession number for microar-
ray data reported in this paper is GSE53307.
Histological Analysis
Tissues were ﬁxed in 4% paraformaldehyde. Parafﬁn embedding and
sectioning were done by the Dana-Faber/Harvard Cancer Center Research
Pathology core facility. Adipocyte size was calculated as described (Vitali
et al., 2012). The mean area of 200 random adipocytes (100 per section)
from each animal was calculated using the Nikon LUCIA image program
(version 4.61; Laboratory Imaging).
Immunohistochemistry
Immunohistochemistry was performed as previously described (Giordano
et al., 2013) and as in the Extended Experimental Procedures.
Respiration
Tissue respiration was performed using a Clark electrode (Strathkelvin Instru-
ments). Freshly isolated tissues were isolated from untreated mice or after ﬁve
daily injections of 1.0 mg/kg CL (Sigma). Tissues were minced and placed in
respiration buffer. For each adipose depot, readings were taken with three
separate pieces of tissue of equivalent size. O2 consumption was normalized
to tissue weight. For assays on cultured cells, fully differentiated adipocytes
were trypsinized and a single-cell suspension was placed in respiration buffer.
Total respiration was measured and then oliogmycin was added to measure
uncoupled respiration.
Flow Cytometry
Epididymal VISC and inguinal SubQ adipose tissue and spleen were excised
and digested for 20 min with collagenase type II (Sigma). Cell suspensions
were ﬁltered through a 40 mm sieve, and the SVF was collected after centrifu-
gation at450gfor 10min.ForT cellanalysis, cellswerestained withanti-CD45
(clone 30-F11), -CD3 (145-2C11), -CD4 (GK1.5), -CD8 (5H10), and -CD25
(PC61) (BioLegend) and were ﬁxed, permeabilized, and intracellularly stained
for Foxp3 (FJK-16 s) and GATA3 (TWAJ) (eBiosciences). For myeloid cell anal-
ysis, cells were stained with anti-CD45, -CD3 (145-2C11), -CD11b (M1/70),
-CD11c (N418), F4/80 (CI:A3-1), and anti-Ly6c (HK1.4) (BioLegend). B cells
were stained with anti-CD45, and anti-CD19 (6D5) (BioLegend). Cells were
analyzed using an LSRII instrument (BD Bioscience) and FlowJo software.
Metabolic Phenotyping
Metabolic phenotyping and hyperinsulinemic-euglycemic clamps were per-
formed as described (Jurczak et al., 2012; Ye et al., 2012) and as in the
Extended Experimental Procedures. All experiments were done with male
mice, with the exception of the CL gene expression and tissue respiration
studies. Energy expenditure was analyzed using a Comprehensive Lab Animal
Monitoring System (Columbus Instruments). Fat and lean mass was measured
by MRI. Cold exposure and thermoneutrality experiments were done at either
4Co r3 0 C. Total adiponectin levels were measured by ELISA (Millipore).
Fat Transplant Studies
Inguinal SubQ adipose tissue was removed from 2- to 3-week-old Adipo-
PRDM16 KO, littermate control mice, or aP2-PRDM16 transgenic mice
(donors) and transplanted into the SubQ space of C57Bl6 mice (recipients)
that had been on HFD for 6 weeks. Transplants were performed as described
(Gunawardana and Piston, 2012). Glucose tolerance tests were done 6 weeks
posttransplant. Animals were fasted for 4 hr and then received intraperitoneal
glucose (1.5 mg/kg). Insulintolerancetests weredone 8weeks posttransplant.
Animals were fasted for 4 hr and then received intraperitoneal Humulin R insu-
lin (1.0 U/kg, Lilly).
Cell Culture
Forprimary adipocytes, SVF from inguinal or epididymal fatfrom 5- to6-week-
old mice was prepared and differentiated for 6–8 days as described (Kajimura
et al., 2009). Where indicated, cells were treated with isoproterenol 10 mM for
6 hr (Sigma) or FGF21 100 ng/ml overnight (R&D).
Statistics
The Student’s t test was used for single comparisons. Two-way ANOVA with
repeated-measures was used for the GTT studies. Chi-square was used
to compare the VISC-selective gene set to a randomly selected set of genes.
Unless speciﬁed, an asterisk (*) indicates p < 0.05.
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EXTENDED EXPERIMENTAL PROCEDURES
Animals
To generate PRDM16
lox/lox mice, BAC recombineering was used to retrieve  16 kb of genomic sequence encompassing exon 9 of
Prdm16 from a 129Sv BAC clone (RPCIB731F20213Q from 129s7/AB2.2 BAC library) into plasmid PL253 (Adams et al., 2005; Liu
etal.,2003). Aﬂoxed PGK-Neo cassette fromPL452 was integrated  280bpupstream of exon9, followed byCre mediated excision
of PGK-Neo in bacteria, leaving a single LoxP site upstream of exon 9. A cassette containing FRT-PGK-Neo-FRT-LoxP was inte-
grated 300 bp downstream of Exon 9. The resulting targeting construct (PL253-Prdm16Ex9Neo) was electroporated into 129Sv
ES cells (courtesy of Dr. Brad Lowell). ES clones were screened for homologous recombination by Southern blotting using probes
50 and 30 of the targeting area. Positive clones were injected into C57Bl6 blastocysts to derive chimeric mice. Germline transmission
ofthetargetedallelewasconﬁrmedbySouthernblotting.ThePGK-NeoselectioncassettewasexcisedbybreedingwithRosa26-Flp
deleter mice (Jackson Laboratory). PRDM16
lox/lox mice were backcrossed to C57Bl6 mice for at least 8 generations. PRDM16
lox/lox
micewerethencrossedtoeitherZp3-cre(JacksonLaboratory)orAdiponectin-cremice(providedbyDr.EvanRosen).Wt1
lox/loxmice
were provided by Dr. Vicki Huff.
Molecular Studies
Total RNA from cultured cells or tissues was isolated using TRIzol (Invitrogen) along with QIAGEN RNeasy mini kits. For qPCR anal-
ysis, RNA was reverse transcribed using the ABI high capacity cDNA synthesis kit. cDNA was used in qPCR reactions containing
SYBR-green ﬂuorescent dye (ABI). Relative mRNA expression was determined by normalization with TBP levels using the DD Ct
method.Primersequencesareavailableonrequest.Forwesternblotting,nuclearextractsorwholecelllysateswereprepared,sepa-
rated by SDS-PAGE, and transferred to ImmobilonP membranes (Millipore).
Immunohistochemistry
For UCP1 immunohistochemistry, slides were deparafﬁnized in xylene, hydrated in 95%, 80% and 70% ethanol, and rinsed in water
beforeheat-mediatedantigenretrievalin10mMpH6.0sodiumcitratebuffer.Quenchingofendogenousperoxidaseswasperformed
usingperoxidasequenching solution(Invitrogen).Slideswereblockedin10%goatserumandincubatedwithrabbitpolyclonal UCP1
antibody (Abcam, ab10983) at 2 mg/ml in PBS-T/1% BSA overnight at 4 C. Slides were washed in PBS-T and incubated with 1:500
donkey anti-rabbit IgG HRP-linked antibody (GE healthcare) before developing using SuperPicture 3rd Gen IHC Detection Kit (Invi-
trogen). Hematoxylin was used as counterstain. Crown-like structures were detected by immunohistochemistry using mouse mono-
clonal anti-MAC2 (Cederlane Labs) as described (Giordano et al., 2013).
Metabolic Phenotyping
Miceweremaintainedonstandardchowor60%HFD(ResearchDiets)with12hrlightcycles.Energyexpenditurewasanalyzedusing
a Comprehensive Lab Animal Monitoring System (Columbus Instruments). Mice were acclimated for at least 24 hr before measure-
ments were taken. Hyperinsulinemic euglycemic clamps were performed as described (Jurczak et al., 2012). After an overnight fast,
micewere infused for120min with3-
3H-glucose to determine basal glucose turnover. Next,mice were given aprimed/constant infu-
sion of insulin [(3 mU/kg-min)] and 3-
3H-glucose (0.1 mCi/min) and variable infusion of 20% dextrose to maintain euglycemia. A bolus
injection of
14C-2-deoxyglucose was given during the last 50 min to assess tissue-speciﬁc glucose uptake. Plasma samples were
collected by tail bleed at set time points to determine plasma glucose, tracer, insulin and fatty acid concentrations. Calculations
of glucose turnover were made at steady state during the last 40 min of the clamp.
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Figure S1. PRDM16 Deletion in Adipocytes Results in Altered Gene Expression, Related to Figure 1
(A and B) qPCR analysis of Ucp1 mRNA from multiple adipose tissues from 8- to 10-week-old male wild-type mice (n = 9), normalized to mRNA expression in
brown adipose tissue (A) or from in vitro differentiated primary adipocytes, normalized to mRNA expression in inguinal cells (n = 3) (B).
(C) Targeting construct for PRDM16.
(D) Metabolic characterization of male Adiponectin-Cre
+ and wild-type control mice, n = 7 per group.
(E)Normalizedgene expression of thermogenic, brownadipose, and mitochondrialgenesinvisceraladipose tissue(F) from Adipo-PRDM16 KOand controlmice
at ambient temperature. Mice were males, 6–8 weeks old, n = 5 per group.
Data are presented as mean ± SEM.
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117Figure S2. PRDM16 Regulates Thermogenic Gene Expression In Vivo and In Vitro, Related to Figure 2
(AandB)NormalizedthermogenicgeneexpressioninbrownadiposetissueandsubcutaneousadiposetissuefromAdipo-PRDM16 KOandcontrolmiceeitherat
room temperature or following 6 days at 4 C. Cold exposure was done with male 6- to 8-week-old mice, n = 4 per group.
(C)NormalizedthermogenicgeneexpressioninvisceraladiposetissuefromAdipo-PRDM16KOandcontrolmiceeitheruntreatedorfollowingﬁvedailyinjections
of CL 316,243 at a dose of 1 mg/kg. CL treatment was done with female 6- to 8-week-old mice, n = 5–6 per group.
Dataarepresentedasmean±SEM.*p<0.05knockoutversuscontrolcoldexposedorCL316,243treated.#,p<0.05knockout versuscontrolroomtemperature
or untreated.
(D) Core body temperature over a time course of acute cold exposure at 4 C in control and Adipo-PRDM16 KO mice. 6-8 week old male mice were used, n = 3–4
per group.
(E) Gene expression in subcutaneous adipocytes from control and Adipo-PRDM16 KO mice, differentiated in vitro. *p < 0.05 knockout versus control.
(F and G) Subcutaneous adipocytes from control and Adipo-PRDM16 KO mice, differentiated in vitro and treated with isoproterenol (C) or FGF21 (D). #, p < 0.05
control versus knockout untreated. *p < 0.05 control versus knockout treated. n = 3 per group.
Data are presented as mean ± SEM.
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Figure S3. Metabolic Analysis in Adipo-PRDM16 KO Mice, Related to Figure 3
(A) Food intake (g/24 hr).
(B) Activity in day and night.
(C) Oxygen consumption.
(D) Respiratory exchange ratio (RER).
Data are from 10- to 12-week-old, male control and Adipo-PRDM16 KO and mice.
Data are presented as mean ± SEM. *p < 0.05.
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Figure S4. Metabolic Analysis in Adipo-PRDM16 KO Mice at Thermoneutrality or on HFD, Related to Figure 4
(A and B) Weight curves of control and Adipo-PRDM16 KO mice at thermoneutrality and fed either a standard chow (A) or HFD (B). Experiments were done with
male mice, 6–8 weeks old at the start of the experiment. n = 4–6 per group.
(C) Food intake (g/24 hr).
(D) Activity in day and night.
(E) Oxygen consumption.
(F) Respiratory exchange ratio (RER).
Data in (C)–(F) are from control and Adipo-PRDM16 KO and mice after 2 weeks on HFD. The experiment was done with male mice, 8 weeks old at the start of the
experiment, n = 8 per group.
Data are presented as mean ± SEM. *p < 0.05.
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Figure S5. Altered Cell Size and Immune Cell Inﬁltration in Subcutaneous Adipose Tissue in Adipo-PRDM16 KO Mice, Related to Figure 5
(A) Expression levels of adipocyte differentiation genes in subcutaneous adipose tissue from male control and Adipo-PRDM16 KO mice after 18 weeks on HFD.
n = 11 per group.
(B)CellsizeinepididymalvisceraladiposetissuefromAdipo-PRDM16 KOandcontrolmicefollowing18weeksonHFD.Representativeimagesfromhematoxylin
and eosin (H&E) strained sections. Images are shown at 53 magniﬁcation.
(C) CD11b
+F4/80
+ macrophages in visceral fat and spleen from high-fat fed control and Adipo-PRDM16 KO mice.
(D) Foxp3
+ T regulatory cells in subcutaneous and visceral fat and spleen from high-fat fed control and Adipo-PRDM16 KO mice.
For (C) and (D), experiment was done with male mice 8–10 weeks old at start of high-fat feeding, n = 5–6 per group.
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121Figure S6. Hyperinsulinemic-Euglycemic Clamp Studies in Adipo-PRDM16 KO Mice, Related to Figure 6
(A) Fasting and clamped glucose values.
(B) Glucose infusion rate.
(C) Fasting and clamped insulin levels.
(D) mRNA expression levels in brown adipose tissue and subcutaneous adipose tissue.
The clamp studies were done with male mice, 8 weeks old at the start of high-fat feeding. n = 7–8 per group.
(E) Total adiponectin levels by ELISA. Levels measured in make mice after 6 weeks on HFD, n = 10 per group.
For (A)–(E), data are presented as mean ± SEM. *p < 0.05. #, 0.06 for Pgc1a and 0.10 for Ucp1.
(F) Western blot for total and phosphorylated Akt in primary subcutaneous adipocytes.
Data are from control and Adipo-PRDM16 KO primary subcutaneous adipocytes.
(G) Intraperitoneal glucose tolerance test (1.5 mg/kg) in high-fat fed recipients of Adipo-PRDM16 KO, control, or PRDM16 transgenic subcutaneous adipose
tissue. The GTT was done 6 weeks following transplantation. n = 5 per group.
Data are presented as mean ± SEM. *p < 0.05 by ANOVA.
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Figure S7. Cell-Autonomous Induction of a Visceral Adipose Tissue Gene Expression Proﬁle in Adipo-PRDM16 KO Subcutaneous Adipo-
cytes, Related to Figure 7
(A) Normalized expression of proinﬂammatory genes and (B) transcription factors in visceral adipose tissue from high-fat fed control and Adipo-PRDM16 KO
mice. Experiments were done in male mice after 18 weeks on HFD. n = 11 per group.
(C) Normalized expression of proinﬂammatory genes and (D) transcription factors in primary subcutaneous adipocytes differentiated in vitro from control and
Adipo-PRDM16 KO mice. n = 3 per group.
(E) Differentiation time course showing PRDM16 and Wt1 mRNA levels in primary subcutaneous adipocytes from control and Adipo-PRDM16 KO mice. *p < 0.05
versus day 4 mRNA expression level.
Data are presented as mean ± SEM. *p < 0.05. # in (C), p = 0.057.
S8 Cell 156, 304–316, January 16, 2014 ª2014 Elsevier Inc.
123A Special Population
of Regulatory T Cells
Potentiates Muscle Repair
Dalia Burzyn,1 Wilson Kuswanto,1 Dmitriy Kolodin,1 Jennifer L. Shadrach,2,3 Massimiliano Cerletti,2 Young Jang,2
Esen Seﬁk,1 Tze Guan Tan,1 Amy J. Wagers,2,3 Christophe Benoist,1 and Diane Mathis1,*
1Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA
2Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA
3Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
*Correspondence: cbdm@hms.harvard.edu
http://dx.doi.org/10.1016/j.cell.2013.10.054
SUMMARY
Long recognized to be potent suppressors of
immune responses, Foxp3
+CD4
+ regulatory T (Treg)
cells are being rediscovered as regulators of nonim-
munological processes. We describe a phenotypi-
cally and functionally distinctpopulationofTreg cells
that rapidly accumulated in the acutely injured
skeletal muscle of mice, just as invading myeloid-
lineage cells switched from a proinﬂammatory to a
proregenerative state. A Treg population of similar
phenotype accumulated in muscles of genetically
dystrophic mice. Punctual depletion of Treg cells
during the repair process prolonged the proinﬂam-
matory inﬁltrate and impaired muscle repair, while
treatments that increased or decreased Treg activ-
ities diminished or enhanced (respectively) muscle
damage in a dystrophy model. Muscle Treg cells ex-
pressedthegrowthfactorAmphiregulin,whichacted
directlyonmusclesatellitecellsinvitroandimproved
muscle repair in vivo. Thus, Treg cells and their prod-
ucts may provide new therapeutic opportunities for
wound repair and muscular dystrophies.
INTRODUCTION
Regulatory T (Treg) cells, particularly those of the Foxp3
+CD4
+
subset, are critical regulators of immune responses (Josefowicz
et al., 2012). They were originally described as controlling the
activities of other T cells but were later recognized to regulate
B cells and several innate immune system players. There have
alsobeenrecentreportsofTregcellcontrolovernonimmunolog-
ical processes. Perhaps the best-characterized example is a
unique population of Treg cells residing in the visceral adipose
tissue (VAT) and regulating metabolic indices (Feuerer et al.,
2009; Cipolletta et al., 2011). The prevalence, transcriptome,
and T cell receptor (TCR) repertoire of this population are all
distinct from those of their counterparts in lymphoid organs.
Surveying a variety of tissues to see whether other nonimmuno-
logical processes might be controlled by analogous Treg popu-
lations, our attention was drawn to a substantial accumulation of
Foxp3
+CD4
+ T cells in skeletal muscle undergoing repair after
acute injury.
Skeletal muscle regeneration follows the same orchestrated
plan regardless of the cause of muscle damage. It is driven
largely by satellite cells, a pool of quiescent precursors closely
associated with muscle ﬁbers (Tabebordbar et al., 2013). In
response to injury, these cells become activated, proliferate,
differentiate, migrate, and fuse to form new myoﬁbers. This
series of events is controlled by the sequential activation and
repression of speciﬁc transcription factors (Rudnicki et al.,
2008). With muscular dystrophies, in which chronic myoﬁber
loss occurs due to genetic defects, the satellite cell pool is called
on repeatedly, so it can exhaust or lose function over time,
dampening the repair process (Tabebordbar et al., 2013).
Regeneration of skeletal muscle is inﬂuenced by inﬂammatory
events that accompany repair (Tidball and Villalta, 2010).
Following an early, transient recruitment of neutrophils, myeloid
mononuclear cells, mainly derived from a pool of circulating
monocytes, inﬁltrate the injured tissue. Within days, the myeloid
inﬁltrate transitions from a pro- to an anti-inﬂammatory pheno-
type, a shift that is critical for proper muscle repair. An initial
population of proinﬂammatory, or M1-type, macrophages is
required for clearance of apoptotic or necrotic cells and deriva-
tive debris; a subsequent population of anti-inﬂammatory, or
M2-type, macrophages has various proregenerative functions,
suchasmatrix remodeling and promotion ofangiogenesis. Abla-
tion or impaired recruitment of macrophages severely compro-
mises muscle repair.
Though far less markedly, lymphocytes also accumulate in
skeletal muscle after acute injury, as well as in the dystrophin-
deﬁcientmusclesofmiceharboringthemdxmutationorhumans
with Duchenne muscular dystrophy (DMD) (Tidball and Villalta,
2010). Their function has not been well studied, although both
CD4
+ and CD8
+ T cells seem to promote the mdx pathology.
Even less is known about the composition and function of inﬁl-
trating T cell populations in models of acute muscle injury. In
particular, the contribution of Treg cells is yet to be addressed.
Here, we uncover a unique population of CD4
+Foxp3
+ Treg
cells that accumulates in skeletal muscle shortly after acute
1282 Cell 155, 1282–1295, December 5, 2013 ª2013 Elsevier Inc.
124injury. We address the impact of this population on muscle
repair, its implication in genetically determined muscle aber-
rancies, and the potential therapeutic effects of modulating this
population and one of the proregenerative factors it produces.
RESULTS
Treg Cells Accumulate in Acutely Injured Skeletal
Muscle Just as the Myeloid Cell Inﬁltrate Switches from
a Proinﬂammatory to a Proregenerative Phenotype
Intramuscular (i.m.) administration of cardiotoxin (Ctx), which
rapidly induces myoﬁber necrosis, provides a convenient and
well-studied model of tissue repair after acuteinjury. We injected
thetibialisanterior(TA),gastrocnemius,andquadricepsmuscles
of C57Bl/6 (B6) mice with Ctx and analyzed the resulting cellular
inﬁltrate various times later; control cells isolated from the unin-
jured contralateral muscles or the spleen were evaluated in
parallel. As anticipated (Arnold et al., 2007), there was a rapid
increase in CD11b
+Gr1
  myeloid mononuclear cells beginning
before day 1, initially a proinﬂammatory Ly6c
hi population but
switching to an anti-inﬂammatory Ly6c
lo population by day 4
(Figure 1A, top). Around this time, Treg cells began to accumu-
late in the injured muscle, their frequency within the CD4
+
T cell compartment gradually increasing to  50% by 14 days
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Figure 1. Treg Accumulation at the Site of Injury
(A–C)CytoﬂuorometricanalysesofhindlimbmuscleinﬁltratesafterCtxinjury.(A)Top:Ly6cexpressionbyCD11b
+cells.Middleandbottom:Foxp3expressionby
CD4
+ cells. Numbers depict % of gated cells. Representative of three experiments. (B and C) Summary data on fraction and number of cells. Mean ± SD (n R 4).
(D) Immunoﬂuorescence microscopy of muscle sections 7 days after injury. The same section without (top) or with (bottom) DAPI. Arrows show Tregs in close
contact with regenerating myoﬁbers. Original magniﬁcation 3400.
(E) As in (B), but after cryoinjury.
See also Figure S1.
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125after Ctx injection and remaining at that level until at least day 30
(Figures 1A, middle, and 1B). Numbers of Treg and conventional
CD4
+T(Tconv)cellsbothpeakedatday4afterinjury(Figure1C),
mirroring the total number of CD45
+ cells and T cells in the
inﬁltrate (Figure S1 available online). However, while Tconv cell
numbers had dropped to levels characteristic of uninjured
muscle by 28 days after Ctx injection, the number of Treg cells
remained elevated by 8-fold (1.05 ± 0.38 3 10
4 versus 0.13 ±
0.06310
4cells/gmuscle;p=0.01;Figure1C).Stainingoffrozen
sections with a ﬂuorescently tagged anti-Foxp3 monoclonal
antibody (mAb) revealed Foxp3
+ cells both in heavily inﬁltrated
(probably necrotic) areas and in regions between regenerating
ﬁbers (recognizable as centrally nucleated, dystrophin-positive
cells) (Figure 1D). An analogous accumulation of Treg cells was
observed in a cryoinjury model (Figure 1E).
The Transcriptome of Muscle Treg Cells Is Distinct from
that of Other Treg Populations, Especially Those
Located in Lymphoid Organs
Four or 14 days after i.m. Ctx injection, we isolated Treg and
Tconv cells from muscles and lymphoid organs and performed
microarray-based gene-expression proﬁling. (Note that inade-
quate numbers precluded a comparison with analogous pop-
ulations from uninjured muscles.) According to both simple
comparison plots (Figure 2A) and principal components analysis
(PCA)(Figure2B),thetranscriptomeofmuscleTregcellsdiffered
from that of their spleen or lymph node counterparts much more
than the latter two did from each other. Muscle Tregs were most
like Treg cells located in adipose tissue (Figure 2B) but were still
readily distinguishable; afewhundred transcriptsup-ordownre-
gulated >2-fold in one vis-a `-vis the other. The similarity to
another Treg population residing in nonlymphoid tissue, and
dissimilarity to lymphoid-organ Treg cells, did not simply reﬂect
a higher activation state in tissues, because few of the distin-
guishing transcripts were members of a previously determined
Treg activation signature (Hill et al., 2007)( Figure 2C). Neither
did itreﬂect a universal ‘‘inﬂammation signature,’’ since the mus-
cle Treg transcriptome was distinguishable from those of Tregs
at several inﬂamed sites (Figure S2). While exhibiting a distinct
gene-expression proﬁle, muscle Treg cells are clearly ‘‘Treg,’’
showing the anticipated pattern of expression of 91% of the
canonical Treg signature (Hill et al., 2007); in particular, elevated
levels of diagnostic transcripts such as those encoding Foxp3,
CD25, and CTLA-4 (Figure 2D).
A fold-change/fold-change (FC/FC) plot afforded a more
detailed look at the muscle Treg transcriptome, revealing a set
of genes (highlighted in orange) that distinguish muscle Treg
from spleen Treg cells and spleen or muscle Tconv cells, and
another set (in gray) overexpressed by the two muscle popula-
tions vis-a `-vis their two spleen counterparts (Figure 2E; Table
S1). The ﬁrst group includes loci encoding an anti-inﬂammatory
cytokine (interleukin [IL]-10), chemokine receptors (e.g., CCR1),
and two well-known growth factors (platelet-derived growth
factor [PDGF] and Amphiregulin [Areg]] (Pastore et al., 2008).
Loci upregulated in both Treg and Tconv cells from injured mus-
cle include those encoding KLRG1, an activation marker; CCR2,
important for the recruitment of various leukocyte populations to
injured muscle (Warren et al., 2005); and ST2 (encoded by Il1rl1),
which is the receptor for the ‘‘alarmin’’ IL-33 (Schmitz et al.,
2005). A third group of genes (in pink) was repressed in muscle
Treg (and to varying degrees Tconv) cells; notably, those encod-
ing certain chemokine receptors (CXCR5 and CCR7) and several
proteins implicated in the Wnt signaling pathway (TCF7, LEF1,
SATB1).
We selected several of the genes upregulated in muscle Treg
cells and conﬁrmed their induced expression at the protein level
by ﬂow cytometry (Figure 2F). Such an analysis also revealed
muscle Tregs to be high-level expressors of Helios and Neuropi-
lin (Figure 2G) and were therefore likely to be Treg cells exported
as such from the thymus.
Treg Cells in Injured Muscle Are Clonally Expanded and
Display a Unique Repertoire of TCRs
The rapid accumulation of Treg cells at the injury site could
reﬂect their inﬂux, proliferation, or some combination of the
two. Four days after Ctx injection, almost all muscle Treg cells
stained for Ki67 (Figure 3A), which is expressed in all stages of
the cell cycle except for the resting, G0, phase. EdU (5-ethynyl-
20-deoxyuridine), incorporated by cells in S phase, was detected
in20%ofmuscleTregsafter24hroflabeling(Figure3B).Amuch
lower fraction of splenic Treg cells was proliferating according to
both staining criteria. The muscle Tconv population also
exhibited an increased frequency of Ki67
+ and EdU
+ cells
compared with the spleen Tconv subset, although the values
remained signiﬁcantly lower than those observed for muscle
Treg cells (Figures 3A and 3B).
ToassessclonalityoftheTregpopulationexpandinginacutely
injured skeletal muscle, we studied TCR repertoires by
sequencing the complementarity-determining region (CDR) 3
of the TCR a and TCR b chains of individually sorted cells.
Already at day 2 after injury, and continuing out at least until
day 8, a substantial proportion (20%–40%) of muscle Treg cells
were clonally expanded (Figures 3C and 3D; Table S2). This
sequence proﬁle contrasted starkly with that of splenic Treg
cells, for which there was not one repeat sequence in the 692
sampled. As expected from the Ki67 and EdU stainings, we
also found clonal expansion of muscle Tconv cells (Figure 3D;
Table S2). However, there was not a single example of TCR-
sequence sharing between muscle Treg and Tconv cells.
In the muscle Treg data sets, there was a striking case of a
repeatedly detected TCR: identical paired CDR3 a and b (and
corresponding nucleotide) sequences picked up in multiple
mice in completely independent experiments (Figure 3E). Inter-
estingly, there were a few Treg cells (from multiple individuals)
that had the same TCR b chain paired with an a chain whose
CDR3 was modiﬁed only conservatively (AV/VL). These repeat
sequences were found in mice 2 or 4, but not 8, days postinjury.
They never showed up in the bulk spleen Treg or muscle Tconv
cell pools.
Ablation of Treg Cells Compromises Muscle Repair
According to Multiple Criteria
Having uncovered a unique population of Treg cells in the inﬁl-
trates of skeletal muscle undergoing repair in response to acute
injury, we asked whether they play a role in muscle regeneration.
We punctually ablated Treg cells at the time of muscle injury,
1284 Cell 155, 1282–1295, December 5, 2013 ª2013 Elsevier Inc.
126exploiting a mouse line wherein the diphtheria toxin receptor
(DTR) is expressed under the control of Foxp3 regulatory
elements (Kim et al., 2007). B6.Foxp3-DTR
+ and B6.Foxp3-
DTR
  littermates (hereafter referred to as DTR
+ and DTR
 ,
respectively) were given DT intraperitoneally (i.p.) starting from
the time of im Ctx injection and were analyzed 1 week later, a
time chosen to avoid the multiorgan autoimmunity provoked
by long-term ablation of Treg cells (Kim et al., 2007). This proto-
col resulted in effective depletion of Tregs in the injured muscle
of the DTR
+ mice (Figure 4A, top) as well as in the lymphoid
organs (Figure 4A, bottom).
According to multiple criteria, the loss of Treg cells had
profound effects on the muscle repair process. First, the size
of the cellular inﬁltrate was increased in the absence of Treg
cells, assessed either as numbers of total CD45
+ cells or as
the fraction of T cells (Figure S3A). In addition, the myeloid cell
compartment failed to undergo the expected switch from a pri-
marily proinﬂammatory, Ly6c
hi to a primarily anti-inﬂammatory,
A B
E
Spleen/LN Tregs
VAT Tregs
Muscle Tregs
Kidney/liver/lung/skin Tregs
F
Injured muscle Tregs 
S
p
l
e
e
n
 
T
r
e
g
s
 
L
y
m
p
h
 
n
o
d
e
 
T
r
e
g
s
  153
371
420
529
28
44
L
y
m
p
h
 
n
o
d
e
 
T
r
e
g
s
 
Spleen Tregs  Injured muscle Tregs 
10
103
104
102
10 103 104 102
10
103
104
102
10 103 104 102
10
103
104
102
10 103 104 102
Muscle Tregs vs Spleen Tregs 
M
u
s
c
l
e
 
T
c
o
n
v
s
 
v
s
 
S
p
l
e
e
n
 
T
c
o
n
v
s
1
10
0.1 30 1 10
CD103 KLRG1 CCR2 TIM-3 ST2
D
91
234 0
0
86
209 25
5
10-7
10-9
10-3
10-5
1
Tregs vs Tconvs 
Spleen
Muscle
0 3 1 . 01 1 0
10-7
10-9
10-3
10-5
1
t
-
t
e
s
t
 
p
-
v
a
l
u
e
 
T
r
e
g
s
 
v
s
 
T
c
o
n
v
s
Treg up signature Treg down signature
Helios Neuropilin-1 G
Muscle Tregs vs Spleen Tregs
10-7
10-9
10-3
10-5
1
0 3 1 . 011 0 2 0.5
10-7
10-9
10-3
10-5
1
t
-
t
e
s
t
 
p
-
v
a
l
u
e
 
m
u
s
c
l
e
 
T
r
e
g
s
 
v
s
 
s
p
l
e
e
n
 
T
r
e
g
s
Complete transcriptome
Minus Treg activation signature
Foxp3
CD25
CTLA4
Foxp3
CD25
CTLA4 Havcr2
Il10
Areg
Ccr1
Ccr8
Il1rl1
Gzmb
Ccr2
Klrg1
Ccr5
Cxcl10
Gpr83
Tcf7
Lef1
Satb1
Ccr7
Dtx1
Cxcr5
Ccrl2
Sell
128 335
153 369
IL-10
Spleen
Tregs
Muscle
Tregs
Isotype
control
Spleen
Tregs
Muscle
Tregs
Isotype
control
C
Nebl
Neb
Figure 2. A Unique Population
(A–E) Gene-expression analyses on cells 14 days after Ctx injury. (A) Comparison plots of normalized expression values. Numbers indicate the number of genes
whose expression differed by more than 2-fold. (B) PCA analysis comparing muscle Tregs 4 or 14 days after Ctx injury with other Treg populations. Each dot
representsthemeanofthreeindependentexperiments.(C)Top:volcano plotcomparinggeneexpressionofmuscleversusspleen Tregs.Bottom:sameplotafter
subtraction of the Treg activation signature (Hill et al., 2007). Numbers represent the number of differentially expressed genes (>2-fold). (D) Volcano plots
comparing gene expression of Treg versus Tconv cells. Treg signature genes (Hill et al., 2007) are highlighted in red (induced) or blue (repressed). Numbers
represent the number of genes from eachsignature expressed byeachpopulation. (E)Fold-change differences ingene expressionbetween Treg and Tconv cells
from muscle and spleen. Differentially expressed genes are highlighted in orange, gray, or pink.
(F and G) Cytoﬂuorometric analyses of surface and intracellular markers. Histograms depict expression by Foxp3
+ T cells from muscle (red) or spleen (black).
Gray: isotype control.
See also Figure S2 and Table S1.
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127Ly6c
lo phenotype (Figures 4B and S3A). Similar results were
obtained when DT was administered i.m., which speciﬁcally
depleted muscle Treg cells without detectably affecting their
counterparts in lymphoid organs (data not shown).
DTR-mediated in vivo ablation of a designated cell population
is known to be apoptotic and noninﬂammatory (Bennett and
Clausen, 2007). Nonetheless, as detailed in Figure S3B and its
legend, we performed an experiment on female heterozygous
DTR-positive mice to show that the more inﬂammatory ﬂavor
of the inﬁltrate in mice lacking Treg cells was not a simple artifact
related to their death, but rather a reﬂection of their functional
absence.
Second, Treg cell ablation altered the histological features of
skeletal muscle repair (Figure 4C). Although centrally nucleated
ﬁbers indicative of regeneration could be detected in muscle
from both DTR
  and DTR
+ mice, in the latter case, the tissue
structure showed a disorganized pattern, with several foci of
inﬂammation. As anticipated, no inﬁltrate or regenerating ﬁbers
were found in the contralateral, uninjured muscles from mice
that did or did not have Treg cells (data not shown). One of
the later consequences of impaired muscle repair is ﬁbrosis:
Gomori’s Trichrome staining showed Treg-less mice to have a
substantial accumulation of collagen in the injured muscle
compared with their Treg-positive littermates (Figure 4D). To
provide a more quantitative view, we returned to the cryo-injury
model, wherein the area of injury is clearly delimited. Global
examination conﬁrmed the impaired reparative capacity in
Treg depleted mice; a quantitative evaluation indicated that the
C
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Figure 3. Clonal Expansion of the Treg Population at the Injury Site
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(C) TCR CDR3 a and CDR3 b sequences for individual cells. Each pie chart represents a single mouse. n, number of analyzed sequences per mouse. Total
frequency of expanded clones shown at the top right.
(D) Summary of clonal TCR frequencies over time. Open circles correspond to mice analyzed later in independent experiments for Figure 7. Mean ± SD (n R 3).
(E) Identical paired CDR3-a and b sequences found in multiple individuals in independent experiments. Two CDR3 a sequences from independent mice bear two
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See also Table S2.
1286 Cell 155, 1282–1295, December 5, 2013 ª2013 Elsevier Inc.
128number of centrally nucleated ﬁbers was signiﬁcantly lower in
Treg-depleted than in normal muscles, with some muscles
from DTR
+ mice showing an almost complete absence of regen-
erative ﬁbers (Figure 4E).
Third, the absence of Treg cells during muscle repair had an
impactonmuscleprogenitorcells.Satellitecellsarethepredom-
inant, if not sole, source of regenerated muscle ﬁbers after acute
injury (Tabebordbar et al., 2013). Satellite cells were isolated
from uninjured or Ctx-injured muscle of DT-treated DTR
+ or
DTR
  mice by double-sorting CD45
 Sca-1
 Mac-1
 CXCR4
+
b1-integrin
+ myoﬁber-associated cells (Cerletti et al., 2008),
and their functionality was evaluated in clonal myogenesis
assays, as described in (Cerletti et al., 2012)( Figure 4F). Injury
substantially enhanced the fraction of satellite cells from DTR
 
mice that formed myogenic colonies; in contrast, there was far
less (not signiﬁcant) injury-induced enhancement of myogenic
activity in mice lacking Treg cells.
Fourth, to obtain a broad, unbiased view of the repair path-
ways impacted by Treg ablation, we performed microarray-
based gene-expression proﬁling of whole, unfractionated
muscle tissue. In general, for standard (DTR
 ) mice, sets of
genes were up- or downregulated early after injury (day 4),
and expression values began to return to normal as the wound
started to repair (day 8). The pattern of expression of many
genes was altered in the absence of Treg cells (DTR
+)( Figures
4G, S3C, and S3D; Table S3), with three main clusters meriting
discussion: One group (highlighted in blue) is composed of
genes encoding proteins with important roles in muscle homeo-
stasis and function. These loci were highly expressed in unin-
jured muscle and were downregulated in both DTR
  and
DTR
+ mice at day 4 after injury owing to the loss of mature mus-
cle ﬁbers. In muscle of DTR
  mice, transcript levels began to
increase by day 8, as efﬁcient repair ensued; however, in mus-
cle of DTR
+ individuals, expression of these loci remained low
or in decline at day 8, conﬁrming that the lack of Treg cells
compromised the recovery of muscle homeostasis after injury.
Another group (green) includes genes encoding proteins neces-
sary for muscle repair, like MyoG (myogenin) and Mmp12
(metallopeptidase-12), but also some factors related to the
immune response, in particular a number of chemokines and
chemokine receptors, some cytokine receptors, and C1qa, a
complement cascade trigger. In DTR
  mice, expression of
these loci was increased at day 4 but rapidly crashed there-
after, approaching the level in muscles of uninjured mice by
day 8. However, in DTR
+ mice, this drop did not occur or was
greatly attenuated, again suggesting an ineffective and pro-
longed repair process, especially given the recent report that
C1qa and related molecules strongly inhibit muscle regenera-
tion (Naito et al., 2012). Strikingly, the expression pattern of
C1qa in injured muscle was mirrored by that of C1qb, C1qc,
C1r, C1rb, and C1s as well (Figure S3D). A ﬁnal group (high-
lighted in red) is composed of two types of genes: those encod-
ing molecules characteristic of immune cells (e.g., CD8a, CD2)
and those specifying matrix proteins (e.g., Col6a5). Expression
of these loci was upregulated at day 4 and even more so at day
8 only in mice lacking Treg cells, reﬂecting their more pro-
nounced muscle inﬁltrate (Figure S3A) and ﬁbrotic collagen
deposition. Microarray expression values for multiple examples
of each of these groups are plotted in Figures 4G and S3D, and
conﬁrmatory quantitative PCR data for representative group
members are presented in Figure S3C. Monitoring expression
of these groups of genes should provide a novel and conve-
nient means to quantitatively assess the ﬁdelity of events
underlying muscle repair.
As illustrated in Figures S3E and S3F, Rag-deﬁcient mice,
lacking all lymphoid cells, showed more pronounced ﬁbrosis
than did wild-type individuals, measured histologically or by
quantifying collagen transcripts. However, ﬁbrosis was milder
and repair progressed more effectively in Rag-1-deﬁcient mice
than in Treg-depleted mice.
In summary, evaluations of myeloid cell numbers and pheno-
type, histology, satellite cell function, and global patterns of
gene expression all argue that Treg cells are important for
effective repair after acute injury of skeletal muscle. These
observations raise the question of whether Treg cells impact
muscle aberrancies in other contexts.
An Analogous Treg Population Is Expanded in the
Damaged Muscles of Mouse Models of Muscular
Dystrophy
In muscular dystrophies, chronic destruction of muscle ﬁbers is
accompanied by an inﬂammatory response and, in general, a
permanent inﬁltrate. Mdx mice carry a nonsense mutation in
the Dmd gene (encoding Dystrophin), which is analogous to
those found in DMD patients. In the mouse model, as in the
human disease, the most affected sites are the diaphragm and
hindlimb muscles. We analyzed the muscle inﬁltrate in 4-week-
old mdx mice, when the disease is in its acute phase, and at
12 weeks, during the chronic phase. In both muscle groups at
both ages, the fraction of Treg cells was signiﬁcantly elevated
vis-a `-vis the frequency in corresponding muscles of wild-type
mice; such an increase was not observed in the spleen (Fig-
ure 5A). Likewise, the muscle inﬁltrates of Dysferlin-deﬁcient
mice, which model limb-girdle muscular dystrophy type 2B or
Miyoshi myopathy (Tabebordbar et al., 2013), were enriched in
Treg cells, while their frequency in the spleen was the same as
in wild-type controls (Figure S4A).
That the Treg cells accumulating in dystrophic muscle of mdx
mice were bona ﬁde muscle Tregs was indicated by their
elevated expression of phenotypic markers such as Areg, ST2,
KLRG1, and TIM-3 (Figure S4B). (Unfortunately, we could not
isolate adequate numbers of Treg cells from the muscles of
mdx mice to perform a transcriptome analysis [<500 Tregs/
mouse].) In addition, the Treg populations of mdx muscle ex-
hibited clonal expansions, with an even greater fraction of the
population derived from expanded clones and an even larger
average clone size than found for Ctx-injured muscles of wild-
type mice (compare Figures 5B and 3C; also see Table S2).
Next, we performed loss- and gain-of-function studies to
evaluate the role(s) of muscle Treg cells in mdx mice. It was
not feasible to use the B6.Foxp3-DTR system for the loss-of-
function experiments because both the Foxp3 and Dmd genes
are located on the X chromosome. Therefore, we manipulated
levels of Treg cells by treatment with an anti-CD25 mAb, an
approach that has been exploited by a number of investigators
to study Treg function (e.g., Suvas et al., 2004). Administration
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130of anti-CD25 to 2.5-week-old mdx mice did not reduce overall
Treg cell numbers, whether in skeletal muscle or the spleen,
but did largely eliminate the fraction expressing high levels of
CD25(Figure5C).Thischangewasaccompaniedbyasigniﬁcant
increase in serum levels of creatine kinase (CK), an enzyme
released into the blood upon muscle damage and a standard
indicator of muscle damage in dystrophic mouse models.
For the gain-of-function experiments, we made use of the
published observation that complexes of recombinant IL-2
and a particular anti-IL-2 mAb (clone JES6-1A12) can prefer-
entially expand Treg populations after injection into mice
(Boyman et al., 2006). A few days before the peak of acute dis-
ease (3 weeks of age), we administered IL-2:JES6-1A12 com-
plexes to mdx mice for 6 consecutive days. As anticipated,
this treatment induced a signiﬁcant increase in the frequency
of Treg cells in the muscle, which, in addition, displayed higher
levels of CD25 (Figure 5D, bottom). An elevated fraction of
Treg cells was also observed in the spleen immediately after
the cessation of treatment (14% and 42% of CD4
+ cells in
control and complex-administered mice, respectively; data
not shown), but this increase was not sustained (Figure 5D,
top). Accompanying the boost in Treg cells was a signiﬁcant
reduction in serum CK levels (Figure 5D), indicative of less
muscle damage.
To gain further insight into the effects of Treg depletion in
dystrophic muscle, we performed whole-muscle transcriptional
analyses, comparing muscles from control and Treg-depleted
mdx mice (Figure S4C). The genes encoding osteopontin
(Spp1; 2.1-fold) and connective-tissue growth factor (Ctgf;
1.8-fold), both of which promote skeletal muscle ﬁbrosis and
mdx pathology (Morales et al., 2011; Vetrone et al., 2009),
were upregulated in the absence of Tregs. More generally, it
became clear that, on the one hand, Treg cells were protecting
mdx mice from muscle pathology, as their ablation downregu-
lated most of the aforementioned gene set related to muscle
homeostasis and function (highly expressed in healthy wild-
type muscle), but that, on the other hand, Treg cells were pro-
moting muscle repair because their removal upregulated
expression of the set of genes whose inhibition was normally
an accompaniment to healthy repair (Figure S4C). (In addition,
there was a striking correspondence between the genes
induced in muscle from Treg-ablated mdx mice and those
repressed in muscle from amphiregulin-treated mice [dis-
cussed below].)
Amphiregulin, a Growth Factor Overexpressed by
Muscle Treg Cells, Enhances Muscle Regeneration
The regulation that muscle Treg cells imposed on inﬁltrating
myeloid cells was probably responsible, at least in part, for the
impaired muscle repair observed in the absence of Tregs. How-
ever, analogous to the situation with VAT (Feuerer et al., 2009;
Cipolletta et al., 2012), it is likely that other mechanisms also
play a role, including a direct effect of muscle Tregs on muscle
progenitors, nascent myoﬁbers, or other nonhematopoietic cell
types within muscle. Among the transcripts preferentially ex-
pressed by muscle Tregs vis-a `-vis lymphoid-organ Tregs, Areg
stood out as encoding a candidate factor capable of directly
impacting muscle regeneration. Areg belongs to the epithelial
growth factor (EGF) family and signals through the EGF receptor
(EGFR) system (Shoyab et al., 1989). EGFR is expressed by a
variety of cells, including muscle satellite cells and a myoblast
cell line, in which it appears to have antiapoptotic/survival func-
tions (Golding et al., 2007; Horikawa et al., 1999). Examination
of the ImmGen database (http://www.immgen.org) indicated
that most hematopoietic cell-types express no or only low levels
of Areg transcripts (Figure 6A). Nor is Areg expressed at signiﬁ-
cantlevelsinthenonhematopoieticcell-typesexaminedbyImm-
Gen (Figure S5A). In addition, the base-line levels of Areg
transcriptsininjuredoruninjuredwhole-musclesamples,wherein
muscle-lineage cells were in great preponderance, argues that
muscle cells do not make signiﬁcant Areg in this context either
(Figure S5A). However, Areg transcripts were readily detectable
in a few Treg populations. They were found at high levels in
muscle and adipose-tissue Treg cells, although hardly, if at all,
in lymphoid-organ Tregs. Substantial expression of Areg protein
in muscle Tregs, but only limited expression by their splenic
counterparts, was conﬁrmed by ﬂow cytometry (Figure 6B). The
fractionofmuscleTregcellsexpressingAregproteinbegantoin-
crease at day 4 and peaked at day 7 after Ctx injury (Figure S5B).
If Areg is important for the proregenerative function of muscle
Treg cells, then treatment of Treg-ablated mice with this growth
factorshouldamelioratetheirdeﬁcitinmusclerepairsubsequent
to acute injury. To test this notion, we administered Areg to Ctx-
injected, DT-treated DTR
+ mice according to the protocol
illustrated in Figure 6C, and evaluated gene-expression proﬁles
of repairing muscles at days 4 and 8 after injury. (Note that the
initial Areg injection was done i.m., promoting the muscle spec-
iﬁcity of its effects.) Transcriptome changes were evaluated in
terms of the three gene clusters deﬁned in Figure 4G and
Figure 4. Treg Ablation Impairs Muscle Regeneration after Wounding
Eight-week-old Foxp3
 DTR
+ or DTR
  littermates were injured with Ctx and treated with DT to induce Treg depletion.
(A and B) Flow cytometry of Treg and myeloid-lineage population, 7 days postinjury. Numbers in (A) refer to % CD4
+ T cells that are Foxp3
+, and numbers in (B)
refer to % Ly6c
 /lo or Ly6c
hi of CD11b
+ cells.
(C) Hematoxylin and eosin (H&E) staining of muscle sections 7 days after Ctx injury. Representative of at least three experiments. Original magniﬁcation 3100.
(D) Left: ﬁbrosis detection byGomori trichrome staining of muscle sections 13days after injury. Collagen stained inblue. Representative examplesof seven DTR
+
and seven DTR
  mice. Original magniﬁcation 3200. Right: summary quantiﬁcation.
(E) Left: H&E staining of muscle sections 7 days after cryoinjury. Original magniﬁcation 325 (left) and 3100 (middle and right). Representative examples of six
samples. Right: quantiﬁcation of regenerative ﬁbers per mm
2 of injured area. ***p < 0.001.
(F) Clonal myogenesis assays of satellite cells from uninjured or day 4 Ctx-injured muscles. Percent of wells seeded that showed a myogenic colony at day 5.
Summary of six clonal assays *p < 0.05; **p < 0.01.
(G) Left: FC/FC plot of gene expression values in muscle 4 versus 8 days after Ctx-induced injury in mice without (DTR
+) or with (DTR
 ) Tregs. Highlighted in
different colors are sets of genes described in the text. Right, representative examples of genes in each highlighted set.
See also Figure S3 and Table S3.
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Figure 5. Treg Cells Are Enriched in Muscles of Dystrophic Mice and Impact Muscle Damage
(A) Frequency of Foxp3
+ cells for mdx and control C57Bl/10 mice. Left: representative dot plots. Right: summary data. n = 5; **p < 0.01; ***p < 0.001.
(B) Treg clonal expansion in mdx muscle measured as described in the legend to Figure 3C.
(C) Loss-of-function experiments. Mdx mice treated with anti-CD25 mAb (clone PC61) over 10 days.
(D) Gain-of-function experiments. Mice treated with complexes of recombinant IL-2 and anti-iL-2 mAb (clone JES6-1A12).
(C and D) Left: representative dot plot numbers refer to % of cells in the indicated gates in total CD4
+ cells. Middle: summary data. Right: quantiﬁcation of serum
CKe. *p < 0.05; ***p < 0.001.
See also Figure S4 and Table S2.
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132detailed above. Expression of all three gene groups was largely
normalized in Areg-treated Treg-less mice: vis-a `-vis buffer-only
controls: ‘‘muscle homeostasis/function’’ genes were upregu-
lated; muscle ‘‘repair/regeneration’’ loci were repressed as
required for effective repair; and inﬂammatory transcripts and
collagens were also downregulated (Figure 6C). These results
were conﬁrmed in representative RT-PCR assays (Figure S5C).
We also tested whether administration of Areg was effective in
acontextwhereTregswerepresentasnormal(DTR
 orB6mice).
Under these conditions, Areg had a strong and rapid impact on
the ‘‘muscle homeostasis/function’’ and ‘‘repair/regeneration’’
gene groups but no signiﬁcant effect on the ‘‘immune response/
inﬂammation’’ groups, at least according to volcano-plot visuali-
zation and representative RT-PCR assays (Figures 6D and S5D).
More detailed analysis showed that Areg dampened expression
ofseverallociencodingproteinsrelatedtoﬁbrosis(e.g.,abattery
of collagens, Acta2, Adam12), and enhanced expression of loci
encoding molecules highly represented in healthy muscle, like
Pfkfb1 and 3 and Myl2 (Figure 6E).
Because our previous results indicated that Treg cells can in-
ﬂuence the efﬁcacy of myogenic colony formation by muscle
precursor cells (Figure 4F), and given the high-level expression
of Egfr by the satellite cells employed in our assays (and, paren-
thetically, minimal expression by muscle Treg cells; Figure S5E),
we investigated whether Areg might have a direct effect on sat-
ellite cells. Addition of Areg to myogenic assays signiﬁcantly
augmented the colony-forming efﬁciency of satellite cells from
unmanipulated B6 mice (Figure 6F). In addition, Areg enhanced
myogenic differentiation in bulk cultures of satellite cells, as indi-
cated both by increased levels of transcripts encoding myosin
heavy chain (MyHC) (Figure 6G, left) and by increased numbers
of cells that stained for MyHC protein (Figure 6G, center). In
contrast, there was no apparent difference in proliferation in sat-
ellite cell cultures with or without Areg (Figure 6G, right).
Since Areg was expressed by a small fraction of splenic Treg
cells in addition to a considerable proportion of muscle Tregs
(Figure 6B), we wondered whether the two Areg
+ populations
might somehow be related. As opposed to the lack of clonality
characteristic of bulk splenic Treg cells (Figure 3C),  5% of
the splenic Areg
+ subset was clonally expanded (Figure 7A).
There was, indeed, some degree of overlap between the CDR3
a and CDR3 b sequences of splenic Areg
+ Treg cells and those
of muscle Tregs (independent of their expression of Areg)
(Figure 7B). The muscle Areg
+ and Areg
  subsets showed no
difference in their extent of clonal expansion (Figure 7C) or in
theirrepresentationoftheoft-repeatedTCRsequenceillustrated
in Figure 3E( Table S2).
DISCUSSION
A Unique Population of Treg Cells that Accumulates in
Skeletal Muscle
There is growing appreciation that the Treg compartment is
heterogeneous, has multiple functions, and exerts inﬂuences
exceeding the boundaries of the immune system (Josefowicz
et al., 2012). Here, we have described a previously unrecognized
population of Treg cells that emerges in skeletal muscle sub-
jected to acute or chronic damage and have demonstrated
that these cells are important players in the muscle-repair
process.
Treg cells began to accumulate in injured muscle within days
after an insult. That this enrichment represents a conversion of
the Tconv to the Treg phenotype is unlikely given that essentially
all of the muscle Treg cells expressed Helios and Neuropilin,
considered to be markers of Treg cells exported as such from
thethymus,andthatnoneoftheirTCRsweresharedwithmuscle
(or lymphoid-organ) Tconv cells. Rather, the elevated levels of
muscle Tregs appear to reﬂect population expansion: they
were proliferating in the muscle, substantially more so than in
the spleen, and constituted a number of clonally expanded
micropopulations. There might also be preferential recruitment
of muscle-type Tregs to injured muscle, perhaps driven by one
or more members of the constellation of chemokine receptors
up- or downregulated vis-a `-vis lymphoid-organ Tregs, certain
of which have been implicated in migration of diverse leukocyte
subsets to skeletal muscle (Warren et al., 2005). Interestingly, a
small population of Areg
+ splenic Treg cells appeared to include
a muscle Treg constituent, evidenced by shared TCR se-
quences. But it is not clear at present whether the splenic popu-
lation seeds or arises from the Treg population accumulating in
injured muscle.
Several other elements of the muscle Treg transcriptome
distinguish it from that of lymphoid-organ Treg cells. Included
in the list of repressed genes is Satb1, which encodes a
chromatin organizer that inhibits Treg suppressive activity
(Beyer et al., 2011). The reduced numbers of Satb1 transcripts,
coupled with enhanced expression of transcripts encoding
other molecules linked to Treg suppressive function, like IL-
10, Gzmb, CTLA-4, and TIM-3 (Josefowicz et al., 2012),
support the idea that muscle Treg cells might be endowed
with especially strong suppressor activity. Moreover, muscle
Treg cells overexpressed certain genes whose products could
arm them to perform particularly effectively in the context of
regenerating muscle. Areg is a prime example. Interestingly, it
was recently reported that Areg might also impact Treg cells
directly and enhance their ability to suppress immune re-
sponses (Zaiss et al., 2013). However, expression of Egfr was
undetectable in Treg cells from lymphoid (spleen, lymph
node) or nonlymphoid (muscle, VAT) tissues in our microarray
studies.
In addition, the TCR repertoires of injured-muscle and
lymphoid-organ Treg cells were clearly distinct. There were
striking clonal expansions in the muscle Treg population and
one TCR a and TCR b chain pair was found over and over again
in different individuals despite Draconian measures to avoid
contamination. Interestingly, the small subset of Areg
+ splenic
Tregs did share TCR sequences with muscle Treg cells, whether
Aregpositive ornegative.Theseﬁndings raise the possibility that
a muscle antigen might be involved in recruiting Treg cells to the
site of injury and/or retaining them therein.
How Might Treg Cells Inﬂuence Muscle Repair?
Muscle repair subsequent to acute injury was impaired in the
absence of Treg cells, an inﬂuence no doubt exerted at several
levels. First, Tregs regulated the myeloid populations that inﬁl-
trated the damaged tissue, appearing to contain their numbers
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(A) Expression of Areg in ImmGen microarray data sets from hematopoietic-lineage cells. Mo, monocytes; MF, macrophages; DC, dendritic cells; GN,
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(B) Expression of Areg 2 weeks after Ctx-induced injury. Numbers represent % Foxp3
+ cells that are Areg
+.
(C) Volcano plots of transcriptomes of whole muscle from injured DTR
+ (Treg-less) mice treated or not treated with Areg. Left: experimental protocol. Right:
superimposition of transcript sets highlighted in Figure 4G and identically color-coded. Values refer to the number of genes upregulated (right) or downregulated
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2 test.
(D) As in (C), except DTR
  mice were used.
(E) The same data set shown in (D) plotted as the fold-change for Areg- versus PBS-treated muscles versus the mean expression value for each transcript.
Highlighted in orange and purple are genes up- or downregulated by Areg, respectively.
(F)MyogenicclonalassayinthepresenceofAreg.Resultswereplottedasthefold-changeoverthemeanofvehicle-controltreatedsamplesperexperiment.Data
represent mean ± SD and ﬁve independent experiments. **p < 0.01.
(legend continued on next page)
1292 Cell 155, 1282–1295, December 5, 2013 ª2013 Elsevier Inc.
134and to promote their switch from a pro- to an anti-inﬂammatory
phenotype. Both ‘‘ﬂavors’’ of myeloid cell are important for
proper muscle repair, and any alteration in the tightly orches-
trated scenario wherein each accumulates and functions at the
site of injury can be detrimental (Tidball and Villalta, 2010). A
variety of intrinsic and extrinsic factors are responsible for their
phenotypic polarization; we propose that Treg cells represent
an additional layer of control.
Second, Treg cells also regulated coinﬁltrating conventional
T cell populations. Upon Treg depletion, the total number and
frequency of T cells in the injured muscle was signiﬁcantly
increased,andmanyTcell-speciﬁcgeneswereoverrepresented
in whole-muscle microarrays of injured muscle from standard
versus Treg-less mice. Moreover, depletion of Treg cells in
Rag-deﬁcient mice had a less severe inﬂuence on muscle regen-
eration after acute injury than did ablation of Tregs alone,
suggesting that inﬁltrating Tconv cells (and/or CD8
+ or B cells)
normally have a negative impact on muscle repair that is kept
in check by Treg cells. Yet, the effect of removing Treg cells
was not abrogated by eliminating the other lymphocyte classes,
indicating that Tregs can impact muscle regeneration indepen-
dently of either T or B cells.
Third, Treg cells impacted the activities of muscle-lineage
cells, speciﬁcally satellite cells. According to clonal myogenic
assays, satellite cells from Treg-deﬁcient mice had decreased
colony-forming capacity, consistent with the reduced in vivo
regenerative potential of Treg-depleted muscle. Thus, Treg cells
can regulate the cells that are directly responsible for the repair
of injured muscle. In vitro experiments have shown that macro-
phages can directly inﬂuence muscle progenitors (Bosurgi
et al., 2011); it is possible, then, that Treg cells act on satellite
cells indirectly, by modulation of the inﬁltrating myeloid popula-
tions. However, two of our results suggest a more direct effect:
(1) histological evidence that Treg cells were located in close
proximity to regenerating ﬁbers (in addition to being present in
heavily inﬁltrated areas); and (2) the demonstration that muscle
Tregs expressed Areg and that this molecule enhanced satellite
cell differentiation in vitro and in vivo. Areg is an EGF family
member known to promote healing and regeneration of multiple
tissues, for example intestinal mucosa and lung epithelium
(Shao and Sheng, 2010; Monticelli et al., 2011). Most relevant
in the current context, previous studies have suggested
that Areg might act directly on muscle cells (Golding et al.,
2007; Andrechek et al., 2002). Together with these previous
studies, our results suggest that Areg may directly modulate
muscle repair.
Tregcellsandtheirproducts arenewplayers toconsiderinthe
orchestrated series of events underlying muscle repair in both
acute and chronic contexts. Poor wound healing is a growing
problem, especially given its association with diabetes and
aging, both of which affect a large and increasing fraction of
the population. Moreover, adequate treatments for muscular
dystrophies remain elusive. Harnessing the power of Treg cells,
whether in cell- or molecule-based strategies, opens novel ther-
apeutic avenues.
EXPERIMENTAL PROCEDURES
Mice and Their Manipulation
C57BL/6, C57BL/10ScSn,RAG1-deﬁcient, andC57BL/10ScSn-Dmd
mdxmice
were purchased from Jackson Laboratory. Foxp3-DTR, Foxp3-IRES-gfp, and
Dysferlin-deﬁcient mice were obtained from A. Rudensky, V. Kuchroo, and R.
(G) Induction of satellite cells differentiation by Areg. Satellite cells were bulk-cultured in the presence of Areg or vehicle control for 12 days. Left: MyHC mRNA
titered by quantitative PCR, represented as fold-change expression of Myh2 relative to vehicle control. Center: MyHC protein quantiﬁed by immunoﬂuorescence
microscopy; differentiation index calculated as the mean ratio of MyHC-positive nuclei to the total nuclei per ﬁeld of view. Right: sum of DAPI-positive nuclei per
well. Data represent mean ± SD and four experiments. *p < 0.05; ***p < 0.0001.
See also Figure S5.
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Mouse ID CDR3β #%#%#%# %
d4 Mouse #4 CASGDAWVNYGGQFF 1 2.0 6 7.6 3 6.5 3 9.1
CTCSADQGGNTLYF 3 6.0 2 2.5 1 2.2 1 3.0
d4 Mouse #5 CASRPLGTYAEQFF 1 2.4 3 3.4 1 2.2 2 4.7
CASSPQGATEVFF 1 2.4 4 4.5 3 6.5 1 2.3
d4 Mouse #6 CGAFPGQGTTEVFF 1 1.6 1 0.8 1 1.9 0 0.0
d4 Mouse #7 CSSRDLGGSYEQYF 1 1.4 2 1.5 2 2.8 0 0.0
d4 Mouse #8 CTCSATGDSDYTF 1 0.9 1 0.9 0 0.0 1 1.9
Areg+
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Total
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Areg+
muscle
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n = 114
Figure 7. Sharing of TCR Sequences between Areg
+ Splenic and Muscle-Inﬁltrating Treg Cells
(A) TCR CDR3 a and b sequences for individual Areg
+ splenic Treg cells. Each pie chart represents a single mouse. n, number of analyzed sequences per mouse.
Total frequency of expanded clones shown at the top right.
(B) Identical paired CDR3 a (data not shown) and b sequences found in splenic Areg
+ and muscle Areg
+ and Areg
  Treg cells from the same individual in
independent experiments. #: number of times the sequence was found. %: frequency of Tregs expressing the same sequence.
(C) As in (A), for muscle Treg cells. Clones represented in Areg
+, Areg
 , or both subsets of muscle Tregs were labeled in red, blue, and green, respectively. See
also Table S2.
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135Bittner, respectively. All mice were bred in our speciﬁc-pathogen-free facilities
at Harvard Medical School. Protocols were approved by Harvard Medical
School’s Institutional Animal Care and Use Committee.
We injected anesthetized mice i.m. with 0.03 ml/muscle of Naja
mossambica mossambica cardiotoxin (0.03 mg/ml) (Sigma) in one or more
hindlimb muscles. Alternatively, TA muscles were directly exposed to dry ice
for 5 s.
A total of 1 mg of EdU was injected intravenously, and 24 hr later cells were
processed for detection by the Click-iT EdU kit (Molecular Probes).
Foxp3-DTR
+ mice and Foxp3-DTR littermates were injected i.p. with
DT (Sigma), at 6 ng/g body weight, every other day for 6 days, starting at
the day of injury. Depletion of CD25
+ cells was accomplished by i.p. injection
of 100 mg of anti-CD25 mAb (clone PC61) or rat IgG (Jackson
ImmunoResearch) at days 17 and 20 of age. Muscle inﬁltrate and serum
CK were analyzed 7 days after the last injection, the latter via the Creatine
Kinase-SL kit (Genzyme). For expansion of Tregs, we incubated 2.5 mg
of anti-mouse IL-2 mAb (JES6-1A12) and 0.25 mg of mouse IL-2 per mouse
for 20 min on ice followed by i.p. injection. Then 17-day-old mdx mice
were given daily injections for 6 days and were analyzed 10 days after the
last injection. Control mice were administered phosphate-buffered saline
(PBS).
Recombinant mouse Areg (R&D Systems) was administered i.m. (1 mg/
muscle) together with Ctx at day 0. Areg was then injected i.p. (7 mg/mouse)
every other day until the time of analysis.
Muscle Leukocytes and Manipulations of Them
MicewereperfusedwithPBS.Muscleswereexcised,cutup,andcollagenase/
DNase digested, and leukocytes were isolated by standard procedures. For
RT-PCR analyses and single-cell TCR sequencing, published protocols
(Wong et al., 2007; Baker et al., 2002) were followed with some modiﬁcations
to the primer sets used. Raw sequencing ﬁles were ﬁltered for sequence qual-
ity, processed in automated fashion, and parsed using IMGT/V-QUEST (Bro-
chet et al., 2008). See detailed protocols in the Extended Experimental
Procedures.
Microarray
Cells were double-sorted into TRIzol (Invitrogen). Whole-muscle tissue was
ﬂash frozen in liquid nitrogen and homogenized in TRIzol. Data sets used
for comparison in the PCA were previously generated in our lab. All samples
were generated in duplicate or (usually) triplicate. Sample processing
and data analysis were performed as previously described (Cipolletta et al.,
2012).
Clonal Myogenesis and Myogenic Differentiation Assays
Fortheclonalassays,myoﬁber-associatedcellswerepreparedfromhind-limb
muscles as described (Cerletti et al., 2008). Satellite cells (CD45
 Sca-
1
 Mac-1
 CXCR4
+b1-integrin
+) were double-sorted individually into 96-well
plates and cultured for 5–7 days. Wells containing myogenic colonies were
scored as described in Extended Experimental Procedures.
For differentiation assays, 3,000 satellite cells were double-sorted onto 24-
well plates, cells were cultured ±1 ng/ml recombinant mouse Areg, and after
12 days the cultures were processed for RT-PCR or immunoﬂuorescence
microscopy of myosin expression as described in the Extended Experimental
Procedures, which also details our method of scoring and calculation of the
differentiation index.
Statistical Analyses
Data were routinely presented as means ± SD. Signiﬁcance was assessed by
the Student’s t test or ANOVA. A p value of < 0.05 was deemed statistically
signiﬁcant.
ACCESSION NUMBERS
Microarraydataare available from the National Center for Biotechnology Infor-
mation/Gene Expression Omnibus repository under accession numbers
GSE50096, GSE50094, GSE50095, and GSE50097.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, ﬁve
ﬁgures, and four tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.10.054.
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EXTENDED EXPERIMENTAL PROCEDURES
Isolation of Leukocytes from Muscle
TA, gastrocnemius and quadriceps muscles were excised after perfusing the mice with PBS. Muscles were cut in small pieces and
digested for 30 min with collagenase II (2 mg/ml, Invitrogen) and DNase I (150 mg/ml, Sigma). The digested product was ﬁltered
through a 70 mm mesh using a plunger to disrupt undigested tissue and washed with DMEM supplemented with serum. To separate
the leukocyte fraction, the cells were resuspended in 40% Percoll, overlayed on 80% Percoll and spun for 25 min. The interphase
containing leukocytes was recovered, washed and stained for analysis or sorting by ﬂow cytometry.
Flow Cytometry
Sampleswerestainedwiththefollowingantibodies:anti-TCRb,-CD4,-CD25,-CD11b,-CD45,-Ly6c,-Gr1,-CD103,-KLRG1,-IL-10,
-TIM3, -Helios (all Biolegend); anti-CCR2, -amphiregulin, -neuropilin and -ST2 (all R&D); anti-Foxp3 (eBioscience) and anti-Ki67 (BD
Pharmingen). Intracellular expression of Foxp3 and Ki67 was determined using the Intracellular Fixation &Permeabilization buffer set
(eBioscience) according to the manufacturer’s protocol. EdU detection was done after the last wash with permeabilization buffer
following the Click-iT EdU kit (Molecular Probes) instructions. Samples were acquired with an LSR II (BD Bioscience) and data
were analyzed with FlowJo (Tree Star).
Single-Cell Sorting, RT-PCR, and TCR Sequence Analysis
CD4
+Foxp3
+ and CD4
+Foxp3
 from injured Foxp3-IRES-gfp mice and CD4
+CD25
+ cells from mdx mice were ﬁrst sorted in bulk
before resorting as individual cells into wells of 96-well PCR plates containing the reverse transcriptase reaction mix and cDNA
was prepared as described by (Wong et al., 2007). Extreme caution was taken to minimize PCR and cross-contamination between
wells. Preparation of reversetranscriptase reactionmix, cDNAsynthesis,and ﬁrst round ofPCR was performed in a different building
from second round PCR and ﬁnal PCR product isolation. At least 2 columns of every plate were left blank for negative controls to
monitor for contamination. Experiments showing evidence of PCR contamination were discarded. Resulting cDNA (1.5 ml) from
each cell was split to perform multiplex nested PCR reactions to amplify the corresponding CDR3 a and b transcripts using the
protocol and CDR3b primers published in (Baker et al., 2002). Primers used to amplify CDR3 a were designed based on nucleotide
sequences of the TCRa families from the IMGT database (http://www.imgt.org; Brochet et al., 2008)( Table S4). Aliquots of the PCR
products were visualized on a 1.5% agarose gel. Samples containing PCR product for both TCRa and TCRb chains were cleaned up
using ExoSAP-IT For PCR Clean-Up (Affymetrix) per manufacturers protocol and were subjected to automated sequencing (Dana-
Farber/Harvard Cancer Center High-Throughput Sequencing Core). Raw sequencing ﬁles were ﬁltered for sequence quality, pro-
cessed in automated fashion, and parsed using IMGT/V-QUEST (Brochet et al., 2008). Only sequences that produced functional
in-frame rearrangements of both TCRa and TCRb chains were used for analysis.
Quantitative PCR Analysis
Muscle tissue was frozen in liquid N2 and homogenized in Trizol (Invitrogen) before RNA extraction following Trizol manufacturer’s
instructions. RNA was reverse transcribed with oligo(dT) primers and SuperScript Polymerase 2 (Invitrogen). Real-time quantitative
PCR was performed using gene-speciﬁc ﬂuorogenic assays (TaqMan; Applied Biosystems). Transcript levels were normalized to
those from the mouse Gapdh gene. Primers and probe sequences are listed in Table S4.
Histology
TAmuscleswereexcisedandﬁxedin4%paraformaldehyde.ParafﬁnsectionswerestainedwithH&EorGomori’sTrichromestaining
(to detect collagen deposition). Fibrosis scoring was performed in a blinded fashion by two independent investigators.
For immunoﬂuorescence microscopy, harvested muscle was snap-frozen in liquid nitrogen cooled isopentane and sectioned
using Microm HM550 cryostat (Thermo Scientiﬁc). After ﬁxation with 4% paraformaldehyde, sections were treated with 0.2% Triton
X-100 (2 min.), blocked and stained with polyclonal rabbit anti-mouse anti-dystrophin (1:200) (Abcam, Cambridge, MA), anti-mouse
Foxp3 (1:50) (clone FJK-16, eBioscience) and anti-mouse CD4 (1:100) (clone RM4-5, Biolegend). Images were acquired with a Zeiss
Axio Imager.M1 microscope. Foranalysis of cryo-injury, harvested muscle was snap-frozen in liquid nitrogen-cooled isopentane and
sectioned using Microm HM550 cryostat (Thermo Scientiﬁc). H&E staining was performed on 8-10 mm tissue cryo-sections for quan-
tiﬁcation of newly-formed (centrally nucleated) regenerative myoﬁbers.
Clonal Myogenesis Assay
Satellite cells (CD45
Sca-1
Mac-1
CXCR4
+b1-integrin
+) were ﬁrst sorted in bulk and then individually into 96-well plates coated
with collagen (1 mg/ml, Sigma) and laminin (10 mg/ml, Invitrogen). Cells were cultured in F10 medium with 20% horse serum and
5 ng/ml bFGF (Sigma) for 5-7 days, with fresh bFGF added daily, and wells containing myogenic colonies were scored by brightﬁeld
microscopy at day 5 or 7.
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3000 satellite cells were double sorted onto collagen/laminin coated 24-well plates as described above. Cells were fed 5 ng of bFGF
(Sigma) per well for 2 days. 1 ng/ml of recombinant mouse Areg (R&D systems) or vehicle control was added daily. Following 12 days
in culture, cells were either ﬁxed in 4% paraformaldehyde or mixed extensively with TRIzol (Invitrogen) for quantitative PCR. For
immunoﬂuorescence microscopy, ﬁxed cells were permeabilized and blocked with 1% bovine serum albumin/0.5% triton-X/0.5%
goat serum. Cells were then labeled with anti-skeletal myosin (FAST) antibody (Sigma), goat anti-mouse IgG (H
+L)-Cy3 (Jackson
ImmunoResearch), and DAPI (Invitrogen). The same 20 representative ﬁeld-of-views in a well were captured on an ImageXpress
Micro plate reader and analyzed using MetaXpress and ImageJ. The nuclei in a given ﬁeld-of-view were counted using the Nucleil-
Count algorithm on MetaXpress. Samples were blinded and myosin-heavy-chain associated nuclei were manually counted using
ImageJ. The differentiation index was calculated as the average ratio of myosin-heavy-chain positive nuclei to total nuclei per ﬁeld
of view.
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139Figure S1. Treg Accumulation at the Site of Injury, Related to Figure 1
Cytoﬂuorometric analysis of the muscle immune inﬁltrate after injury with cardiotoxin.
(A) Number of CD45
+ cells per g of muscle.
(B) Number of TCRb
+ cells per g of muscle.
Data represent means ± SD (n R 4).
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140Figure S2. Muscle Treg Cells Have a Unique Transcriptome Compared with Other Inﬂamed-Tissue Treg Cells, Related to Figure 2
TranscriptomecomparisonofVAT,muscle,colonic laminapropriaandpre-diabeticNODpancreasTregcells(triplicatespergroup).Hierarchicalclusteringbased
onalistof1,853up-anddownregulatedgenesinnonlymphoidtissue-Tregcellsversuslymphoid-Tregcells(poolofallgeneswitha>2-foldchangeineachtissue
versus spleen/LN). Values (each square) represent the fold change of non-lymphoid tissue Treg versus lymphoid tissue Treg. Highlighted on the right, a few
examples of similarities and dissimilarities between muscle Treg cells and the other populations.
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141Figure S3. Treg Ablation Impairs Muscle Regeneration after Wounding, Related to Figure 4
DTR
+ and DTR
 mice were injured by im injection of Ctx at day 0 and treated with diphtheria toxin from day 0 to induce Treg depletion.
(A)Themuscleinﬁltratewasanalyzedbyﬂowcytometry 7daysafterinjury.Left:thefrequencyofTcells (CD45
+TCR
+)inthemuscle inﬁltrate wasassessed.Right:
total number of CD45
+ cells and frequency of Ly6c
high/CD11b
+ cells. Results are representative of 3 experiments, each with 2-4 animals per group. **p < 0.01;
***p < 0.001.
(B)Toassessthepossibility thatthedeath,ratherthantheabsenceof,Tregcellsinrepairingmuscleexplainedthepersistentinﬂammationobserved,weanalyzed
the frequency of Ly6c
high cells in the inﬁltrate of Ctx-injured DTR
/, DTR
+/ and DTR
+/+ females. In the heterozygous female setting, DTR is expressed on only
half of the Treg cells owing to X chromosome inactivation, so there is substantial cell demise in response to DT treatment – but this death occurs in the continued
presence of Tregs. ***p < 0.001.
(C) Expression of representative genes of the 3 gene clusters highlighted in Figure 4C, as measured by quantitative PCR. A representative experiment of three is
shown.
(D) Additional representative examples of genes belonging to each gene cluster from Figure 4C. Normalized expression values from the microarray are shown.
(E) Analysis of muscle inﬁltrate in Ctx-injured RAG1-KO mice by ﬂow cytometry. Data represent mean ± SD (n = 7).
(F) Analysis of ﬁbrosis in Ctx-injured RAG1-KO muscles. Left: Fibrosis detection by Gomori’s Trichrome staining of muscle sections 13 days after injury. Collagen
is stained in blue. Representative examples of 6 WT and 6 RAG1-KO mice. Magniﬁcation: 200X. Top right: summary quantiﬁcation. Bottom right: expression of
collagen, type VI, alpha 5 in muscle by quantitative RT-PCR. *p < 0.05. Data represent means ± SD.
Cell 155, 1282–1295, December 5, 2013 ª2013 Elsevier Inc. S5
142Figure S4. Treg Cells Are Enriched in Muscles of Dystrophic Mice and Impact Muscle Damage, Related to Figure 5
(A) Frequency of Foxp3
+ T cells in abdominal muscle, hind limb muscles and spleen of 8 months-old dysferlin-deﬁcient or C57BL/10 mice. **p < 0.01; *p < 0.05.
(B) Cytoﬂuorometric analysis of surface markers expressed by muscle Treg cells from mdx mice. Dot plots depict the expression of selected markers in
TCR
+CD4
+ cells from spleen (top) or muscle (bottom). Numbers refer to % marker
+ Treg cells. Representative plots of n = 4 are shown.
(C) Microarrayanalysisofwhole-muscletissuefrommdxmicetreated withanti-CD25.Highlightedinblueandgreen (topleftandtopright),gene setsdescribedin
Figure 4G. Highlighted in purple (bottom): gene set described in Figure 6E.
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Figure S5. Areg Improves Muscle Repair after Injury, Related to Figure 6
(A) Expression of Areg in ImmGen microarray data sets from nonhematopoietic-lineage cells and in whole-muscle samples. AU, arbitrary units.
(B) Frequency of Areg
+ muscle Tregs at different time points after Ctx injury, measured by ﬂow cytometry. Data represent mean ± SD (n = 4).
(C and D) Expression of representative genes of the 3 gene clusters highlighted in Figure 4G, as measured by quantitative RT-PCR in muscles from injured DTR
+
(C) or DTR
 (D) mice treated or not treated with Areg, normalized to the expression of that transcript in uninjured muscle. AU: arbitrary units. Two to three in-
dependent experiments.
(E)GeneexpressionlevelsofmembersoftheEFGRfamilyinsatellite cellssortedfromuninjuredorinjuredmuscle(left)orinTregcellsfromdifferenttissues(right).
Normalized expression values from microarray analyses are shown (each bar represents one experimental replicate). AU, arbitrary units. Data represent
means ± SD.
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Foxp3+CD4+
  regulatory
  T
  (Treg)
  cells
  are
  a
  key
  population
  in
  controlling
  the
  immune
  response.
  Recently,
their
  roles
  have
  been
  expanded
  to
  broader,
  non-immune,
  contexts,
  in
  particular
  the
  metabolic
  conse-
quences
  downstream
  of
  obesity-induced
  inﬂammation,
  e.g.
  type-2
  diabetes
  and
  cardiovascular
  disease.
This
  review
  highlights
  the
  major
  innate
  and
  adaptive
  immune
  cell
  subsets
  contributing
  to
  adipose-tissue
inﬂammation,
  the
  key
  role
  played
  by
  fat-resident
  Tregs,
  and
  the
  potential
  of
  Treg-based
  therapies
  for
treatment
  of
  the
  metabolic
  syndrome.
© 2011 Elsevier Ltd. All rights reserved.
1.
  Introduction
In
  recent
  years,
  regulatory
  T
  (Treg)
  cells
  have
  emerged
  as
  one
of
  the
  most
  important
  guardians
  of
  the
  immune
  response.
  Usually
making
  up
  approximately
  5–20%
  of
  the
  CD4+
  T
  cell
  compartment,
Tregs play
 a
 key
 role
 in
 controlling
 autoimmunity,
 allergic
 responses,
inﬂammation,
  and
  responses
  to
  infection
  [1].
  Traditionally,
  they
were
  thought
  to
  regulate
  the
  activities
  of
  other
  T
  cells,
  but
  there
has
  been
  growing
  appreciation
  of
  their
  impact
  on
  innate
  immune
system
  cells,
  e.g.
  macrophages
  and
  neutrophils.
  Recent
  data
  argue
for
  an
  even
  broader
  role,
  in
  non-immune
  contexts
  such
  as
  cardio-
vascular
 disease
 [2–4]
 and,
 obesity-induced
 insulin
 resistance
 [5,6],
the
  focus
  of
  this
  review.
Over
  the
  past
  several
  decades,
  there
  has
  been
  a
  world-wide
increase
  in
  obesity,
  in
  parallel
  with
  an
  impressive
  rise
  in
  a
  cluster
of
  abnormalities
  termed
  the
  “metabolic
  syndrome”,
  in
  particular
type-2
  diabetes
  (TD2).
  According
  to
  the
  latest
  estimates
  from
  the
Centers
  for
  Disease
  Control,
  over
  25
  million
  people
  in
  the
  United
States
  suffer
  from
  diabetes,
  which
  is
  associated
  with
  tremen-
dous
  societal
  and
  economic
  burdens
  [7].
  There
  is
  by
  now
  a
  large
body
  of
  evidence
  that
  implicates
  obesity
  in
  provoking
  chronic,
low-grade
  inﬂammation
  which,
  in
  turn,
  promotes
  metabolic
  dys-
regulation
  and
  systemic
  insulin
  resistance
  [8,9].
  It
  turns
  out
  that
the
  function
  of
  adipose
  tissue
  is
  not
  limited
  to
  the
  storage
  of
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excess
  triglycerides,
  but
  that
  it
  is
  also
  an
  active
  endocrine
  organ
playing
  multiple
  roles
  in
  orchestrating
  system-wide
  metabolism.
A
  seminal
  insight
  into
  the
  pro-inﬂammatory
  potential
  of
  adipose
tissue
  in
  response
  to
  obesity
  came
  from
  Hotamisligil
  et
  al.,
  who
demonstrated
  increased
  levels
  of
  tumor
  necrosis
  factor-
  (TNF-
)
  mRNA
  in
  adipocytes
  in
  visceral
  adipose
  tissue
  (epidydimal,
omental,
  etc.),
  but
  not
  subcutaneous
  fat,
  of
  obese
  versus
  lean
  mice
[10].
  Since
  then,
  an
  increasing
  number
  of
  adipocyte-derived
  medi-
ators,
  collectively
  called
  adipokines,
  have
  been
  described.
  These
molecules,
  which
  can
  increase
  or
  decrease
  in
  response
  to
  extended
caloric
  excess,
  have
  multiple
  effects
  on
  a
  variety
  of
  cell
  popula-
tions,
  both
  locally
  in
  adipose
  tissue
  and
  systemically
  (reviewed
  in
[11]).
  They
  include,
  but
  are
  not
  limited
  to,
  interleukin-1
  (IL-1)
[12],
  IL-6
  [13],
  serum
  amyloid
  A3
  (SAA3)
  [14],
  and
  macrophage
chemoattractant
  protein-1
  (MCP-1)
  [15].
  Obesity,
  by
  triggering
endoplasmic
 reticulum
 (ER)
 stress
 [16],
 hypoxia
 [17],
 and
 oxidative
stress
  [18],
  results
  in
  adipocyte
  dysfunction,
  dysregulated
  expres-
sion
 of
 adipokines,
 and
 inappropriate
 inﬂammatory
 responses
 [8,9].
There
  are
  changes
  in
  the
  cellular
  composition
  of
  adipose
  tissue,
including
  adjustments
  in
  the
  numbers,
  phenotypes,
  and
  localiza-
tion
  of
  multiple
  immune
  cell
  subsets.
  There
  are
  also
  systemic
metabolic
  alterations
  through
  a
  complex
  signaling
  network
  that
affects
  insulin
  signaling
  in
  the
  liver,
  kidney,
  and
  skeletal
  muscle.
Activation
  of
  NF-B
  [19]
  and
  the
  JUN
  N-terminal
  kinase
  family
  of
serine/threonine
  protein
  kinases
  [20]
  leads
  to
  phosphorylation
  and
inactivation
  of
  the
  insulin
  receptor
  substrate
  (IRS)
  family,
  which
collectively
 results
 in
 tissues
 becoming
 unresponsive
 to
 insulin
 sig-
naling
  [16,21,22].
Here,
  we
  will
  outline
  contributions
  of
  both
  the
  innate
  and
  the
adaptive
  immune
  systems
  to
  obesity-associated
  pathologies,
  high-
light
  the
  protective
  role
  of
  fat-resident
  Treg cells,
  and
  discuss
  the
possible
 clinical
 implications
 of
 these
 ﬁndings
 for
 treatment
 of
 T2D.
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2.
  Immune
  effector
  cells
  in
  obesity-induced
  T2D
2.1.
  Innate
  immune
  system
A
 number
 of
 studies
 have
 implicated
 innate
 immune
 system
 cell
types,
  such
  as
  neutrophils,
  mast
  cells,
  and
  macrophages
  in
  obesity-
induced
 pathology.
 In
 a
 mouse
 model
 of
 obesity
 triggered
 by
 a
 high-
fat
  diet
  (HFD),
  neutrophils
  were
  early
  inﬁltrators
  of
  the
  adipose
tissue,
  detectable
  already
  at
  3
  weeks
  of
  HFD,
  suggesting
  a
  possible
role
  in
  early
  phases
  of
  adipose
  tissue
  inﬂammation.
  However,
  the
importance
 of
 neutrophils
 in
 downstream
 metabolic
 consequences
remains
  to
  be
  established
  [23].
Recently,
  Liu
  et
  al.
  argued
  for
  a
  role
  for
  mast
  cells
  in
  obe-
sity
  and
  its
  sequelae
  [24].
  They
  found
  that
  mast
  cell
  numbers
were
  increased
  in
  the
  adipose
  tissue
  of
  obese
  mice
  and
  humans
compared
  with
  those
  of
  lean
  controls.
  Mice
  carrying
  a
  genetic
  deﬁ-
ciency
  in
  mast
  cells
  or
  treated
  with
  mast-cell-stabilizing
  drugs
displayed
  a
  signiﬁcantly
  reduced
  body
  weight
  and
  visceral
  fat
  pad
mass
  when
  on
  HFD
  through
  a
  proposed
  mechanism
  of
  decreased
angiogenesis
  and
  increased
  apoptosis
  of
  muscle
  and
  adipose
  tis-
sue.
  It
  is
  important
  to
  note
  that
  the
  primary
  effect
  of
  mast
cell
  deﬁciency/stabilization
  was
  on
  obesity-induced
  weight
  gain,
which
  would
  have
  secondarily
  altered
  insulin
  sensitivity.
  Finally,
using
  genetic
  knockout
  mice,
  the
  authors
  showed
  that
  IL-6
  and
interferon-
  (IFN-)
  produced
  by
  mast
  cells
  were
  key
  cytokines
for
  attenuating
  weight
  gain.
  These
  ﬁndings
  suggest
  a
  role
  for
  mast
cells
  in
  obesity-associated
  abnormalities
  through
  promoting
  adi-
pose
  tissue
  growth.
To
  date,
  the
  largest
  body
  of
  evidence
  implicates
  subsets
  of
macrophages/monocytes
  as
  major
  effectors
  in
  obesity-induced
pathology.
  Accumulations
  of
  large
  numbers
  of
  macrophages
around
  dead
  adipocytes,
  forming
  “crown-like
  structures,”
  have
been
  observed
  in
  visceral
  fat
  tissue
  of
  obese
  mice
  and
humans
  [25,26].
  Under
  normal
  chow
  conditions,
  adipose
  tis-
sue
  presents
  an
  anti-inﬂammatory
  environment,
  where
  resident
macrophages
 display
 a
 phenotype
 similar
 to
 the
 anti-inﬂammatory
or
  alternatively-activated
  “M2”
  state,
  producing
  factors
  such
  as
interleukin-10
  (IL-10)
  and
  transforming
  growth
  factor-
  (TGF-
)
  [15,27–31].
  In
  contrast,
  in
  obese
  adipose
  tissue,
  resident
  and
inﬁltrating
  macrophages
  appear
  to
  be
  in
  the
  pro-inﬂammatory
or
  classically
  activated
  “M1”
  state,
  synthesizing
  numerous
inﬂammatory
  factors,
  including
  TNF-,
  IL-6,
  matrix
  metallopro-
teinases,
  and
  peroxisome
  proliferator
  activated
  receptor-
  (Pparg)
[15,26,29–31].
It
  is
  important
  to
  note,
  however,
  that,
  while
  adipose
  tissue
macrophages
  have
  been
  historically
  subdivided
  into
  M1
  and
  M2
subsets
 [30,31],
 and
 this
 is
 an
 attractively
 simple
 dichotomy,
 recent
studies
 have
 challenged
 this
 binary
 classiﬁcation,
 instead
 arguing
 in
favor
  of
  a
  spectral
  classiﬁcation
  [27,32,33].
  A
  recent
  study
  demon-
strated
  the
  importance
  of
  the
  NLRP3
  (nucleotide-binding
  domain
leucine-rich
  repeat
  containing
  family,
  pyrin
  domain
  containing
  3)
inﬂammasome
  in
  activation
  of
  adipose-tissue
  macrophages
  and
subsequent
  development
  of
  insulin
  resistance
  [34].
  The
  inﬂamma-
some
  is
  a
  key
  player
  in
  sensing
  various
  “danger”
  stimuli,
  leading
to
  secretion
  of
  IL-1
  and
  initiation
  of
  a
  pro-inﬂammatory
  immune
response
  (reviewed
  in
  [35]).
  Previous
  studies
  have
  demonstrated
that
 cholesterol
 or
 similar
 crystals
 cause
 Nlrp3
 inﬂammasome
 acti-
vation
  in
  macrophages
  found
  in
  atherosclerotic
  lesions
  [36,37].
By
  analogy,
  one
  might
  speculate
  that
  HFD
  leads
  to
  formation
  of
cholesterol
  crystals
  activate
  the
  Nlrp3
  inﬂammasome,
  in
  particu-
lar
  in
  adipose
  tissue
  macrophages,
  resulting
  in
  a
  pro-inﬂammatory
activation
  state
  and
  ultimately
  resulting
  in
  systemic
  inﬂammation
and
  insulin
  resistance.
  Additionally,
  activation
  of
  adipose
  tissue
macrophages
  has
  been
  shown
  to
  result
  from
  recognition
  of
  free
fatty
 acids
 by
 Toll-like
 receptors
 (TLR)
 2
 and
 4
 in
 mice
 on
 HFD
 (Fig.
 1)
[38].
2.2.
  Adaptive
  immune
  system
The
  contributions
  of
  the
  innate
  immune
  system,
  in
  particular
  of
macrophages,
  to
  obesity-induced
  inﬂammation
  have
  been
  the
  cen-
tral
  focus
  of
  by
  far
  most
  of
  the
  relevant
  studies,
  but
  of
  late
  there
  has
been
  a
  growing
  interest
  in
  the
  role
  of
  the
  adaptive
  immune
  system
as
  well.
  A
  T
  cell
  implication
  in
  T2D
  would
  not
  be
  so
  surprising
  given
their
  crucial
  roles
  in
  various
  other
  inﬂammatory
  contexts.
  Early
studies
  noted
  an
  increased
  frequency
  of
  CD3+
  cells
  in
  the
  adipose
tissue
  of
  obese
  humans
  and
  mice
  [39].
  Since
  then,
  accumulations
of
  both
  CD4+
  and
  CD8+
  T
  cells
  have
  been
  reported,
  and
  evidence
  of
a
  signiﬁcant
  role
  presented,
  but
  there
  remains
  substantial
  contro-
versy
  over
  the
  extent
  to
  which
  the
  two
  compartments
  contribute
to
  disease
  progression.
Several
  recent
  studies
  have
  evaluated
  the
  role
  of
  CD8+
  T
  cells
in
  adipose
  tissue
  inﬂammation.
  They
  were
  found
  inﬁltrate
  vis-
ceral
  adipose
  tissue
  in
  response
  to
  HFD,
  reportedly
  prior
  to
  the
characteristic
  increase
  in
  macrophages
  [40].
  Depletion
  of
  CD8+
  T
cells
  via
  either
  antibody
  treatment
  or
  genetic
  ablation
  resulted
  in
reduced
  macrophage
  inﬁltration
  into
  visceral
  fat
  depots,
  decreased
production
  of
  key
  pro-inﬂammatory
  mediators
  such
  as
  TNF-,
IL-1,
  IL-6,
  and
  MCP-1,
  and
  improved
  insulin
  sensitivity.
  In
  vitro
experiments
  demonstrated
  that
  CD8+
  T
  cells
  isolated
  from
  obese
adipose
  tissue
  had
  a
  highly
  activated
  phenotype
  and
  produced
large
  quantities
  of
  pro-inﬂammatory
  mediators
  known
  to
  function
in
  macrophage
  recruitment
  and
  activation
  [40,41].
  The
  frequency
of
  CD44+CD62L−
  effector-memory
  cells
  was
  signiﬁcantly
  higher,
while
  naïve
  CD44−CD62L+CD8+
  T
  cells
  was
  decreased,
  in
  obese
compared
  with
  lean
  adipose
  tissue,
  consistent
  with
  the
  notion
  of
an
  activated
  CD8+
  T
  cell
  phenotype
  in
  obese
  fat
  [41].
  Together,
these
  ﬁndings
  suggest
  that
  obesity
  promotes
  activation
  of
  CD8+
T
  cells
  in
  fat,
  which,
  in
  turn,
  leads
  to
  the
  recruitment,
  differentia-
tion
 and
 activation
 of
 activated
 macrophages
 via
 pro-inﬂammatory
mediators.
Other
  studies
  have
  characterized
  the
  pro-inﬂammatory
  prop-
erties
  of
  adipose-resident
  effector
  CD4+
  T
  cells,
  especially
  given
their
  well-established
  ability
  to
  promote
  inﬂammation
  and
  recruit
macrophages.
  A
  signiﬁcant
  increase
  in
  CD4+
  T
  cells
  residing
  in
  adi-
pose
  tissue
  of
  obese
  humans
  and
  mice
  was
  reported
  [41,42].
  The
fat-resident
  CD4+
  T
  cell
  compartment
  of
  obese
  mice
  was
  enriched
for
  CD44+CD62L−
  effector-memory
  cells
  [41],
  phenotype
  char-
acterized
  by
  production
  of
  IFN-
  [5,42,43].
  T
  cell
  receptor
  (TCR)
sequence
  analysis
  revealed
  a
  repertoire
  bias
  among
  T
  cells
  iso-
lated
  from
  obese
  compared
  with
  lean
  adipose
  tissue,
  suggestive
of
  antigen-driven
  T
  cell
  activation,
  expansion,
  and/or
  inﬁltration
[41,42].
  An
  increase
  in
  IFN-
  expression
  can
  enhance
  the
  accumu-
lation
  of
  M1
  macrophages
  in
  obese
  fat,
  accompanied
  by
  elevated
expression
  of
  TNF,
  and
  MCP-1
  [44].
  Finally,
  enﬂamed
  adipose
tissue
 may
 further
 propagate
 Th1
 cell
 polarization
 through
 the
 pro-
duction
  of
  leptin,
  which
  can
  act
  on
  T
  cells
  directly
  and
  indirectly
  to
promote
  increased
  proliferation
  and
  cytokine
  production,
  speciﬁ-
cally
  of
  IL-2
  and
  IFN
  [45].
  The
  proposal
  that
  Th1
  polarization
  is
  at
the
 expense
 of
 Th2
 cells
 [42]
 is
 poorly
 substantiated
 as
 Gata3+CD4+
and
  Th2
  cells
  cannot
  be
  equated
  [46].
One
  report
  has
  proposed
  a
  protective
  role
  for
  effector
  CD4+
  T
cells
  in
  obesity-induced
  insulin
  resistance
  [42].
  CD4+
  T
  cells
  were
adoptively
  transferred
  into
  recombination-activating
  genes
  (RAG)-
null
  mice,
  which
  have
  no
  T
  or
  B
  cells
  [47],
  and
  a
  decreased
  body
weight
  and
  fat
  pad
  mass,
  and
  an
  improved
  insulin
  sensitivity
  were
observed
  2–4
  weeks
  later.
  The
  authors
  proposed
  that
  the
  improved
metabolic
  parameters
  reﬂected
  protection
  by
  Th2
  cells.
  However,
an
  alternative
  interpretation
  is
  that
  the
  improvement
  is
  due
  to
  a
lower
  body
  weight
  in
  the
  recipient
  mice
  coupled
  with
  the
  insulin-
sensitizing
  effect
  of
  Treg cells.
  Transfer
  of
  CD4+
  T
  cell
  populations
depleted
  of
  Foxp3+
  Tregs or
  CD4+
  T
  cells
  from
  IL-10-deﬁcient
  mice
into
  immunodeﬁcient
  recipients
  are
  both
  well-established
  animal
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Fig.
  1.
  Obesity
  results
  in
  systemic,
  chronic,
  low-grade
  inﬂammation
  and
  insulin
  resistance.
  Excess
  weight
  gain
  leads
  to
  necrotic
  and
  apoptotic
  death
  of
  adipocytes,
  thereby
activating
  various
  inﬂammatory
  responses
  such
  as
  TLR
  and
  inﬂammasome
  activation,
  release
  of
  reactive
  oxygen
  species
  (ROS),
  and
  endoplasmic
  reticulum
  (ER)
  stress.
  In
response
  to
  these
  inﬂammatory
  stimuli,
  adipocytes
  and
  inﬁltrating
  leukocytes
  release
  a
  variety
  of
  pro-inﬂammatory
  mediators
  that
  act
  locally
  in
  adipose
  tissue
  and
  distally
in
  liver,
  muscle,
  and
  kidneys
  to
  inactivate
  insulin
  receptor
  substrates
  (IRS),
  leading
  to
  insulin
  resistance
  and
  persistent
  high
  blood
  glucose.
models
  of
  colitis
  [48,49].
  Therefore,
  the
  decreased
  weight
  gain
  of
the
  recipient
  RAG-null
  mice
  following
  CD4+
  T
  cell
  transfer
  was
likely
  due
  to
  the
  initiation
  of
  colitis,
  and
  the
  improved
  metabolic
parameters
  were
  merely
  a
  reﬂection
  of
  decreased
  body
  weight.
The
  presence
  of
  colitis
  is
  further
  substantiated
  by
  the
  fact
  that
there
  was
  no
  attenuated
  weight
  gain
  or
  improvement
  in
  metabolic
parameters
  following
  the
  transfer
  of
  CD8+
  T
  cells
  [49]
  or
  OT2
  TCR-
transgenic
  CD4+
  T
  cells
  [50],
  because
  neither
  of
  these
  cell
  types
is
  able
  to
  transfer
  colitis.
  In
  addition,
  the
  authors
  proposed
  that
the
  protective
  effect
  of
  CD4+
  T
  cells
  was
  a
  result
  of
  their
  Th2
polarization
  by
  showing
  that
  transferred
  CD4+
  T
  cells
  produced
  IL-
4
  and
  IL-13
  following
  restimulation
  and
  that
  there
  was
  a
  lower
frequency
  of
  Gata3+
  T
  cells
  in
  visceral
  adipose
  tissue
  of
  obese
  com-
pared
  with
  lean
  animals.
  Under
  lymphopenic
  conditions,
  CD4+
  T
cells
  become
  activated
  and
  differentiate
  into
  Th2
  cells,
  as
  sug-
gested
  by
  the
  authors,
  but
  they
  also
  differentiate
  into
  Th1
  cells;
therefore,
  upon
  restimulation,
  CD4+
  T
  cells
  from
  a
  lymphopenic
host
  may
  produce
  IL-4
  and
  IL-13,
  as
  seen
  in
  the
  paper,
  but
  they
would
  also
  produce
  IFN,
  which
  was
  not
  measured.
  Furthermore,
it
  was
  recently
  shown
  that
  Tregs can
  express
  high
  levels
  of
  Gata-3
[46].
  Therefore,
  it
  is
  possible
  that
  the
  loss
  of
  Gata3+CD4+
  T
  cells
from
  abdominal
  adipose
  tissue
  following
  HFD
  is
  actually
  due
  to
loss
  of
  Treg cells.
  Thus,
  the
  root
  of
  the
  observed
  protection
  bears
re-examination.
There
 are
 substantial
 contradictions
 among
 the
 aforementioned
studies
  on
  the
  contributions
  of
  CD4+
  and
  CD8+
  T
  cells
  to
  obesity-
associated
  inﬂammation
  and
  insulin
  resistance.
  Several
  groups
reported
  an
  increase
  in
  the
  fraction
  of
  CD8+
  T
  cells
  in
  response
to
  HFD
  [40,41,51];
  however,
  a
  more
  recent
  study
  found
  no
  such
difference
  [43].
  Similarly,
  some
  groups
  described
  signiﬁcant
  CD4+
T
  cell
  accumulation
  in
  adipose
  tissue
  of
  obese
  humans
  and
  HFD-
fed
  mouse
  models
  [42,51],
  while
  another
  study
  did
  not
  see
  this
increase
  [43],
  and
  still
  another
  saw
  a
  decrease
  [40].
  In
  interpret-
ing
  and
  comparing
  these
  seemingly
  contradictory
  results,
  it
  needs
to
  be
  kept
  in
  mind
  that
  methods
  used
  to
  quantify
  T
  cells
  by
  ﬂow
cytometry
  differed
  in
  various
  studies.
  In
  addition,
  there
  were
  mul-
tiple
  divergences
  in
  the
  HFD
  protocols
  used,
  including
  the
  age
  of
the
  mice
  at
  introduction
  of
  the
  enriched
  diet,
  length
  of
  time
  on
  the
diet,
  and
  the
  composition,
  in
  particular
  the
  fat
  content,
  of
  the
  HFD
and
  normal
  chow
  comparator.
With
  the
  recognition
  of
  an
  important
  role
  for
  T
  cells
  in
  obesity-
associated
 pathologies,
 there
 is
 an
 increased
 interest
 in
 the
 function
of
  B
  cells
  in
  these
  abnormalities.
  Recent
  studies
  on
  HFD-fed
  mice
revealed
  that
  B
  cells
  inﬁltrated
  adipose
  tissue
  within
  the
  ﬁrst
3
  weeks
  of
  diet
  changes
  [52,53],
  and
  that
  there
  was
  a
  rise
  in
serum
 immunoglobulin
 (Ig)
 levels.
 Analysis
 of
 B-cell-deﬁcient
 mice
on
  HFD
  revealed
  that
  the
  absence
  of
  B
  cells
  led
  to
  increased
insulin
  sensitivity
  compared
  with
  wild-type
  controls.
  Additionally,
transfer
  of
  B
  cells
  or
  serum
  IgG
  isolated
  from
  HFD-fed
  mice
  into
B-cell-deﬁcient
  recipients
  resulted
  in
  transfer
  of
  insulin
  resistance;
however,
  there
  was
  no
  change
  in
  insulin
  resistance
  when
  trans-
ferred
 B
 cells
 or
 IgG
 were
 isolated
 from
 lean
 normal-chow-fed
 mice.
Finally,
  the
  authors
  showed
  that
  insulin
  resistant
  human
  patients
had
  a
  distinct
  IgG
  proﬁle
  compared
  with
  age-
  and
  weight-matched
insulin
  sensitive
  subjects.
  While
  it
  is
  clear
  from
  this
  study
  that
  Igs
can
  have
  an
  effector
  function
  in
  promoting
  insulin
  resistance,
  per-
haps
 through
 adipocyte
 death
 and
 the
 generation
 of
 antibodies
 that
inhibit
  insulin
  signaling
  molecules,
  their
  role
  in
  more
  upstream
events
  is
  more
  cloudy,
  given
  the
  well-known
  T
  cell
  aberrancies
  in
B-cell
  deﬁcient
  mice
  [54–56].
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3.
  Role
  of
  fat-resident
  Treg cells
  in
  obesity-induced
  T2D
Foxp3+
  Treg cells
  are
  important
  regulators
  of
  essentially
  every
category
  of
  immune
  response.
  While
  Foxp3
  is
  a
  critical
  orchestra-
tor
  of
  the
  Treg phenotype,
  it,
  alone,
  is
  not
  sufﬁcient
  to
  drive
  the
  full
phenotype
  program
  [57,58].
  For
  example,
  the
  induction
  of
  Foxp3
expression
  through
  “conversion”
  of
  conventional
  T
  (Tconv)
  cells
  (by
in
  vitro
  culture
  with
  TGF-,
  in
  vivo
  exposure
  to
  agonist
  peptide,
  or
in
  vivo
  homeostatic
  proliferation)
  or
  by
  retroviral
  transduction
  of
Tconv cells
  with
  Foxp3
  can
  only
  partially
  recapitulate
  the
  canonical
“Treg signature”
  [57,58].
  Furthermore,
  Foxp3
  is
  not
  necessary
  for
expression
  of
  all
  of
  the
  suppressive
  activities
  characteristic
  of
  Treg
cells.
  Disruption
  of
  the
  Foxp3
  gene
  in
  mice
  by
  insertion
  of
  the
  green
ﬂuorescent
  protein
  (GFP)
  results
  in
  the
  generation
  of
  so-called
Treg “wannabes,”
  cells
  expressing
  a
  number
  of
  the
  canonical
  Treg
markers
  (such
  as
  CTLA4,
  ICOS,
  IL-2ra),
  but
  lacking
  any
  suppressive
function
  [59,60].
  These
  ﬁndings
  suggest
  that
  the
  regulatory
  activi-
ties
  of
  Tregs are
  subject
  to
  a
  level
  of
  regulation
  upstream
  of
  Foxp3.
Finally,
 the
 gene-expression
 proﬁles
 of
 different
 subtypes
 of
 Foxp3+
cells
 (thymus-derived
 Tregs,
 splenic,
 converted,
 etc.)
 [57,58,61]
 cou-
pled
  with
  ﬁndings
  on
  transcription
  factor
  knockout
  mice
  [62–64],
have
 revealed
 that
 Treg cells
 come
 in
 “different
 ﬂavors”,
 determined
by
  distinct
  origins
  and
  anatomic
  locations.
So
  far,
  the
  most
  striking
  example
  of
  a
  distinct
  subset
  of
  Treg cells
came
  from
  the
  identiﬁcation
  of
  an
  adipose-tissue-resident
  popu-
lation
  that
  seems
  to
  impact
  metabolic
  parameters,
  in
  particular
  of
insulin
  resistance
  secondary
  to
  obesity
  [5].
  Such
  cells
  accumulated
with
  age
  in
  lean
  mice
  to
  eventually
  represent
  more
  than
  half
  of
the
  CD4+
  T
  lymphocytes
  residing
  in
  the
  visceral
  fat.
  This
  is
  a
  much
greater
  fraction
  than
  the
  15%
  or
  so
  normally
  found
  in
  lymphoid
tissues.
  Interestingly,
  Tregs were
  not
  enriched
  in
  subcutaneous
  adi-
pose
  depots
  –
  interesting
  because
  changes
  in
  visceral,
  but
  not
  a
subcutaneous,
 fat
 have
 been
 associated
 with
 insulin
 resistance
 [65].
Characterization
  of
  fat
  Treg cells
  via
  gene-expression
  proﬁling
and
  TCR
  repertoire
  analysis
  revealed
  a
  population
  distinct
  from
counterparts
  in
  lymphoid
  organs.
  Fat-resident
  Foxp3+CD4+
  cells
retained
  about
  60%
  of
  the
  canonical
  Treg signature;
  however,
  they
speciﬁcally
  over-
  or
  under-expressed
  many
  genes,
  especially
  those
coding
  for
  molecules
  involved
  in
  leukocyte
  migration
  and
  extrava-
sation,
  such
  as
  CCR1,
  CCR2,
  CCR9,
  CXCL10
  (over-represented
  in
  fat
Tregs);
 and
 CCL5
 and
 CXCR3
 (under-represented
 in
 fat
 Tregs).
 In
 addi-
tion,
  the
  repertoire
  of
  TCRs
  displayed
  by
  adipose
  Tregs was
  distinct
from
  that
  of
  fat
  Tconvs as
  well
  as
  Treg and
  Tconvs from
  lymphoid
  tis-
sues.
  Intriguingly,
  there
  were
  multiple
  examples,
  in
  the
  same
  or
  in
different
  mice,
  of
  a
  particular
  CDR3
  amino-acid
  sequence
  encoded
by
 different
 nucleotide
 sequences.
 This
 ﬁnding
 suggests
 that
 in
 adi-
pose
  tissue,
  Tregs may
  undergo
  a
  selective
  pressure
  favoring
  the
display
  of
  a
  TCR
  with
  a
  particular
  antigenic
  speciﬁcity.
  Moreover,
the
  fact
  that
  fat
  Tregs shared
  almost
  no
  TCR
  sequences
  with
  the
Tconv cells
  in
  fat
  or
  LN,
  suggested
  that
  the
  accumulation
  of
  Foxp3+
Tregs in
  the
  abdominal
  adipose
  tissue
  is
  unlikely
  to
  be
  due
  to
  a
  local
conversion
  of
  Tconv cells
  [5].
Interestingly,
  fat
  Tregs expressed
  a
  very
  high
  level
  of
  the
  anti-
inﬂammatory
  cytokine,
  IL-10
  [5].
  In
  an
  in
  vitro
  experimental
  model
that
 reproduces
 the
 main
 mechanism
 of
 induction
 of
 cellular
 insulin
resistance
  (treatment
  of
  a
  cultured
  pre-adipocyte
  line
  with
  TNF-
),
  IL-10
  could
  suppress
  markers
  of
  inﬂammation
  and
  restore
  the
expression
  of
  the
  transporter
  for
  glucose,
  GLUT4
  [5].
  However,
other
  mechanisms
  of
  suppression
  are
  also
  possible,
  even
  likely,
given
 that
 they
 express
 other
 molecules
 like
 Granzyme-b
 and
 CTLA-
4
  that
  could
  be
  responsible
  for
  their
  regulatory
  activity
  [66].
The
  potential
  role
  of
  fat
  Treg cells
  in
  modulating
  adipose
  tissue
inﬂammation
 was
 also
 demonstrated
 via
 gain-
 and
 loss-of-function
experiments.
  It
  is
  possible
  to
  expand
  Tregs in
  vivo
  using
  IL-2/anti-IL-
2
  complexes
  or,
  conversely,
  deplete
  them
  by
  injecting
  diphtheria
toxin
  (DT)
  in
  a
  mouse
  model
  where
  Foxp3
  promoter/enhance
elements
  drive
  the
  expression
  of
  the
  diphtheria
  toxin
  receptor
(Foxp3-DTR
  mice)
  [67,68].
  Both
  in
  vivo
  manipulations
  impacted
metabolic
  parameters,
  improving
  (by
  IL-2/anti-IL-2
  complexes)
  or
compromising
  (by
  DT)
  their
  insulin
  sensitivity
  [5].
  Moreover,
  an
interesting,
  but
  indirect,
  indication
  of
  the
  involvement
  of
  Tregs in
the
  control
  of
  metabolic
  functions
  came
  from
  studies
  performed
using
  several
  animal
  models
  of
  obesity
  and
  insulin
  resistance,
  such
as
 leptin-deﬁcient
 mice
 (Lepob/ob),
 mice
 heterozygous
 for
 the
 yellow
spontaneous
  mutation
  (Ay/a)
  and
  mice
  chronically
  fed
  a
  high-fat
diet
  (HFD).
  In
  all
  of
  these
  models,
  the
  percentage
  and
  number
  of
  fat
Tregs was
 substantially
 reduced
 compared
 with
 that
 of
 lean
 controls
[5,69–71].
  Similar
  to
  the
  mouse
  data,
  a
  reduction
  in
  Foxp3
  tran-
scripts
  was
  also
  observed
  in
  the
  omental
  vis-à-vis
  subcutaneous
fat
  of
  obese
  humans
  [5].
However,
  Winer
  et
  al.
  did
  not
  see
  a
  dramatic
  decrease
  in
  fat
  Treg
numbers
  in
  mice
  fed
  an
  HFD
  [42].
  We
  attribute
  this
  difference
  to
their
  use
  of
  the
  “Foxp3-GFP”
  mouse
  line,
  in
  which
  the
  GFP
  reporter
is
 fused
 near
 the
 N
 terminus
 of
 the
 Foxp3
 protein.
 Our
 group,
 as
 well
as
 other
 laboratories,
 has
 found
 abnormal
 Treg activity
 in
 these
 mice
in
 the
 context
 of
 autoimmune
 and
 inﬂammatory
 diseases,
 including
in
  the
  fat
  (unpublished
  data).
Why
 the
 Treg fraction
 in
 abdominal
 adipose
 tissue
 decreases
 dur-
ing
  obesity
  is
  still
  not
  clear.
  Even
  though
  only
  a
  few
  years
  have
passed
  since
  the
  ﬁrst
  report
  on
  fat
  Tregs and
  their
  role
  in
  guarding
against
  insulin
  resistance,
  several
  groups
  have
  already
  contributed
to
  this
  discussion.
  An
  interesting
  model
  to
  explain
  such
  a
  dra-
matic
  reduction
  in
  fat
  Tregs with
  obesity
  has
  been
  proposed
  by
Matarese
  et
  al.
  [71].
  Leptin
  is
  an
  adipokine
  that
  controls
  food
  intake
and
  promotes
  the
  activation
  of
  T
  lymphocytes,
  enhancing
  the
  pro-
liferation
  of
  Th1
  cells
  and
  their
  production
  of
  pro-inﬂammatory
cytokines
  [72].
  Conversely,
  leptin
  inhibits
  the
  proliferation
  of
  Treg
cells
  [73,74].
  The
  elevated
  levels
  of
  leptin
  accompanying
  obesity
could
  dampen
  Treg proliferation,
  perhaps
  explaining
  why
  their
numbers
 decrease.
 But,
 this
 speculation
 is
 difﬁcult
 to
 reconcile
 with
the
  striking
  loss
  of
  fat
  Tregs in
  the
  leptin-deﬁcient
  mouse
  model
[5].
  Alternatively,
  Deiuliis
  et
  al.
  have
  argued
  that
  the
  reduced
  accu-
mulation
  of
  fat
  Tregs in
  obese
  individuals
  is
  a
  direct
  consequence
of
  inﬂammatory
  signals
  produced
  by
  macrophages
  [6].
  However,
their
  arguments
  assumed
  that
  fat
  Tregs result
  from
  peripheral
  con-
version
  of
  Tconv cells,
  for
  which
  there
  are
  few
  supporting
  data
  but
several
  lines
  of
  evidence
  in
  contradiction
  [5].
  Further,
  while
  this
group
  suggested
  that
  peripheral
  Tregs may
  home
  to
  the
  adipose
  tis-
sue
 through
 the
 expression
 of
 CXCR3
 and
 CCR7,
 it
 has
 been
 reported
that
  these
  chemokine
  receptors
  are
  down-regulated
  in
  fat
  Treg cells
[5,6].
Lastly,
  there
  seems
  to
  be
  an
  interesting
  parallelism
  in
  the
cellular
  mechanisms
  underlying
  insulin
  resistance
  and
  atheroscle-
rosis.
  Tregs were
  prominent
  in
  the
  atherosclerotic
  lesion
  of
Apolipoprotein-E-deﬁcient
  mice,
  a
  standard
  model,
  and
  they
decreased
  with
  age
  [2,75].
  Moreover,
  depletion
  of
  Tregs through
genetic
  ablation
  of
  CD80/86,
  CD28
  or
  ICOS,
  or
  via
  anti-CD25
  mAb
treatment,
  enhanced
  atherogenesis
  and
  lesion
  inﬂammation.
  Con-
versely,
  adoptive
  transfer
  of
  Tregs prevented
  the
  development
  of
atherosclerotic
  plaques
  [3,76].
  In
  humans,
  impairment
  in
  the
  num-
ber
  and
  function
  of
  circulating
  Tregs was
  observed
  in
  patients
  with
acute
  coronary
  syndrome
  [77].
  Interestingly,
  no
  T
  cells
  were
  found
in
 normal
 vessel
 fragments
 while
 a
 few
 Tregs (0.5–5%)
 were
 detected
in
  the
  intima
  during
  all
  stages
  of
  plaque
  development
  [77].
  It
  has
not
 been
 clear
 whether
 the
 loss/lack
 of
 Tregs is
 the
 cause
 or
 the
 effect
of
  the
  atherosclerotic
  lesions.
4.
  Regulatory
  T
  cells
  as
  potential
  immunotherapy
As
  illustrated
  using
  many
  rodent
  disease
  models,
  the
  therapeu-
tic
  potential
  of
  manipulating
  Treg cells
  is
  enormous.
  Treg activity
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can
 be
 attenuated
 to
 improve
 anti-tumor
 or
 anti-microbe
 responses
[78,79],
 or
 enhanced
 to
 treat
 allergic,
 inﬂammatory
 or
 autoimmune
diseases
  [80–87].
  Treatment
  with
  anti-CD3
  mAb
  is
  a
  promising
approach,
 already
 in
 the
 clinic:
 this
 agent
 seems
 to
 evacuate
 T
 effec-
tors
  cells
  while
  concomitantly
  enhancing
  the
  representation
  of
  Treg
cells
  [88].
Potential
  application
  of
  Tregs to
  therapy
  of
  T2D
  has
  only
recently
  been
  explored.
  Winer
  et
  al.,
  using
  the
  non-mitogenic
F(ab1)2 fragment
  of
  anti-CD3
  mAb,
  described
  a
  long-term
  normal-
izing
  effect
  on
  insulin
  resistance
  and
  glucose
  tolerance
  in
  mice
treated
  with
  a
  short
  regime
  of
  5
  days
  [42].
  They
  highlighted
a
  correlation
  between
  the
  improved
  metabolic
  proﬁle
  and
  the
increase
  in
  numbers
  of
  adipose-tissue
  Tregs and
  anti-inﬂammatory
macrophages.
Ilan
  et
  al.,
  on
  the
  other
  hand,
  employed
  oral
  administration
  of
anti-CD3-mAb
  in
  combination
  with
  -glucosylceramide
  (GC)
  [89].
GC,
  an
  intermediate
  of
  glycosphingolipid
  metabolism,
  interacts
with
  CD1d,
  a
  molecule
  recognized
  by
  NK-T
  cells.
  Oral
  administra-
tion
  of
  GC
  led
  to
  decreased
  intra-hepatic
  NK-T
  cell
  numbers
  and
amelioration
  of
  the
  metabolic
  syndrome
  in
  Lepob/ob mice
  [90].
  This
protocol
  results
  in
  anti-CD3s
  uptake
  by
  the
  gut-associated
  lym-
phoid
  tissue,
  and
  the
  induction
  of
  CD4+CD25− Treg cells
  expressing
TGF-1
  latency-associated
  peptide
  (LAP)
  [91].
  The
  suppressive
capacity
  of
  such
  cells
  has
  been
  studied
  in
  several
  diseases,
  like
autoimmune
  diabetes,
  experimental
  encephalomyelitis
  and
  sys-
temic
  erythematosus
  lupus
  [91–93].
  Body
  weight
  did
  not
  change
after
  oral
  treatment
  of
  Lepob/ob mice
  with
  anti-CD3
  mAb.
  There
was
  an
  induction
  of
  CD4+
  LAP+
  T
  cells,
  and
  a
  concomitant
  reduc-
tion
  of
  NK-T
  cells,
  in
  the
  mesenteric
  lymph
  nodes,
  blood
  and
spleen,
  but,
  surprisingly,
  there
  was
  an
  increase
  of
  Tregs,
  but
  not
of
  CD4+LAP+
  T
  cells,
  in
  the
  adipose
  tissue.
  The
  authors
  suggested
that
  the
  increase
  in
  fat
  Tregs may
  have
  resulted
  from
  increased
  pro-
duction
  of
  TGF-
  by
  LAP-positive
  T
  cells,
  which
  correlates
  with
a
  decrease
  in
  adipose
  tissue
  inﬂammation.
  Metabolic
  parameters
were
  impaired
  by
  oral
  anti-CD3
  mAb
  treatment:
  a
  reduction
  in
blood-glucose,
  cholesterol
  and
  aspartate
  amino
  transferase
  lev-
els.
Interestingly,
  none
  of
  effects
  on
  the
  metabolic
  and
  pathologic
abnormalities
  could
  be
  recapitulated
  when
  Lepob/ob mice
  were
treated
  singly
  with
  either
  anti-CD3
  or
  GC.
  The
  authors
  hypothe-
sized
  that
  Tregs activation
  was
  induced
  through
  engagement
  of
  the
TCR
  by
  anti-CD3,
  and
  that
  tolerogenic
  DCs
  were
  promoted
  by
  NK-
T
  cells,
  further
  inducing
  Treg.
  In
  conclusion,
  this
  report
  made
  the
novel
  suggestion
  that
  a
  previously
  described
  interaction
  between
Tregs and
  NK-T
  cells
  may
  play
  an
  important
  role
  in
  controlling
  the
inﬂammation
  associated
  with
  T2D
  [94].
  However,
  transfer
  of
  the
induced
 CD4+LAP+
 (but
 not
 CD4+LAP−)
 T
 cells
 to
 Lepob/ob mice
 ame-
liorated
  blood
  glucose
  and
  aspartate
  amino
  transferase
  levels
  and
reduced
  levels
  of
  inﬂammatory
  mediators
  like
  IL-6,
  IFN-
  and
  IL-
17
  produced
  by
  stimulated
  splenocytes,
  suggesting
  that
  the
  main
factor
  in
  controlling
  insulin
  resistance
  may
  rather
  be
  the
  expansion
of
  CD4+LAP+
  T
  cells
  in
  the
  periphery
  rather
  than
  the
  induction
  of
Treg cells.
  Finally,
  it
  would
  be
  useful
  to
  supplement
  these
  results
with
  data
  on
  the
  commonly
  accepted
  measures
  of
  insulin
  resis-
tance,
  including
  levels
  of
  blood
  insulin,
  the
  glucose
  tolerance
  test
and
  HOMA-IR
  (Homeostatic
  Model
  Insulin
  Resistance)
  to
  better
situate
  them
  in
  the
  context
  of
  T2D
  in
  humans
  and
  animal
  mod-
els.
To
  date,
  approaches
  to
  T2D
  therapy
  have
  been
  focused
  on
sulfonylureas,
  biguanides,
  and
  thiazolidinediones.
  However,
  the
aforementioned
  studies
  all
  support
  the
  idea
  that
  Tregs and
  their
products
 may
 represent
 novel
 targets.
 Similarly,
 the
 use
 of
 anti-CD3
mAb
  has
  been
  proposed
  to
  explore
  the
  potential
  beneﬁcial
  effect
  of
in
  vivo
  Treg induction
  in
  the
  context
  of
  atherosclerosis.
  Preventive
therapy
  with
  anti-CD3
  reduced
  plaque
  development
  and
  its
  ther-
apeutic
  use
  decreased
  lesion
  progression
  in
  mice
  with
  established
atherosclerosis
  [95].
Cellular
 therapy
 based
 on
 the
 administration
 of
 ex
 vivo
 expanded
Tregs is
  currently
  the
  object
  of
  extensive
  research
  for
  the
  treatment
of
  autoimmune
  and
  graft-versus-host
  disease.
  However,
  several
issues
  must
  be
  addressed
  before
  their
  clinical
  use.
  First
  of
  all,
large
  numbers
  of
  customized
  Tregs will
  be
  needed
  for
  transfer
  into
humans.
  Presently,
  much
  effort
  is
  directed
  at
  developing
  protocols
to
  achieve
  their
  ex
  vivo
  expansion
  and
  to
  ensure
  the
  maintenance
of
  their
  phenotypic
  and
  functional
  purity.
  Moreover,
  the
  possibil-
ity
  for
  contamination
  of
  Treg preparations
  by
  effector
  T
  cells
  must
be
  carefully
  addressed
  because
  this
  could
  result
  in
  exacerbation
  of
inﬂammatory
  responses
  on
  adoptive
  transfer.
  Achieving
  the
  goal
of
  a
  pure
  preparation
  of
  patient-derived
  Treg cells
  will
  require
  the
identiﬁcation
 of
 a
 more
 speciﬁc
 surface
 marker
 of
 natural
 Tregs or,
 as
proposed
  by
  Battaglia
  et
  al.,
  the
  use
  of
  drugs
  like
  rapamycin
  which
appear
  to
  induce
  Tregs while
  blocking
  the
  proliferation
  of
  effector
  T
cells
  [96].
In
 conclusion,
 Treg numbers,
 purity,
 diversity,
 allo-reactivity
 and
antigen
  speciﬁcity
  are
  all
  factors
  that
  render
  their
  translation
  from
the
  bench
  to
  the
  bedside
  very
  difﬁcult.
  The
  identiﬁcation/design
of
  compounds
  that
  can
  selectively
  expand
  Treg cells
  in
  vivo
  would
be
  an
  elegant
  solution
  to
  the
  aforementioned
  concerns.
  Given
  our
recent
  appreciation
  of
  Treg heterogeneity
  based
  on
  anatomic
  loca-
tion
  and
  physiologic
  functions,
  this
  goal
  is
  simultaneously
  made
more
  complex
  and
  more
  attractive
  with
  regard
  to
  the
  speciﬁcity
  of
targets.
Fig.
  2.
  Cellular
  and
  metabolic
  alterations
  in
  adipose
  tissue
  during
  obesity.
  In
  lean
  mice,
  the
  abdominal
  adipose
  tissue
  hosts
  anti-inﬂammatory
  macrophages,
  as
  well
  as
  an
elevated
  fraction
  of
  Tregs.
  In
  obese
  mice,
  by
  contrast,
  there
  is
  a
  switch
  in
  cellular
  equilibrium:
  more
  CD8+
  than
  Th1
  CD4+
  T
  cells,
  fewer
  regulatory
  T
  cells
  and
  a
  preponderance
of
  pro-inﬂammatory
  macrophages.
  These
  effector
  cells
  promote
  inﬂammation
  and
  exacerbate
  adipose
  tissue
  dysfunction
  through
  the
  production
  of
  inﬂammatory
  cytokines.
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5.
  Concluding
  remarks
  and
  future
  prospects
Inﬂammation
  is
  a
  critical
  link
  between
  obesity
  and
  T2D.
  Recent
studies
  have
  painted
  a
  picture
  in
  which
  the
  inﬂammation
  of
  adi-
pose
  tissue
  is
  correlated
  with
  alterations
  in
  the
  balance
  between
different
  T
  cell
  populations.
  In
  lean
  mice,
  production
  of
  IL-10
  by
regulatory
  T
  cells
  and
  anti-inﬂammatory
  macrophages
  ensures
  the
maintenance
  of
  adipocyte
  insulin
  sensitivity.
  Conversely,
  in
  obese
mice,
  the
  equilibrium
  is
  shifted
  in
  the
  direction
  of
  CD8+
  T
  cells
  and
pro-inﬂammatory
  macrophages
  (Fig.
  2).
Finding
  a
  unique
  population
  of
  regulatory
  T
  lymphocytes
  in
  the
abdominal
  adipose
  tissue
  of
  lean,
  but
  not
  obese,
  mice
  gives
  rise
  to
many
  interesting
  questions.
  First,
  where
  do
  fat
  Tregs come
  from?
When
  and
  where
  do
  they
  acquire
  their
  unique
  phenotype?
  Why
and
  how
  do
  they
  accumulate
  in
  the
  visceral
  fat
  with
  age?
  Do
  they
respond
  to
  an
  antigen
  or
  antigens
  and,
  if
  so,
  what
  is
  it?
  What
chemokine/chemokine
  receptors
  are
  necessary
  for
  their
  homing
to/retention
  in
  the
  fat?
  What
  precise
  functions
  do
  they
  perform
  in
the
  adipose
  tissue?
  By
  what
  mechanisms?
  Do
  they
  operate
  directly
on
  adipocytes,
  on
  macrophages
  or
  both?
  Why
  do
  Tregs evacuate
obese
  adipose
  tissue?
Studies
  aimed
  to
  address
  these
  questions
  ultimately
  may
  result
in
  treatments
  to
  modulate
  fat
  Treg cell
  numbers
  and
  function
  in
order
  to
  address
  the
  inﬂammation
  of
  the
  adipose
  tissue
  that
  pro-
motes
  the
  metabolic
  syndrome.
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